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Abstract
TGF-pi plays ait important role in the pathogenesis of experimental and clinical 
glomerulosclerosis and tubufointerstitial fibrosis. Associations have been described 
between polymorphisms of cytokine and growth factor genes and susceptibility to. 
or progression of, an increasing number of diseases. In this study, single nucleotide 
polymorphisms (SNPs) in the TGFB1 gene were investigated as possible markers for 
the progression of chronic renal failure (CRF). One hundred and forty two 
Caucasian patients with CRF were screened for four TGFB1 SNPs: T-509C in the 
promoter region; ArglSPr© and Leu I OPro in exon 1 and Thr263Ile in exon 5. There 
were significant differences between CRF patients and controls in allele frequencies 
of two of the SNPs (LeelOPr© and C-509T), indicating an association with 
susceptibility to CRF, We also observed a significant association between rate of 
progression of CRF (the slope of the reciprocal of serum creatinine v time) and 
genotype, both at codon 25 (odds ratio 3.77, 95% confidence interval, 2.2 - 6, p 
<0.001) and at the -509 promoter site (odds ratio 1.67, 95% confidence interval 1.1- 
2.5), p <0.005) in patients with primary nephropathy (excluding PKD). Genotype at 
codon 25 was also associated with severity of proteinuria (p= 0.038), plasma TGF-{31 
protein levels (p = 0.01), and the severity of glomerulosclerosis (p<0.05). Genotype at 
C-509T was associated with the level of renal tubular TGF-pl immunostaining (p = 
0,9006) and with renal interstitial inflammatory cellular infiltration (p=0.015). 
There was a highly significant correlation between the degree of cellular infiltration 
in renal tissues and tubular TGF-pi immunostaining.
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ABBREVIATIONS
AAV: ANCA-associaled vasculitis 
ABC: avidin-biotin-peroxidase 
ACE: angiotensin I converting enzyme 
ActR: activin receptor type
ADPKD: Autosomal dominant jwlycysfic kidney disease
AEC: 3s amino- 9r etoyi-carffimazoie
AGT: angiotensinogen
ALK: activin receptor-like kinase
AMHR: anliHmnllerian hormone receptor
Aug It angiotensin H
Apo: apoKpoprotem
Arg: arginine
ARMS-PCR: amplification refectory mutation-screening polymerase chain reaction
AT1R: angiotensin type 1 receptor
bFGF: basic fibroblast growth factor
BMPs: bone moiphogenic proteins
CAPD: continuous ambulatory peritoneal dialysis
GGN: crescentic gfomeralonepfaritis
GEN: chronic interstitial nephritis
CrCl: creatinine clearance
CRD: chronic renal diseases
CREB: cAMP respond element binding protein
CRF: chronic renal failure
CTGF: connective tissue growth fetor
D*: coefficient o f linkage disecpiiibriwa
DBP: diastolic blood pressure
DBPd: diastolic blood pressure at diagnosis
DBPf: diastolic blood pressure during follow up
DM: diabetes mellf tits
IV
DIN: diabetic nephropathy
DMA: deoxyribonucleic Add
dMTPs: deoxynucleotide triprosphatcs
EcNOS: endothelial constitutive nitric oxide synthase
ECM: extracellular collagenous matrix
EGF: epidermal growth fader
ELISA: enzyme linked Immunoassay
ERK: extracellular signal-regulated Meases
ESRD: end stage renal disease
ESRF: end stage renal ladine
ETliendotbelin I
FGF: fibroblast growth factor
FSGS: focal and segmental glomerulosclerosis
GDFs: growth and differentiation factors
GDNF: glial cell line-derived souotaDfduc factor
GLUT: glucose transporter
GN: glomerulonephritis
GS: glycine serine domain
gTGF-pi: glomeruli TGF-pl
gTGF-pit-: glomeruli stained with TGF-pi
gTGF-p 1-: glomeruli did not seined for TGF-p 1
HD: haemodialysis
ICI: interstitial cellular infiltration
ICI-: renal tissue without inflammatory ceftular infiltration
ICH: renal tissue with inflammatoiy cellular infiltration.
IGF-l: insulin-like growth feetor-l
IF: interstitial fibrosis
IL-1: interleukin 1
ILIra: interleukin 1 teoepSor antagonist
¥
IL1RN*2: interleukin 1 receptor antagonist allele 2
He: isoleucine
KLK: kallikrein
LAP: latency associated peptide
LDL: low-density lipoproteins
Leu: leucine
LLC: large latent complex
LTBP: latent precursor molecule fomdmg protein
LTGF-p: latent tEecufsor molecule
MAP: mean arterial blood pressure
MAPK: mitogen-activated protein kinase
MCGN: mesangiocapillaiy gtomeralonepliritis
MCP-1: monocyte ctono-attractenl protein 1
MDRD: modification o f diet.in lend disease
MH: mad homology
MIF-2: macrophage inhibitory factor-2
MIS: mullerian inhibitory- substance
MMP: metaUoproteiimse
MN: membranous nepbiopa%
MRFIT: multiple Risk Factor Intervention Trial
mRNA: messenger ribonucleic acid
MTHFR: melliyleneielraliydrofoMe reductase
NGF: nerve growth factor
NO: nitric oxide
NOS: nitric oxide synthase
NP: non-progressive chronic renal M ure
OU: obstructive uropatby
P: progressors chronic renal M ore
PAl-1: plasminogen activator Mnbitor-l
VI
PCR: polymerase chain reaction 
PDGF: platelet derived growth fetor  
PKD: polycystic kidney disease 
Pro: proline
RI: type 1 transforming growth factor beta receptor
R lt type 2 transforming growth factor beta receptor
RIH: type 3 transforming growth factor beta receptor
RANTES: regulated on activation, normal T expressed and secreted
RRT: renal replacement therapy
SARA: Smad anchor for receptor activation
SBPd: systolic blood pressure at diagnosis
SBPf: systolic blood pressure during follow up
l/Scr reciprocal o f serum creatinine
SLC: small latent complex
SLE: systemic lupus erythematosus
SMAD: signalling mother against decapentaplegic protein
SNPs: single nucleotide polymorphisms
TBE: Tris borate EDTA
TpR: transforming growth factor beta receptor
TGF-a: transforming growth fetor alpha
TGF-pi: transforming growth fetor beta-1
Thn therionine
TIF: tubulointerstitial fibrosis
TIMP: tissue inMbifors o f metalioproteioase
TNF-a: tumour necrosis factor alpha
tRNA: transferase ribomidiee add
TSP-I: thntobospondinl
tTGF-pl: tubular TGF-pl
VC AM-1: vascular cell adhesion molecule-1
YEGF: vascular endotiidial gpowtfc fetor
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1.1 Introduction
Transforming growth factor beta-1 (TGF-pl) is a multifunctional growth factor 
implicated in the pathogenesis ofesqpaunenSal and ctinkal chronic renal M a e  (CRF) 
(Okntia, 1990; Yamamoto, eit a i 1993). It Ms potent fibrogenic propatks through the 
stimulation of synthesis o f extracellular coiagenous matrix (BCM) and inhibition of its 
breakdown {Border and Noble, 1997)1 Although there are three types o f TGF-p (1,2 and 
3), TGF-p i is the growth factor that has been implicated in fiferogenesis (Roberts and 
Sperm 1997). There is considerable experimental and clinical evidence pointing to an 
important role of TGF-pl in renal ffinrogpiesis (section 1.6.2) (Border and Noble,. 1994, 
1997, Peters, ef &L„ 1999, B aste, 1999). However, a clear-cut association between TGF- 
p l and the profession of clinical nephropathies is lacking. In this thesis, the potential 
relationship between TGF-pl genetic polymorphisms and tire profession of human 
nephropathies is studied.
1.2 Chronic renal failure (CRF)
Chronic renal faftuie (CRF) is defined as irreversible, long-stMifcg loss o f renal 
function. End stage renal failure (ESRF) refers to adv anced renal insufficiency when the 
glomerular filtration rate is below I© ml/min prior to the initiation o f either dialysis or 
renal transplantation (El Nahas and Wiwearis, 1997). The patients complain o f a wide 
range of symptoms including pom  appetite, vomiting, bone pain, headache, insomnia, 
itching, dry skin, malaise^ fatigue with light activity, muscle cramps, and change in 
mental alertness (El Nahas & Winearis, 1997). A survey of UK hospital biochemistry 
records revealed, that the prevalence o f CRF (plasma creatinine concentration >15© 
pmel/1) is 2058 adults per sniiioii population (prop) (UK Registry, 2001). The data also 
revealed the incidence of ESRF to fee around 78 pmp/year (UK Registry, 200]) Data 
from the UK registry suggest feat fee incidence of ESRF in the UK is currently .around 
80-110 pmp/year (UK Registry, 2001) Corresponding data from the Untiled States (US) 
suggest an. incidence of 315 pmp/year; US prevalence is currently around 1217 pmp 
(USRDS, 2001% In addition* there as little doubt that the incidence o f ESRF is steadily7
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increasing by aronnd 8-10% eweiy year (USRDS, 2001). One o f the major causes o f 
ESRFintbeUS is diabetes meffitus (DM) (41.8 %). In Norway, type 1 DM progresses to 
ESRF in 40% of patients, while type 2 is thought to lead to renal involvement in 20% of 
patients (Type 2 DM  is 10 times as common as Type 1) (Bergrem and Lea vested, 2001). 
In the US, the second most common cause of ESRF is hypertension (25.4%). Thirdly; 
chronic glomerulonephritis accounts for 21% of patients with end stage renal diseases 
(ESRD). Polycystic kidney disease and wrologic disease account for approximately 15% 
and 20% of cases of ESRD have no known cause (USRDS, 2001) On the other hand, m 
the UK, the most common cause o f ESRF remains chronic gtomemlonephritis as the 
incidence and prevalence o f diabetic nepferopatby remains below 20% (UK Registry' 
2001).
L Z l Natural history o f chrome nm alfailure
Progression of CRF occurs following renal injury regardless o f the underlying cause of 
nephropathy (For review see Locatdli and Del Vecchio, 2000). I1k reciprocal of serum 
creatifii.se (I/Sq) regression slope value against time (described below) determines the 
rate of decline of renal Rmctoon ^progression of CRF). When the pattern of the regression 
is a straight line this means that the rate o f the progression of CRF occurs at a constant 
rate (Mitch, et aL, 1976, Rutherford, et aL, 1977, Bleyer, 1999). Generally speaking foe 
rate of decline o f ienai rimctiom is constant, Implying that the process causing the decline 
of renal function is conthmom. Bl was repotted in the late seventies, that the progression 
of CRF from various diseases was ©marring at a constant rate (linear pattern of I/Sq- 
value against time) In foe majority of patients (Mitch, et aL, 1976 and Rufoerfotd, et aL, 
1977), A non-linear -decline o f renal inaction occurred in around 15% ©f patients (Shah 
and Levey, 1992). Further, some patients have a change in the regression line o f the 
reciprocal o f serum cim tm sm  against time suggesting a spontaneous acceleration or 
slowing down of the rate o f decline. These spontaneous changes are referred to as 
breakpoints in the slope which may be due to intercurrent events such as, infection, 
dehydration, poor Wood pressure control, or changes in the activity level, o f the 
underlying pathological processes which initiated the renal disease (Shah and Levey, 
1992).
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1.2.2 Factors influencing the progression of chronic renal failure
L2.2.1 Age
A ^ttig  is associated with physiological changes in the kidneys, including a reduction in 
renal plasma flow (Riser,, et atti^  19931, increase in filtration fraction (Baylis, et a t, 1990„ 
Flisher, et aL, 1993) and a decrease in renal size due to parenchymal reduction 
(Emamiait, et aL, 1993). Alas, fvim ay involution can be detected in the renal c o t e  with 
relative sparing of renal medulla (HoUenbeig, et aL, 1974). FurthenaMsre, 10 -  30% of the 
total glomeruli are sclerosed between the fourth and eighth decades of life (Kaplan, et aL, 
1975). It is often assumed that GFR is nearly 50% at the age of SO compared to values 
after puberty (Kaysen and Myers, 1985) Ltndeznan and cowockers (1985) showed that 
creatinine clearance was not decreased in one third of healthy elderly people. Many 
studies have shown that the indcfence o f renal failure from various, renal diseases; 
increases- with age (Fees) e t aL  1990, McGowen, 1990 and lungers, e t a t, 1996). 
Berthoux and colleagues (1998) reported that renovascular diseases, and diabetes mellitus; 
(type 2) are the most common causes o f ESRD' in the elderly. The same study also 
showed that primary gSomerolonephritis as common in the elderly as If constitutes about 
12% of ESRD In the elderly . The prognosis of renal diseases in the elderly is also more 
severe than in the younger age group as they have, in general, a higher rate o f progression 
compared to younger patients with similar nephropathies (For review see Locatelli and 
Del Vecchio, K M ).
1.2*2.2 Gender
Regardless of the cause of CRF, ESRD as more common in males than females (For 
review, Locatelli and Del Vecchio, WOO). The USRDS study (2001) revealed that the 
Incidence o f ESRD in men was 348 prop/year compared to 242 pmp/year in women 
(URSDS, 2001) Furthermore, the rate of decline in renal function is usually taster in 
males regardless, o f die underlying nephropathy (Hannedouche, et aL, 1993) Some 
postulated that the decline o f renal function is faster in males due to a higher protein 
ingestion, larger muscle mass and increased creatinine generation (Levey, et aL  1989).
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This is unlikely. Others argued that hormonal factors, including oestrogens, may play an 
important protective role in females with CRF (Velasquez and Bhatitena, 2001; For 
review, Neugartm, et aL„ 2000). Because the faster decline in renal function occurs only 
after puberty, it was assumed Jfeat sex hormones might piay a role in ft (ReckeiftofF, et al, 
1997, Neugarten, et aL  2000). The slope of progression in males cordages with the 
mean arterial Wood pressure, which is generally Wgher in males. In females, ft correlates 
with the type o f nephropathy (For review see Locatelli and Dei Vecchio, 2000)
/.2 .Z J Race
In the US, African-Americans have a four-fold higher incidence o f ESRD compared to 
Caucasians (USRDS, 2001). Freedman and colleagues (.1997) reported that the greater 
risk of ESRF in African-Americans might he due to a genetic predisposition. Tins may 
also be explained by higher levels o f circulating fibrogenic growth factors in African- 
Americans compared to others (Suthanthiran, et aL, 2000). Also, it was reported that 
incidence of increased blood pressure levels in black individuals is twice as high as that 
in the white population (Coraoni, etaL, 1989). Die high blood pressure may contribute to 
the higher incidence o f ESRF. Furthermore, in essential hypertension there is increased 
prevalence of mtrtaalbamhnina in black individuals (Summerson, et aL  1995). The 
prevalence o f DM is twice as high in African-Americans as in Caucasians and. ESRD due 
to DM is 3-6 times more- eenKnesn in African-Americans (Carter, et dL, 1996). Also, 
ESRF was higher in Native Americans and Asian/Pacific Islanders than Caucasians 
(USRDS, 2001). The ineidance of CRF is increased in the first ami second-degree 
relatives of those with retail disorders (Ferguson, et aL, 1988). In Caucasians this 
relationship is weaker than in African-Americans. Pugh and colleagues (1988) found that 
Mexicati-Americans were also at a higher risk of developing ESRD than other 
populations. In the UK, reports suggest a higher prevalence of renal disease in souse 
Asian individuals although die rate o f progression of the nephropathies was not found to 
be faster than Caucasians (For review. Wing and Jones, 2000, UK Registry, 2001).
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1.ZZ4 Systemic hypertension
Systemic hypertension is one of the most important factors conteifeeting to the 
deterioration of renal function and elevated blood pressure, can fee a cause or a 
consequence of lena! mjury (For levsew, Adamczak, et <d.9 2002). The higher the blood 
pressure the faster the rate o f decline o f renal function and the progression of CRF 
(Tiemay, et a l, 1989). Brazy and. cowwkers (1989), showed that increase in mean 
diastolic Wood pressure (DBF) > 90 moiHg was associated with a greater rate o f decline 
in the reciprocal o f serum creatinine versus time compared to patients with CRF with a 
mean DBF < 90 mmHg). Furthermore, there is improvement in renal function with 
intensive antihypertensive therapy (For review, Locatelli and Bel Vecchio, 2000 and 
Adamczak, ei aL, 2002). It Ms even been suggested that a stabilization and even a 
regression of the progression of CRF cm  fee achieved with aggressive antihypertensive 
therapy (For review, Dwmtrin ami Weir, 2000). The Modification of Diet in Renal 
Disease (MDRD) Study Group stowed that the lower the mean arterial blood pressure 
( MAP) value, the slower the decline in GFR (Klahr, et a!.P 1994). This study implied that 
lower blood pressure targets should fee sought for patients with progressive CRF and high 
levels o f proteinuria (Klahr, etttL , 1994). In those with protein excretion rate in excess o f 
3 g24h, it suggested that the MAP should to  reduced to levels around 92 mmHg to 
obtain the same protective effect o f renal function a MAP of 97 mmHg would provide 
those with less proteinuria (Klahr et @L, 1994, Peterson, et aL, 1995).
LZZ5 Prateifuiria
Proteinuria is an important pogprostie indicator of renal disease. Kineaid-Smith and 
Becker (1978) stowed that the presence of proteinuria predicted the progression of CRF 
in patients with chronic fwdtonqdnitisw The presence of proteinuria indicates poor 
prognosis in most cases o f primary glomenilonephritis (Williams, et aL, 1988 and 
Cameron, 1989). El Mates and colleagues (1984) were the first to demonstrate that a 
reduction of proteinuria by dietary protein restriction predicted the renal functional 
response to the diet. Bjorek (1986) Apperloo (1994) and their colleagues showed that 
pharmacological interventions that slow the progression of CRF are associated with a 
reduction o f proteinuria. More recently, a large body of experimental evidence has
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suggested that pioteirama is not os% a marker of poor prognosis but may also be a 
mediator involve! in the progressive scarring process (Bruzzi, et aL, 1997, Eddy, 2001, 
Jafar, et aL  2001). Remuzzi ami Bertani (1998) postulated that the excessive filtration of 
macromolectiles, Including protein, into the glomerulus could accelerate sclerosis. Burton 
and Harris (1996) suggested that proteinuria might also cause tubular dysfunction and 
damage. Renal tubular damage caused by proteinuria can initiate inflammatory and 
fibrotie changes within the renal interstitram. The activation of proximal tubular cells by 
excessive exposure to proteins leads to their release of pro-inflammatory cytokines and 
chemokines as well as their release of proflbrotic growth factors such as platelet derived 
growth factor (PDGF) and TGF-p i (For review, Harris, 2000; Eddy, 2001; Waidle, 2001, 
2002). It was also hypothesised that mesangial accumulation of proteins may produce 
mesangial cell injury and pn ifisation  and consequently increases production o f mesagial 
matrix and gtomeralosclanwis (For review, Harris, 2000). Also, activation of tubular cells 
by proteinuria cm  stimulate their release of extracellular matrix (ECM) components, 
accelerating interstitial flbrosis (For review see, Hams, 2000). Consequently, proteinuria 
is, along with systemic hypeftenstoo, thought to he one of the most significant risk factors 
in progressive CRF. Increasingly, attention is paid when hypertension is treated in 
patients with CRF to lower proteinuria as well (Jafar, et aL, 2001, Adamczak, et aL, 
2002). Data from a European study suggested that the control o f systemic hypertension 
without the concomitant reduction o f proteinuria is ineffective (Locatelli, dtaL, 1996).
L2.2.6 Dxsiipidaemia
ft was postulated over twenty years ago by Moorhead and his colleagues (1982) that 
lipids could he toxic to both the glomeruli and the tubulointerstitium. Since, a growing 
body o f experimental and dtnscal data has supported this hypothesis (Altman, et crl, 
1999; Samuelsson, et d.., 1997). An association has Men shown between
hypercholesterolaemia and die pogressaon of diabetic (Krowieskj, et d ,, 1994) and 
noncbabetic (Samuelsson. et aL  1997) nephropathies. Hyperl ipidaemia can induce 
glomerular toxicity through the accumulation of Jow-densily lipoproteins (LDL) as well 
as oxidized LDL in the mesangiuin, leading to structural and functional changes in 
mesangial cells. Also, hyperiipdacmia increase glomerular capillary pressure, which may
contribute to glomerular hypertension and sclerosis (Keane, at aL  1988, Keane, 2000). It 
was also concluded that hyperiqsdcmia activates mesangial cells and lead to mesangial 
matrix accumulation (Keane, et a t, 1988). Harris and colleagues (1990) showed that a 
diet low in essential fitty acids protects against tubuiointeistitia! inilainniarion. Kees-Foti 
and co in M ’g t e  (1994) showed that free fatty acids lead to the generation of a JipM 
chemotactic factor, which attracts monocytes, and initiates tubulointerstitial inflammation. 
So a high level of non-essential fatty acids may play a role in the inflammatory and 
fibrotie processes in the renal inftevstitnm. Further, it was advanced by some that the 
nephrotoxicity of pcoteinsmaialfouimnuria may be linked to their lipid-carrying capacity 
(For review, Harris, 2000). lip ids rather than protein may fee toe culprit regarding 
tubulointerstitial Mlammatiem and fibrosis in heavy proteinuric states (Tor review, 
Harris, 2000). In experimental animals, there is a large number of experiments showing 
that the reduction o f blood ipkJs levels is associated with a protective effect on kidney 
scarring (Keane, 2000, Praga, 2002). However, similar data is still Jacking in humans 
with CRF, although a recent review analysts suggested that lowering lipids In patients 
with CRF may be beneficial (Fried, et aL  2001).
1.2.2.7 Smoking
Smoking has a deleterious effect cm renal function, as evidenced by the development o f 
mleroalbtmmusM and its progression to overt albuminuria in diabetic nephropathy 
(Chase, et aL 1991). Smoking o f 15 packkyear in non-diabetic patients increases toe risk 
of development of ESRD by 5.8 fold (Orth, et aL  1998). Haemodialysed diabetic patients 
who smoked cigarettes had higher systolic Wood pressure and fibrinogen levels and had a 
higher incidence o f myocardial infarction, than non-smokers (Biesenbach and Zazgomlk, 
1996). A  retrospective rouJticenrtre European case-control study stowed, that smoking is 
an independent risk facta? far ESRF in patients with both inflammatory and non­
inflammatory renal disease* Le. IgA gfomeralonephritis and polycystic kidney disease 
(Orth, et aL  2000). Smoking increases the severity of glomerulonephritis, particularly in 
men older than 40 and/or hypertensive patients (Stengel, et aL  2000, Regalado, et aL  
2000). Furthermore, it was reported in the Multiple Risk Factor Intervention Trial 
(MRFIT) study that smoking suesesses toe renal risk especially m toe male population
(Walker, et a!., 1992), The calculated relative risk for ESRF was found to be 1.69 for 
smokers as compared to non-smokeis (Shqji, et ah, 2001). The deleterious effect of 
cigarette smoking may be through exacerbation of other risk factors such as high blood 
pressure, proteinuria or hjperlipadbemia. Moreover, progressive kidney failure is 
associated with decreased, diminution of nicorine by both renal and non-renal 
mechanisms (Molander, et aL, 2CB0). Furthermore, it was postulated that smoking 
induces renal damage by increasing blood pressure, alteration o f intiarenaf 
hemodynamics and activation of tie  sympathetic nervous system. Discontinuation o f 
smoking improved renal prognosis, and is probably a very effective measure to retard 
progression o f renal failure CPiaga, 2002).
l,Z Z 8A lcoko f
It was reported that cross-sectional data from the 1983 (National Health Interview 
Survey) showed that hypertensive women consumed less alcohol than non-hypertensive 
women (Laforge, et aL, 1990). On the other hand, the same authors reported that alcohol 
consumption was significant^7 associated with a greater risk of hypertension amongst 
men. Moreover, beer consumption and spirits consumption above three drinkxday were 
significant predictors o f male hypertension (Laforge, et aL, 1990). The consumption o f 
more than two alcoholic drinks per day is associated with an increased risk o f ESRD and 
hypertension in the general population (Laforge, et ah, 1990). On the other hand, a lower 
intake of alcohol (< 2 dririksfday) did not appear to be harmful (Peroeger, et. ah, 1999, 
Parekh and Klag, 2001).. Trie mechanisms by which alcohol consumption leads to 
hypertension and, perhaps, renal disease are unknown.
1.2.2.9 Recreational drugs
Use of heroin and/or cocaine increases the risk of ESRD (Perneger, et. aL, 2001). After 
adjusting for patients" age, sex, race, socioeconomic status, and history of hypertension 
and diabetes, persons who had ever used heroin or other opiates (any amount) were at 
increased risk for ESRD (Perneger, et aL, 2001). There was also an increased risk for 
individuals who consumed crack cocaine, although it was difficult to dissociate it from
9
heroin consumption (Perneger, et <stLn 2001). The same authors suggested that cocaine 
might cause accelerated h p ste n sk n , acute renal failure from ihaMomyolysis, and 
progression o f jse-exisilng renal disease.
13 Mechanisms of progression of cferwic renal failure
13.1 G1 om ero J osclerosis
13J 3  System ic am i glom erular hypertension
As previously discussed, systemic hypertension not only induces CRF but also induces a 
faster loss o f ram! funtitkm in squired renal disuses and loss o f renal function 
associated with iwimal ageing (Adamczak, et aL, 2002). In the subtotal nephrectomy 
model of CRF, the loss of function of some nephrons leads to hypertrophy of the 
remaining nephrons and decrease of vascular resistance (especially the afferent renal 
arterioles) due to impaired autoregotelion. (For review see Dworfcin and Weir, 2000) This 
process leads to an increase m the glomerular capillary7 pressure o f the remaining 
nephrons (glomerular hypertension) (Anderson, et aL, 1986). It was postulated that there 
was a significant association between systemic hypertension aw! the increment of 
glomerular capillary pressure (For review see Dworkin and Weir, 2CWQ). The harmful 
effects of renal parenchymal disease, e.g. diabetes, mellitus and systemic hypertension, 
are a result of production or aDceasmaiiou of glomerular capillary hypertension, rather 
than induction of exteagtomerukr vascular injury or glomerular ischaemia. Histological 
examination reveals an increase o f glomerular volume and glomerular sclerosis in 
hypertensive patients (For review see Dworkin and Weir, 2000). fa the presence of an 
underlying nephropathy, the glomerular response to systemic hypertension is impaired 
(For review see Dwaririn and Weir, 2000). This leads to a rise in gkimendar pressure and 
progression of gkxoefulossxdenxdsL Studies suggest that the control o f glomerular 
capillary pressure protects against kidney deterioration with or without control o f 
systemic hypertension (Anderson and Brenner, 1987, For review, Anderson 2000, 
Dworkin and Weir 2000).
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Lowenstein and cow odm  (1970) also argued that systemic hypertension leads to 
ischaemia due to renal vascular disease which, in turn, leads to a decrease in glomerular 
perfusion/ischaemia. Gkmenilasclerasis induces efferent arteriolar hypoperfusion and 
hypoxia (decreased oxygen delivery) of the tubular cells and their release of cytokines 
such as TGF-pl, platdet-derived growth factor (PDGF), endothebn and vascular 
endothelial growth factor (VEGF) lOrphamdes, eta l.f 1997; Fine, e ta lf 1998).
Both systemic hypertension ard non-hypertensive injury? that cause loss o f single nephron 
units results in hypertension in the remaining glomeruli (glomerular hypertension).. 
Glomerular hypertension cm  lead to injury to the glomerular capillary' wall causing it to 
leak plasma proteins into the mine (Anderson and Brenner, 1987; Anderson, 2000).
13. L2 Rale o f proteinuria
Systemic and glomerular hypertension are both associated with proteinuria. Olson and 
colleagues (1985) demonstrated that glomerular hypertension leads to transudation of 
plasma proteins into the endothelial and subendotheliai spaces which can promote 
glomerular hyalioosis, thereby narrowing aid  occluding glomerular capillaries. Increased 
trafficking and accumulation of proteinaeious molecules in the glomerular mesangium 
may also contribute to the pathogenesis o f glomerulosclerosis (Bertani and Remuzri, 
1998). Reimke and Klein (1989/ showed that the increment of glomerular permeability to 
protein affected not only the glomerular mesangium but also the glomerular epithelial 
cells leading to structural and functional changes and this further increased the passage of 
protein molecules across the glomerular capillaries (For review, Harris 2000, Anderson 
2000).
13J 3  Renal hypertrophy
Loss of function of some of the nephrons leads to an increase in the size and cellular 
number of the remaining glomeruli (Wesson, 1989; .Anderson and Mey®; 1997). Several 
growth factors such as insulan-like growth factor-1 (IGF-1), epidermal growth factor 
(EOF), platelet-derived growth factor (PDGF) and TGF-pl are responsible for the
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hypertrophy and hyperplasia o f the remaining glomeruli (fine, et «a£, 1992). Glomerular 
hypertrophy has been t o  forward as a likely pathway to glomerulosclerosis (Ichikawa, et 
aL, 1986). These authors argued that it was glomerular hypertrophy rather than 
gJomeruJar hypertension that initiated and perpetuated glomerulosclerosis (Ichikawa, et 
aL  1986). Moreover, growth factors associated with hypertrophy Might he also 
instrumental in the glomerulosclerosis (Fogo and Ichikawa, 1989)..
Prominent amongst these growth factors, TGF-j31 is known to he a potent hypertrophic 
growth factor (Fine, et a l, 1992),. Increase in glomerular size (hypertrophy) along with an 
increased glomerular capillary pressure (hypertension) would lead to a significant 
increase in the glomerular capillaries' wall tension. Such an increased wait tension with 
the associated shear stress would initiate a cascade of events culminating in 
glomerulosclerosis (For review, Dwoikia and Weir, 2000). Initially, glomerular 
endothelium would fee most affected %  the haemodynamic strain It would initiate a local 
inflammatory response. Glomerular Inflammation with the acctsnnlatkMi of leukocyte 
and monocytes has to n  shown in immune and non-immune-mediated renal diseases 
(Erwig, et aL, 2000). Infiltration o f the glomerular tuft by monocytes leads to their 
interaction with glomerular ceils especially mesangial cells (Mene, et &L 2002). 
Mesangial cells are activated and proliferate in response to the release by 
monocytes/foam cells o f nffitogeoie growth factors such as PDGF (Johnson, 1994). The 
activation of mesangial cells has to n  linked to the trans-differentiation of these cells into 
myofibroblasts (Johnson, et 1991). These cells have been shown to release ECM 
components including interstitial collagen III. Stretching of the glomeruli by hypertrophy 
and hypertension is also likely to lead to the stretching of glomerular epithelial cells 
(Rennke, 1994). This would lead to the denudemeot of areas of the basement membrane 
not covered by the stretched podoeytes (Kriz, et aL  2001). This would facilitate the 
leakage of proteins and otter macromolecules Furthermore, the activation o f epithelial 
cells within the glomerulus has been shown to be associated with their release o f 
fibrogemc growth factors and BCM components. This would also exacerbate 
glomerulosclerosis (Kriz; 1996) Fibrogemc growth factors such as TGF-pi are likely to 
be involved in ail the stages of glomerulosclerosis including hypertrophy* inflammation 
and fibrosis (Basile, 1999)
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In sum m ary, the faypotks^ for induction of glomerulosclerosis have implicated 
glomerular hyperfiltration, hypoperfusion, glomerular hypertension, glomerular 
hypertrophy; nephrotoxicity’ of proteinuria and the role of growth factors such as PDGF 
and TGF-pL
1.3.2 Tubulointerstitial fibrosis (T it')
Local and systemic cytokines play a  role in the induction of TEL There are several cells 
responsible for the production of ECM (scar) in the kidneys. These cells are infiltrating 
macrophages (attracted by activated tubules as discussed above), tubular epithelial cells; 
peritubular capillary7 endothelial cels (after vasoconstriction or ischaemiaTiypoxia) and 
film>blastspencyTes These cells are resident kidney cells, migrating and transformed 
cells (For review, Jernigam and Eddy, 2000). The cells release fibrogeiric factors such as; 
TGF-pl, angiotensin II, endotM in I, TGF-a, PDGF, and FGF (For review, Jemigan and 
Eddy, 2000). Accumulation of ECM te d s  to obliteration of peritubular capillaries and 
the death of tubular cells due to isctaemia (Bohle, et al., 1981; Seron, ef a t, 2001) and 
consequently, progressive renal insufficiency (Jemigan and Eddy, 2000; Eddy, 2001). 
There is a good correlation between die severity of tubulointerstitial fibrosis and renal 
function (Bohle, et aL„ 1994)..
1.3. Z I Composition andformation o f in t erstitialfibrosis
Interstitial fibrosis is the result o f excessive accumulation of ECM in the renal 
interstitium. Matrix is composed o f both normal interstitial proteins such as collagen (L 
III, ¥ , ¥11, XV) and proteins which are normally restricted to the basement membrane 
such as collagen IV and laimmn (For review, Jemigan and Eddy, 2000). Two enzymatic 
pathways regulate matrix protem turnover. The first due to the activation of matrix 
metalloproteinases (MMP) ami the second initiated by the generation of pSasmm from 
plasminogen (For review, Brantom and Kopp, 1999). Plasmin cam degrade fibrin, 
iibronectin, and laminim (Liotta, et a l, 1981), and also activate tire gelafimase class o f 
MMPs (Wong, etaL, 1992). Furthermore, plasmin activates latent cottagenases and TGF- 
pl (Pollanen, et a t, 1991). Tissue and urokinase activators as well as plasminogen 
activator activate plasminogen. Imtersritiaj collagenases such as MMPs, degrade the
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interstitial matrix eolkgees (collagen I, II, III), stromelysin family members degrade the 
basement membrane proteins (collagen IV, V) and other proteins such as ftbronectin, 
gelatinases degrade basement membrane proteins and elastm (Norman and Lewis, 1996). 
Fuithennore, membrane type MMPs (MT-MMP) which degrade collagen III, fibronectm, 
laminin, have been descnbed (Norman and Lewis, 1996). Tissue MMPs are activated by 
membrane-bound MMP proteins and inactivated by tissue inhibitors of 
metallofroteinases (TIMP-1-3). Plasminogen activator inhibitor-! (PA1-I) inhibits the 
other coflagenolytic pathway by Inhibiting plasmin activ ation. During the course of renal 
scarring and interstitial fibrosis, there is a down-regulation of MMPs and npcegulation of 
then inhibitors, TIMPs and PAJ-I (For review, Jemigan and Eddy, 2000). These 
processes lead to decreased breakdown of deposited ECM and, consequently, increase in 
its accumulation in the scarred kidney. Transforming growth factor-p 1 has the capacity to 
directly inhibit MMPs and activate their inhibitors TIMPs and PAM. Therefore, TGF-^1 
stimulation of ECM synthesis as well as Inhibition of its breakdown would lead to 
irreversible renal fibrosis (Border and Noble, 1994, 1997 andBasile 1999).
Figure 4  Mechanisms leading to progressive renal failure.
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1.4. Transforming growth faetor-p
1,4.] Transforming growth factor-ft super fam ily
The transforming growth factor p superfamily (Table 1) is a protein group that includes 
bone morphogenic proteins (BMPs), activm/inhibins, that inhibit pituitary secretion of 
follicle stimulating hormone, Mullerian inhibitory substance (MIS), which is produced by 
the testis and is responsible for the regression of the Mullerian ducts (to induce 
development o f the female reproductive system), and DPP (deeapeotaplegic protein is 
part of the TGF-P superfamily that regulates Drosophila morphogenesis) (Leslie, 1999). 
The supertamily also includes glial cell line-derived neurotrophic factor (GDNF) and 
growth and differentiation factors (GBFs) (Leslie, 1999). Furthermore, this family 
includes the MAD system (the mother against decapentaplegic protein, which is part of 
the TGF-P superfamily that regulates Drosophila morphogenesis) and is also called 
Smad which are the downstream effectors of TGF-P I signalling. Smads molecular 
weights range from 42 to 60 kDa. The Smads have two domains, MH (Mad Homology7) 1 
in the amino terminal regions and MH2 in the C-terminai region (Massague, et: a l, 1997).
The Smad system includes, Smad], 2,3,5 and 8 which are activated by R1 (TGF-p type I 
receptor) sertiir kinase receptor o f TGF-p family including BMPs, DPP, and actcvins 
(Graff, et a l, 1996, Lm. et a l„ 1996 and Kretzehmar, et a l, 1997, Roberts 2002). Smad4 
is a common factor required for TGF-pl, activin and BMP signaling Smadh and SmadT 
are inhibitory' towards TGF-pl signalling (Massague, 1990) (Table 1). The immediate 
TGF-P family includes five members (TGFpl-5), however the mammaliait isoforms of 
TGF-P3 are three (1-3). The structure of these isoforms is nearly identical, as they 
contain nine cysteine residues and share 76 to 80% of the amino acid sequence (Figure 1 
and 2). Et was reported that the mature active form of TGF-p i structure conforms to a 
cysteine knot motif similar to nerve growth factor (NGF) and platelet-derived growth 
factor (PDGF) which do not belong to the TGF-p family and only share 10°/© of the 
amino acid sequence (Daopn, et aL, 1992; Schiunegger and Gruttei, 1992). This knot is
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held together by six cysteines joined together by three intra-chain disulfide bonds, which 
stabilize the beta sheet stands (Figure, X).
Table 1. Members o f TG F-pl sttpeefamily
! L igand Type LI 
Receptor
Type I  Receptor Receptor
regulating
Smad
Common
Smad
Lnkfhkory S a m i
\ \
TGF-p TpRJl ALK5(TpRl)
Smad2 iActivin ActJOI
ActRIfB
ALK4|Act®t!B Smad3
Smao4 Smad6BMPs ActRII
AdtRUB
BMPR1I
ALK2|AolRf}
AL!G(BMFR1A)
ALK(BMPR1B)
Smadi
SmadS
SmadS
SsssacTF
;
I i ? MKS(TSRI) Smadl
I MIS
1
AMHR ?  I ?
!
! ?
:
? ALK7 I! ?
1
(Kfuppef, etmL, 199$,
Abrrevmtiom: TGF-P: transforming growth factor beta; BMPs: bone morphogenk 
proteins; MIS: imiliedan inhMtory substance; ALK: activin receptor-like kinase; Smads: 
signalling mother against skeapentaplegie protein; AMHR: anti-MnSledan honnone 
receptor, AetR: Activin receptor type; TpR: transforming growth factor beta receptor
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1.4.2 Structure qfTG F -ftl
Transforming growth factor-pl is a dimeric protein of 25kDa (Figure 1}. It is secreted as. 
inactive form sailed latent pfeonsor molecule (LTGF-pI). The latent precursor molecule 
consists o f 390-414 amino acids and contains an amino-terminal hydrophobic signal 
peptide region called latency associated peptide (LAP), consisting of 249 residues 
(Hinck. etaL, 1996). The latent precursor molecule (LTGF-pl) contains 112 amino acids 
at the C terminal* which is the potentially bioactive mature region (Figure 2). The latent 
precursor molecule LTGF-pl is secreted as a large latent complex (LLCJ, bound via the 
LAP region to another protein called LTGF-p I binding protein (LTBP) (Miyazono, et a l, 
1991; Taflpale, et d ,  1995),. The Meat precursor molecule binding protein (LTBP) has 
an important role in the assembly and secretion of LTGF-pl and serves to bind LTGF-P 1 
to extracellular matrices to enable proteolytic activation (Nunes, et a t, 1997). Latent 
precursor molecule secreted without LTBP, is called the small latent complex (SLC) 
(Munger, et a l, 1997% The mature (active) form is derived from the latent form, which 
consists of two large polypeptide chains linked by a disulfide bond to the latent TGF-P 1 
binding protein (LTBP). The molecular mass of this complex is 210 kDa The latent 
precursor molecule is secreted and preeleaved mtracefluiarly at dibasic residues located 
between the LAP and the mature region.. The LAP portion blocks the activation of the 
bioactive domains by keeping its folding. The folding of the bioactive domain assists by 
giycosyiation of LAP, which undergoes mannose-6-phosphate addition at N-termina! 
(Schultz, et a l, 1995).
t?
Figure i ,
(h ttp^/epokme.
m
Figure 2, Cartoon o f latent TGF-$l
(Nunes, efaL, 1997)
>  LTBP 
*  LAP
-^TGF-pl
Abbreviations: LTBP: latent precursor molecule binding protein; LAP: latency associated 
peptide; TGF-p: transforming growth factor beta.
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Table Z TGF-fil protein sequentce
?Key (From T& Length |l> es€rip tio!i
SIGNAL !l 23 23 b w iO T M I.
PROPEP ! m  r m '255 BY SIMILARITY.
CHAIN 127939© 112 t g f ^ l
DISVLFID 285 294 BY SIMILARITY.
hnSULFID 1|293356 |®F SIMILARITY.
DISILFID i'322 3S7 1 BY SIMILARITY.
ID1SVLFID 1326 389 B Y  SIMILARITY.
DISILFID 1355 355 |;INTE8€HAIN.
CXRBOmJ) *2 82 ............. P-LIMKED {POTENTMLY
CAMBOHYD 1136 136 '^-LINKED (POTENTIAL\
CARBOHYD 1176 176 ■'A | 1 'T*
JSITE 1244 246 b ICELL ATTACHMENT SITE iPOTESTIAlX
1 0
!i
2 0
ii
3 0
>
4 0
i
5 0
n
6 0
1!
M P P S G L R L L P L L L F L L K L L V
!
l y p g r p a a g l
1
S T C K T  I B M E L
8
¥ K R K R I E A I R
1
© Q X L S K L R . L S
7 0
ii
8 0
n
9 0
i
1 0 0
it
1 1 0
H
1 2 ®
j!!
S P P 5 Q G E W P
II
V P L P E A V L K L
8
Y N E S T R D R V A G
1
E S & E P E P E P E
5
A D Y Y A K E V T R
1
F I L M V E M T N K I
1 3 0 1 4 0 1 5 0
!l
1 6 0
ii
1 7 0
ii
1 8 0
ii1
Y E K V K K S F B 5
1
I Y M L H N T S E L
8
K E A V F E P V L L
8
S R A E L R L L R L
S
K L K A E Q B V E L
II
Y Q K Y S M D S W R
1 9 0
ii
2 0 0
ii
2 1 0
ii
2 2 0
«
2 3 0
ii
2 4 0
iiII
Y L S M R I M P 5
Ii
D T P E M L S f W
1
T t S W R Q W L S H
8
G G E V E G F R L S
II
A H C S C D t S K D N
II
T L Q V D I M G F S
2 5 0
ii
2 6 0
ii
2 7 0 2 8 0
8
2 9 0 3 0 0
»i!
S S R R G D I A T I
II
H ' S M M K P F I J U L
1
M & T P L E R f i Q H
1
L H 3 S R Q R R A I *
II
s h t c c f s s t e
1
K 1 1 C C V R Q L Y I
31® 32® 330 34® 350 36®
i 1 8 I I 1
B F m B M g t m i m p m m m P C X S P C F T I W S L D Y Q Y 3 K V X * J T C R S Q f f l S P & i S A A F O C Y F Q &
390
I  t  ILEFLPiwsfv m m m s^cs
(Derjnck et ak. 1995}
Note: blue sequence sham  the potentially bioactive mature region
1.5 TGF-pl activation
The activation of TGF-pl requires plasmin, thrombin, tissue transglutaminase, 
endoglycosylases and ittincHe acid (Sato, et al, 1990; FlaumenhafL et aL, 1993; Nunes, et 
ai, 1996; Rifkin, et aLn 1999). These compounds, in addition to ttam bospondinl (TSP-
1), activate TGF-pl through a specific binding interaction that alters the conformation of 
LAP (Ribeiro, etaL, 1999) It has teen suggested that the presence of T5P-1 may prevent 
reformation of the inactive latent TGF-pl complexes because when TSP-J is bound to 
LAP it cannot rebind active TGF-pl to confer latency (Ribeiro, et a lK 1999). There are 
two matrix proteoglycans, deeorin and biglycan, which bind TGFps for retention in 
extracellular matrices a te  may play a role in the regulation of TGF-pl feio&vailability 
(Yamaguchi, et dL, 1990; Border and Noble, 1994). Transforming growth tactor-pi is 
then activated by proteolytic cleavage to 112 amino acids. The structure contains nine 
strands, which foim four fingers and three helices. It was thought that the function of 
LTBP is just a carrier for TGF-P, butRusslahti and Pierschbaeher (1987) showed that the 
LTBP contains an endothelial growth factor like domain (Arg-GIy-Asp sequence) which 
mediates the interaction with connective tissue substances such as integral,
L5.1 TGF-p receptors
Three TGF-p receptors b ite  TGF-ps. TGF-p receptors distinguish between the TGF-P 
inform s a te  bind these ligates with different affinities (Cherfetz, et aL„ 1990; MacKay 
and Danielpour, 1991). These receptors are termed type I (RI) (50-60 kD) ranging from 
503-532 amino acids, type II (RIl) (75-85 kD) consisting of 567 amino acids and type III 
(Rilbbetaglycan) consisting of 849 amino acids (280kD) (Lin, e t 1992). The TGF-p 
receptors exist as surface binding proteins (Lin, et a t, 1992; Massague, 1992; Kingsley,
1994). Both RI a te  RII are transmembrane signal-transducing receptors which contain 
serine/threonine kinase cytoplasmic domains (Kingsley, 1994; Newfeld, et aL„ 1999). RI 
and RII kinase domains share 40% amino acid homology (Kingsley, 1994; NewfeldL et 
al,, 1999). RII contains active kinase and cooperates functionally with RI Glycine-Serine 
sequence referred to as the GS domain (GS) is a highly conserved j  uxtamembrane region.
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which plays an important role in the signal transduction pathway (Visser and Themmen,
1998). RII binds to toe ligand consequently, phosphorylates and activates RI which 
initiates toe signai-transduction (Attisano, et a t, 1993). RBI is a non-signalling receptor 
and it plays a role in concentrating TGF-p ligand on the surface of cells and in presenting 
TGF-pi-3 to toe signaling receptors (Lopez-Casillas, et a lr 1994). Type III receptor 
consists of a core protein (11©-139 kD) bound by side chains to chondroitin sulphate and 
heparin. Receptor type HI also can be released by cells and acts as a soluble inhibitor of 
TGF-jls regulating their activity (Lopez-Casillas, et a i, 1994). Eodeglin is another non- 
signaling receptor, which binds TGF-p to Rffi/betaglycan (Letamendia, et a l, 1998). 
EndogJin binds TGF-p III and it is found on endothelial ceils, macrophages, and stromal 
ceils (S t Jacques, et aL, J994; Lastres, et a i, 1996). Endoglin (a receptor with significant 
homology to the type HI receptor) is a homodimeric cell suffice glycoprotein that 
complexes with RI and RII (Zhang, et aLr. 1996).
1.5.2 TGF-pl signal transduction pathway
Signal transduction is the mechanism by which TGF-P I induces its function (Figure 3). 
Transforming growth facior-g receptors and Smads are required for signal transduction 
(tor review, Roberts 2002). Transforming growth iactor-gl binds to R II This leads to a 
phosphory lation and subsequently activation of RI to initiate its downstream signal 
transduction. Consequently?, RI directly interacts with phosphorylated Smad2 at C 
terminal serines (Madas-Silva, etaiL, 1996). Smad2 phosphorylation occurs at C terminal 
MH2 domain on ser465 and ser467 of the SSXS motif (the site of phosphory lation that 
occurs on the last two serines o f a conserv ed SSXS motif at the carhoxy terminus of the 
Smad protein). This leads to phosphorylation of Smad3. Smad I and 5 are activated 
directly by RL Smad2 and 3, activist, and form a hetero-oligomeric complex with Smad4 
(Chen, et aL, 1996). The complex (Smad2, Smad3 and Smad4) enters the nucleus and 
acts as a transcriptional activator o f genes involving TGF-g] function. The Smad MHI 
domain binds to DNA through toe DMA binding motif which is composed of an II- 
residue haiipn turn that forms a loop that fits into the major groove of specific DNA
sequences (Shi, et a l, 1998). Smad 4 hetero-oligomensation is absolutely essential tor 
the €  terminal domain of Smad 4 to perform its transcriptional transact! vating function. 
This process needs a nuclear protan (orphan) that interacts with Smad 4 to mediate 
transcription (Shioda, et a t, 3998). Smad 4 plays an important role in promoting the 
binding of the Smad2/$mad4 (DNA binding partner) complex to DMA through its M 
terminus and in promoting transcriptional activation by Smad i and 2 through the Smad 4 
C terminal region. The Smad 3/Smad4 hetero-oligomeric complex has been shown to 
cooperate with c-jun/c-fbs to mediate TGF-pl transcriptional responses (Zhang, et a t,
1998). Also, there is m  intracellular protein called the Smad anchor for receptor 
activation (SARA) (Zhang, et a l, 1998). This protein plays a role in recruiting 3mad2 
and SmadB to the TGFp receptor complex (Tsukazaki, et a l, 19981 TGF-p 1 is not bound 
to RII in the absence of R1I1 (i.e. TGF-P2). Moreover, RIII acts as a soluble inhibitor of 
TGF-p isofonns and consequently prevents their activity. On the other hand Sniad6 and 
Smad? bind to RI (without phosphorylation) and consequently inhibit RI binding to 
Smad2 or Smad3 and signaling (Massague, 1990) (Figure 3).
23
Figure 5. TraMisforrmng growth faetor-beta (TGF-fil) signalling pathway
Type l Receptor
Cosmati
fejSUDK}'
(http: : irww.gyLkymku-eLOcjp spmi -pathway-' tgf-hetaJitm)
Abbreviations: GS: Glyane-Serine sequence; P: phosphorylated head; Smad: signalling 
mother against decapentaple|pe jrotein.
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1.6 The role of transforming growth factor-pi 
1.6. I Tramjbrmi ng growth factor-jit m health
Transforming growth factor-pi expression was observed in normal gkmerafi (Ando, et 
a l, 1995; Yamamoto, at a l, 1996) renal tubules, and the mtefsthxum (Ando, et al.,
1995).
Transforming growth iaclor-P isoionus are expressed firstly in embryogeoesis (Pehon, et 
aL, 1991) and crania! development (Roth, et al., 1997). Transforming growth factor-pi 
plays a major role not only in vasculogenesis, but also in maintenance of blood vessel 
wall integrity during emfer^genic development (Kulkarni, et a l, 3993, Oshima, et aL
1996). Transforming growth teetor-p I was found also to arrest the growth of most 
epithelial cells, neuroectodermal cells, hepatocytes, lymphocytes, myeloid cells (Moses, 
et a l, 1991, Massagpe, et a l, 1992 and Alexandrow and Moses, 1997) by Mocking cell 
cycle transit late in the Gl phase o f the cell cycle (Han, et a l, 1993).
Transforming growth fector-pi plays a role in inflammation and tissue repair (Spom and 
Robert. 1992; Roberts, 1998) The physiological function of this observation is unclear 
but TGF-P 1 levels could contribute to the maintenance of the im nm i glomerular 
microenvironment (Massagpe, 19901 Under normal conditions, remodeling of the tissue 
(synthesis and degradation) is under the control of several enzymes (Brantan and Kopp,
1999). Plasminogen,, which is produced by liver and kidneys, is delivered by circulation 
to other tissues. Ptasmin, which is the active form of plasminogen, degrades fibrin, 
fibronectin and laimimn (Liotta, ei a t, 1981) Moreover, it activates MMP, latent 
colkgeoase and TGF-pl (Pofiaiien, et a l, 1991 and Wong, et a l, 1992) Transforming 
growth fector p i also inhibits the pksmin system (Tomooka, ei a t, 1992) In response to 
a wound, TGF-P I is activated in two stages. The initial activation o f latest TGF-pl 
occurs within an hour, followed %  the second activation within several days (Yang, et 
aiI 1999) Furthermore, Pelton and colleagues (1991) found that TGF-p l is increased in
keloid and Ghahary and colleagues (1993) reported a similar increase associated in 
hypertrophic scars from bums .
Experimentally, injection of TGF-pl into wounded rabbits induces a fester rate o f wound 
eprtheiiahzafion and wound contraction than controls (Pandit, ei aL, 1999), The role of 
TGF-P 1 was found to be enhancement of fibroblast activity to contract (Montesano and 
Qrti, 1988), Mot only the systemic administration of TGF-p 3 but also its local application 
improves the tensile strength o f the wound healing scar (Becks, et a l, 1993), 
Interestingly, and surprisingly increase o f circulating TGF-pl in mice induced a decrease 
of scarring of the wound, a finding reflecting that the circulating TGF-pl may not 
substitute the local (tissue) TGF-pl (Shah, et a l, 1999). This finding shows the 
dissociation between circulating and tissues levels of TGF-pl.
L6.2 Transforming growth factor-fii and fibrosis
Transforming growth factor p i stimulates the production of fibronectin, collagen, and 
proteoglycan in fibroblasts (Border, et a l, 3990). Border and Ruoslahti (1992) showed 
that fibrosis is a form of inappropriate injjwy repair and its development leads to tissue 
dysfunction and organ failure. Fibrosis represents an excess o f normal repair process that 
follows tissue injury. Spom and Roberts (1992) showed that TGF-pl has a role in tissue 
repair, and has a fibrogenic effect
This is because TGF-pl stimulates the deposition of extracellular matrix by:
1 Stimulation of the synthesis ofECM e .g. fibronectin, coilagens and proteoglycans;
2 Inhibition of proteases, tissue and urokinase activators as well as stimulation of 
plasminogen activator inhibitor (see composition and formation of interstitial scar) 
and consequent blocking of the degradation of the ECM;
3 Modulation of the expression o f integrin receptors on the cells and, consequently, 
matrix deposition by stimulation o f  TIMPs and plasminogen activator inhibitor.
Furthermore, TGF-P 1 induces proliferation of human renal fibroblasts: this process is 
mediated largely by fibroblast growth factor-2 (Strutz, et a l, 2001). The Induction of
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proliferation by TGF-pl via induction of FGF-2 may play an important role In the 
autonomy of renal fibroblast growth and, thus, in the pathogenesis of human fibrogenesis 
(Strutz, et aL„ 2001). If has also been postulated that TGF-pl exerts its fibrogenic effect 
through the induction of connective tissue growth factor (CTGF) (Kothapalli, et a l,
1997).
One model for pulmonary fibrosis was induced by administration o f bleomycin in rats. 
The total lung TGF-pl content in these rats was several times higher than that in normal 
rats, which in turn increased the synthesis of collagens, fibronecfla, and proteoglycans 
(Westergren-Thorsson, et a l, 1993). Alveolar macrophages produce TGF-P 1, and this 
production could cot be suppressed by high-dose corticosteroid treatment. This finding 
might be the explanation for the ineffectiveness of this treatment in patients with 
idiopathic pulmonary fibrosis (Khalil, et a l, 1993).
In humans, it was found that the TGF-P 1 protein levels increased in alveolar walls at the 
sites at which ECM have accumulated in idiopathic pulmonary fibrosis (Broekelmann, et 
a l„ 1991). Compared to norma? subjects or patients with asthma, the bconchoalveolar 
cells obtained by lavage from patients with autoimmune diseases and lung fibrosis 
contained 10 times more TGF-pl mRNA (Deguchi, 1992).
Czaja and eoworkers (1989) found that liver mRNA for type I collagen (the predominant 
matrix component In injured liver) was Increased in cultured rat hepatocytes incubated 
with TGF-PL Also, the amount of TGF-p 1 mRNA closely correlated with type I collagen 
mRNA in liver specimens from patients with chronic liver disease (Castilla, et a l, 1991). 
Chen and Colleagues (2002) also reported that there is a positive correlation between 
TGF-p I mRNA concentrations in the liver and the histological activity o f the liver 
disease. In chronic liver disease, TGF-P I immunostaining was detected in fibrotic areas 
rather than areas with inactive disease (Nagy, et al., 1991). Plasma level o f TGF-pl was 
found to be highly predictive of the development of hepatic fibrosis (veno-occlusive 
disease) in the recipients of bone marrow transplants (Anscher, et al 1993). The level of
expression of TGF-pl is closely correlated with liver fibrosis associated with viral 
hepatitis (MurawukL et at* 1998).
Transforming growth fador-pl and collagens are increase m  tissue sections from 
patients with systemic sclerosis (Kukxzik, et a l, 1990). Transforming growth faetor-pi 
was also found to be increased m stenosed arteries of both rats and humans fJNakol, et a l, 
1992, W olf et a l, 1994). On the other band, TGF-p i has t e n  known to have an anti­
inflammatory action (Park, et al,., 2000). It down-regulates the inflammatory cytokine- 
induced expression o f VCAM.-1 in human glomerular endothelial cells, which could be 
the mechanism of its anti-inflammatory action in human glomerular diseases (Park, et a l,
2000) Furthermore, TGF-pl inhibits proliferation of most cell types, including epithelial 
endothelial, asrd haematopoietic cells (Roberts, 1998). Inhibition o f renal tubuhr 
epithelial cell proliferation fey TGF-P I may promote the tubular cell hypertrophy that is 
characteristic o f tabuloirtarstitial fibrosis (Roberts, 1998). Moreover, TGF-p and 
angioteossB II produced locally cm- delivered in the circulation, appear to play a central 
role in renal fibrosis (Figure 4). Tiansfonning growth factor-pl plays an important role in 
regulating the immune response as it was postulated that the knockout mice die from 
cardiopulmonary inflammation within weeks of weaning (KulkarnL, et aL, 1996).
In TGF-pi transgenic mice (TGF-pl gene under promoter control o f murine albumin), 
the highest level o f the TGF-p l was found in the liver and also had high (> 10-foSd over 
control) plasma levels o f TGF-pi. Fibrosis and apoptotic death also developed in the 
fiver (Kanzler, et a l, 1999). The fiferotie process was characterized by deposition ©f 
collagen around individual hqpatocytes and within the space of Efese in a radiating linear 
pattern. Several extrahepatic lesions developed. Including glomerulonephritis and renal 
failure, arteritis and myocarditis, as well as atrophic changes in pancreas and testis 
(Sanderson, et a l, 1995). Furthermore, TGF-pl mediates pancreatic fibrosis through 
activation of pancreatic stellate cells and deposition of collagen ripe I and III at early 
time points (VogeJmamy et a l, 2001). The results from this transgenic model strongly 
support the proposed aetiolomcal role for TGF-P 1 in a variety o f fibrotic and 
inflammatory disorders.
Figure 4, The m le o f dijfgreat eytoMnes m  induction o f fibrosis
(Brenner and Keane, 2001. wwr, kmertemmnonfine oret
Abbreviations: TGF-p: Transforsnsiisg mzmth factor beta., ET1; eodofcbrfii! 1, CTGF: oonoective tissue 
growth factor, Aug EL ai^otorasm II, PA1-1: plasminogen activator inhibitor 1, PDGF: platelet derived 
.growth factor, hFGF: baric Sferoblast .growth factor, TMF-a; tumour necrcMiring factor alpha, 1L-1; 
iiiterieukin L
1.6-3 Transforming growth factor-01 acid renal diseases
1.63.1 Glomerulosclerosis
Transforming growth taetor-pl is the stogie most important fibrogenie growth factor in 
the pathogenesis of giomeniioscierosis (Border and Noble 1994, 1998, Peters, et aL, 
1997, Basile 1999).
Transforming growth faetor-p! exerts its various effects within the glomeruli through 
interactions with its two receptors (type 1 and JJ). These receptors are expressed on 
glomerular endothelial and mesangta! cells. Two intracellular signal pathways have been
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implicated to mediate the effects o f TGF-pl on renal cells. These consist o f the Smad 
family of proteins ami the nntogen-activated protein kinase (MAPIC) family (Chin, et a t, 
1999), Recent data has shown Smad2 and Smad3 activation by TGF-pl in human 
nsesangjal cells with icsultent increased collagen transcription (Grin, et a l, 2001).. 
Mitogen-activated protein kinase proteins include three groups inelwSng extracellular 
signal-regulated Mouses (ERK), c-jun N-terminal kinases and p3i MAPK. In mesangial 
cells, the adivation by TGF-P I o f ERK and p38 leads, to increased collate11 1 
tenscription (Chin, cf a t, 2001).
163.1 Experimental evidence
The first evidence for the tote o f TGF-pi in increasing the procfacftoft o f ECM was 
increased production of ECM ptcietns, inhibition of protease activity, and increased 
iutegrin expression. These were obtained by incubation of normal glomemb, mesangial 
ceils and nonrenal ceils with TGF-pi (Okuda, et al-., 1990, T om od^ et ai.* 1992, for 
rev iew Border and Noble 1.994, Basie, 1999).
Transforming growth fector-pl induces phenotypic changes in rat mesangial cells in 
vivo, with the expression o f the a-sssaooih muscle actin (Imai, et ai. 199% This may lew! 
to a switch in the type of collagen synthesized by these cells. Changes in mesangial (a- 
smooth muscle actio) and epithelial (desmin) cells can a lso be induced by the infusion of 
angiotensin II into rats (Johnson, et ai, 1992). O f note angiotensin H is known to 
stimulate the synthesis arid release by mesangial cells of TGF-P J (Johnsost, et a l 1992%
in a model o f acute gfomeraJonephritis in rats obtained by a single injection of an 
anti thymocyte antibody extracellular matrix accumulation replied maximum levels after 
2 weeks. The glomeruli returned to normal after 3 weeks (Gkuda, et a l, 1990). 
Transforming growth fador-pl is thought to inhibit the release of matrix 
metelloproteinases and stimulate the synthesis of their inhibitors (TKMPs) (Mazes, et a l9
1999). This would fiwour inevefsible ECM deposition. Mice transgenic for TGF-pl haw 
high circulating levels o f TGF-P 1 and develop proteinuria and progressive 
glomerulosclerosis leading to death from uraemia (Mazes, et aL 1999). This is associated 
with increased matrix (collagen I and III) expression within the mesangium along with a
30
decreased coliagenotytie activity due to increased synthesis o f TIMF1 (IS fold increase) 
(Mozes, et a l, 1999%
Transforming growth fsetar-pl is also a potent pro-apoplotk growth factor contributing 
to glomerular cells deletion. TGF-pl transgenic mice model (under promoter control of 
murine albumin) bad severe apoptosis of podocytes (glomerular epithelial cells), 
Apoptosis induced by pbosptKMylation of p38 and activation of caspiase-3, leading to 
adhesion o f glomerular capillaries to the Bowman's capsule and consequently 
glomerulosclerosis (Schtffor, et al,% 2001),
The second evidence was noticed fey neutralizing the effects o f TGF-P! fey adding anti- 
TGF-pl antibody This led to prevention of the accumulation of ECM (Border, et at1, 
1994, Ztyadeh, et aL„ 2000). Also, the natural antagonists, deeorin, for TGF-pl may play 
a modulating rote. A fall in the glomerular content of deconn, a natural proteoglycan 
antagonist of transforming growth faetor-pl appears to precede the development of 
experimental glomentiosderosis |For review, Basile, 1999).
The third evidence was through the transfection of the TGF-pl gene into normal rat 
kidneys which led to increased production of TGF-pl in glomeruli and, consequently, a 
rapid development o f glomerulosclerosis Osaka, et aL, 1993; tmaL et a i, 1994). The 
constant production o f TGF-pl leads to glomerulosclerosis fibrosis within weeks. This 
very closely resembles foe histological findings in humans with chronic 
glomerulonephritis (For review. Border and Noble, 1994, Basile, 1999).
The fibrogenic effect o f TGF-P I has also been attributed to the stimulation by7 this growth 
factor of another fibrogenic growth factor, connective tissue growth fe to r (CTGF). The 
up-regulation o f this growth, fe to r in mesangial as well as tubular cells has been shown 
to follow TGF-P I-dependent and independent pathways (Yokof et a t, 2002). In
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mesangial odls and fibroblasts CTGF mediates some of TGF-p l indues! increased ECM 
production fay autocrine modes o f action et a l, 200I f
Transforardng growth factor-pl simulates binding of bFGF to ECM, increase ECM 
heparan sulfate proteoglycan, and potentiate the mitogenic activity o f bFGF (Nugent and 
EdelmaiL 1992). Glomerular ©elk express FGF-2 receptors (FGFR-1 and FGFR-3). The 
infusion of high does o f FGF-2 causes mesangial proliferation as well as 
glomerulosclerosis (Floege, etnA 1993; Khz, e ta l 1995%
1.6*3.2 Clinical evidence
In mesangial proliferative glomerulonephritis, TGF-pi Intensity estimated by 
immuisotestcxrhemlsfiy was closely correlated with the amount o f ECM mesangial matrix 
(Yoshioka, etaL, 1993).
Glomeruli of patients with diabetic nephropathy had increased TGF-pl protein and 
matrix proteins (Yamamoto, et a l, 1993).
The levels of renal TGF-pi protein are increased in diabetic (Iwaro, a  a t, 1996) and 
non-diabetic kidney disease (Sufaria, et a l, 1998). In human Immunodeficiency virus- 
associated nefiirofMtiy; chitMik allograft rejection and radiation ncfiiropa^; increased 
TGF-p I has also reported pM ta, et m l 1999).
Urinary7 TGF-P 1 levels are increased in focal glomerulonephritis (GNX meantenous GN 
and interstitial fibrosis but the results are not sufficiently7 consistent to establish a precise 
and predictive correlation (Honfcanen, et a l* 1997; Murakami, et a l„ 1997).,
Tuhulointerstitialfibm sis
Increased expression of TGF-fSl has been detected within most forms of experimental 
and clinical nephropathies associated with interstitial fibrosis (For review, Basile, 1999). 
Transforming growth faetor-p 1 can be derived from tubular cells, infiltrating 
macrophages as well as renal fibroblasts. Transforming growth factor-pl has a high 
affinity to ECM which acts as storage areas for this growth factor. For its activation TGF- 
pi has to be released, from the associated latent TGF-p 1 binding protein (LTBP) and the 
smaller latency associated protein (LAP). Once activated, TGF-P1 is fibrogenic through 
the stimulation of renal tubular as well as fibroblasts synthesis of ECM as well as the 
capacity of this growth factor to inhibit ECM breakdown through the stimulation of 
TIMPs. Many of the fibrogenic effects of TGF-p1 appear to be mediated through 
connective tissue growth factor (CTGF) (For review, Basile, 1999).
Transgenic mice for active foam. o f TGF-pl under promoter control of murine albumin 
and enhancer DMA sequence showed highest expression of TGF-pl in the liver. This 
mice model also had elevated plasma TGF-P I levels and consequently 
glomendosderosis and interstitial fibrosis (Kopp, et «/., 1996). Interventions aimed at 
neutralising TGF-pl through the administration of neutralising antibodies or small 
molecular weight proteoglycan antagonists such as decorin have been effective in 
attenuating interstitial fibrosis in rats with cresentic glomerulonephritis (Stokes, et at.. 
2001).
Basic fibroblast growth factor (bFGF) is also thought to be a fibrogenic growth factor. It 
can act directly or indirectly through the stimulation of tubular TGF-P I release. Basic 
FGF accumulates, like TGF-p 1, in areas of interstitial fibrosis. Recently it was shown 
that TGF-P 1 works through induction of FGF-2, which leads to hypertrophy of 
fibroblasts (Struts; et c$L 2001).
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Bone morphogenic protein-? (BMP-7) is a member of the TGF-p superiamily and has 
been localised to the collecting ducts (Lund, et a l 2002). Proximal tubular and collecting 
duct cells express the type IT BMP-7 receptor (Kopp, 2002). The administration of BMP- 
7 to rats with unilateral ureteral obstruction preserved tubular epithelial integrity; 
inhibited tubular eel! apoptosis and prevented interstitial fibrosis (Piscione, et a l, 2001).
Circulating TGF-pl is higher in African-Americans than Caucasians (Tell, et a lf 1996; 
Suthanthiim el atL, 1998% The increased circulating TGF-pl is associated with 
hypertension, tubuiointerstitial fibrosis and glomerulosclerosis (Bottinger and Kopp,
1998). Circulating TGF-pl is higher m the hypertensive than those with normal blood 
pressure in Afro-Caribbean (SuthaMhiran, et a l, 1998).
It can be concluded that TGF-pl increases deposition of extracellular matrix proteins, by 
several mechanisms:
1) TGF-P 1 stimulates production of several growth factors including basic 
fibroblast growth factor-2 (FGF-2), and connective tissue growth factor 
(CTGF) that stimulate the tbrmation of extracellular matrix (ECM) proteins 
(Strufcz, ei aL  2001).
2) TGF-pi also has a direct effect on ECM protein expression (Tabibzadeh, 
2002>
3) TGF-pl stimulates the formation of the receptors (integral) to which ECM 
proteins adhere (Yastida, et aL„ 1996).
4) TGF-pl increases the expression of tissue inhibitors o f mefalloproteases 
(T1MP) that in ten , prevents proteases from degrading ECM proteins 
(Ichikawa, e ta l, 1996).
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Figure 5. The role o f TGF~fit m  induction o f fibrosis
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t o  f i b r o s i s  a n d  l o s s  
o f  n e p h r o n  u n i t s
(Brenner and Keane, 2001, i^vwm layi^rtensaeMniline org)
Abbreviations: TSP-J: Thrombospondin 1, Ang II: angiotensin II, bFGF: basic fibroblast 
growth factor, PDGF: platelet derived growth factor.
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1.7 Genetic aspects of chronic renal failure
Mew molecular genetics techniques have proved extremely powerful tools to investigate 
the links between genetic susceptibility and the progression of chronic renal diseases. 
Two research strategies have been applied to detect associations. The first is based on the 
candidate gene approach aiming to detect an association between a particular 
polymorphic DNA marker related to a gene coding for a factor thought to fee involved in 
the progression of chronic renal disease. The second approach is based on the genome- 
wide search o f unknown genes potentially associated with progressive CRT. In this 
approach, several hundred highly polymorphic microsatellite markers are tested for co­
inheritance with the disease (Sehork, 1997).
Several candidate genes have been investigated to seek a relationship between genotype 
and the initiation or foe progression of CRF (Table 3 ).
Table3. CamUdate genes in ESRD (For review, Buraczynska and Kskt^ek, 2001)______
Gene i ' jMechanism
. . .
| Vasoactive mediators:
Renin-a ngiotemi n  system
1) angiotensin I converting enzyme (ACE) 
j angiotensinogen (AGT)I  angiotensin type 1 receptor (ATI R)i1
!
Effect on tissue temodynamics 
and glomerular cell function
: nitric oxide synthase (NOS)
| endothelin (ET)
j mefoylenetetrahydrofolate reductase J (MTHFR)
Regulation of vascular tone 
Homocysteine metabolism
!
1Kallikrein-kinsji system Inflammatory  ^processes
j Growth factors and cytokines;
1 interleukin 1 (IL1) j  Kidney mesangial cell prolife- 
I interleukin 1 receptor antagonist (IL lia) rat ion.extracellular matrix 
tumour necrosis factor (TNF-(a ) production, 
transforming growth factor (TGF-p ) 1 Role in renal hypertrophy
i ii
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Molecular genetics studies might give a clue tor the causative or initiative factor of ESRF 
(Table 4).
Table 4, Genetics polymorphisms afESRF
Gene fam ily Associations reported References
\ Reniri-angiotensin system
j  ACEgenefJ D) 
j DD
1
* Progression of diabetic nephropathy in 
type 1 and type II diabetes mellrtus
* Progression of ESRF in non-diabetics
* Progression of IgA nephropathy
* teriatmn of IgA nephropathy
* Progression of parenchymal damage an
rapadqf
* ImtiatkHi of the development o f focal 
segmental glomerulosclerosis
* Worsening o f polycystic kidney 
disease
1996; 
Vel/mifflg. e taL  1999 
Samaelsson, et al,, 200®; : 
Gumprecht, etaL, 2000, 
Lovati, el a l, 2001 
Tanaka, et a t , 199S 
Yorioka et a l, 1995 
aS-JEisa, et atL, 2000
!H otf et td.„ 2001
!
Bsfeoofaf ei a l, 1997v 
Perea-Oller, et a lT 1999
angi&temin&gem (AGT)
M235T (FT)
ATJR (A iim :)
(ACJCC)
* Iniriatioa of the development of diabetic | 
nephropathy in type I diabetes meliitus ;
* Progression of CRF in non-diabetics
* Susceptibility o f CRF J
Rogers, et al., 1998
Lovasti eiaLr 2001 
Toroino. el a l, 1999; 
Buraczynska, o f,2001; 
Filler, et al. , 2001
Endothelial NO synthetase
GIu298A$p
\
!J¥©gressj©jns of type I and type II diabetic |
a q p in ^ t%  i
Fogarty, et al,, 1996; 
Freedman, et al, 1997, 
Loughry, et al., 1998
G ene fa m ily A sso cia tio n s reportedi j R e fere n c esMTHFR
! C677T (TT)
i,
1 Predisposition to and progression of 1 Kimum, et a l, 2000
I
A1298C (CQ Lower incidence of diabetic nephropathy
j
1, Shptetenetsky, et of.,
I 200©; Szabo, et ah, 2001
; ;KaLFtkrem-kmm &yf&em
C699A (CQ  
CIS IT  (IT)
Less essmmsm in CRF and protects fenm 
| progression to ESRF
:
Baehvaroy, eta/., 1998
.....1
| Growth factors and cytokines
ILIRN  
f IU B
j
* Development of diabetic nephropathy
* Progression to ESRF in non-diabetics
Hughes, et a l, 1996 
Freedman, et aL  1997,
L.ocjghrey; et a lr 1998 j|1
| TGF-pl
| LemlOPm
j Thr2631k 
| Arg25Pm
* development of renal failure in patients 
undergoing heart transplantation who 
mm prescribed cyclosporin and steroids
* development of nephropathy in diabetic 
patients
* increased both systolic and diastolic 
Mood pressure in ESRF patients
I
Bean etaL, (2000)
|
Picot, ettd., (1998)
L i etaL, (1999)
i M dodum drki geme
! A3243G mutatimt .Progression of CRF Iwasaki et a t, 2001
| Gitteme tmnspmtergene
( Xbal (+/+)
'
Development of albuminuria in type H
diabetes mellitus
Crzeszczak, et aL,: 2001
,4polipapmtein
ApoE2 andapaE4
1
Development of proteinuria in 
grootemlonepliritis
Cte^etaL, 1999
ApoE2
i 1
Ifevak^mtemr of ESRF Oda, et a t, 1999
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1.7,2 Vasoactive genes
1.7.2.1 Angiotensin I converting enzyme (ACE) gene
Angiotensin I converting enzyme gene at 287 bp has three genotypes at intron 16 (I/D) 
insertion/deletion sites. The patient may be homozygous for I allele (11), heterozygous 
(ID) or homozygous for D allele (DO) (Filler, et a l, 2001).
Cambien and colleagues (1992) showed that increased incidence of cardiovascular 
disease and increased salt sensitivity and consequent hypertension is associated with the 
insertion/deletion polymorphism- Berth II and ID genotype had a lower activity of the 
circulating ACE enzyme compared to DD genotype (Filler, et a l, 2001). Several studies 
showed an association with  both initiation and progression of CRF (Table 4). On the 
other hand, Grzeszczak and colleagues (1998) found that there was no association 
between the ACE gene I/D polymorphism and the development of nephropathy in type 2 
DM. There was also no significant association of this polymorphism and progression of 
CRF (Nakai et a l, 1997* G m prechf et a/., 2000, Aucella, et al., 2000, Sefcena, et a l,
2001). Many studies supported that there was no deviation in terms o f aileie frequencies 
(I/D) in CRF patients (non-diabetics) from normal controls (Hashimoto, et a t, 1998, 
GtimprecM, et a l, 2000, Schema, et a l, 2001, Lovati, et a l, 2001).
For some forms of glomerulonephntis, ACE gene polymorphism may not influence the 
extent of acute mesangia! proliferation and crescents formation. However, the ID/DD 
genotypes are associated with chronic lesions, such as capsular adhesions or 
glomerulosclerosis (Tanaka, e l a l, 1998).
Homozygosity for the D allele implies a worse renal prognosis in adult polycystic .kidney 
disease (ADPKD), based on both the significantly lower median renal survival time and 
significantly greater percentage of patients who reach ESRD before the age of 50 years, 
without implying a greater prevalence of hypertension (Baboolal, et a/.., 1997, Perez-
39
Oiler, et id,, 1999), The date from ACE gene polymorphisms studies in polycystic kidney 
disease (PKD) remain controversial (Hashimoto, et a l, 1998; Lee, etaL , 2000).
J. 7.2.2.. 4 ngiotensinogen gene and angiotensin type 1 receptor
Atfgiotensmogeft gene (ACT) polymorphisms are involved in the regulation of Wood 
pressure and, consequently , have teen investigated for association with induction of 
nephropathy (Rogus, et id., 1998). A point mutation in the angiotensinogen gene resulting 
in substitution of the amino acid threonine for methionine at position 235 (M235T) is 
associated with essential hypertension (Jeunemaitre, et al., 1992), The frequency of the M 
aJJeJe was significantly higher in patients with diabetic nephropathy than in diabetic 
patients without renal involvement The AGT-TT genotype was associated with a fester 
progression to ESRD in patients with glomerulonephritis (Rogus, et a l, 1998, Lovati, et 
a l, 2001), On the other tend, there were no significant associations of AGT 
polymorphisms with regard to the slope of 1/creatinine before or after renal 
transplantation (Yoshida, et a l, 1996, Filler, et a l, 2001).
The C allele in the angiotensin type 1 receptor (AT i R) gene polymorphism increases 
the susceptibility of chronic renal disease (Table 4) (For review, Buraczynska and 
Ksiazek, 2001).
L 7.2.3 Nitric oxide synthase and mdothelin genes
Nitric oxide (NO) and endottelin (ET) are mediators that are release! in inflammation 
and regulate vascular tore and Wood pressure (For review, Freedman, et a l, 2000). 
Abnormalities in NO and ET-1 metabolism or synthesis were revealed to have a rote in 
initiation and progression of CRF, regardless of the cause (Freedman, et id., 2000).
The allele A (AIB) at intmn 4 o f etefothelial constitutive nitric oxide synthase (ecNOS) 
occurs significantly mom frequently in cases with ESRF caused by diabetic and non­
diabetic nephropathy (Asakimori, et n l7 2001; Yokoyama, et aL, 1998).
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Moreover, the Glu298Asp mutation (G—>T) in exon 7 of NOS3 was common in ESRD 
patients regardless of the nephropathy cause (Suzuki, et aL, 2000).
1.7.2.4 Methylenetetrahydrofoiate gene
Hyperhomocystememia is frequent among patients with renal M ure. Furthermore, it can 
accelerate the progression of CRF (Gupta and Robinson, 1997) The C to T mutation at 
C677T in the gene encoding methylenetetrahydrofoiate (MTHFR), tends to decrease 
MTHFR activity, and consequently elevate circulating homocysteine levels in patients 
homozygous for die T allele (TT) (Kimura, et iiL, 2000). The same authors also revealed 
that the homozygous (TT) patients were more likely to develop diabetic nephropathy than 
patients with other genotypes. Furthermore, Shpichinetsky and colleagues (2000) 
reported that C677T and A129SC mailers were associated with diabetic nephropathy in 
type II diabetic patients,
1.7.2.5 KalUkrehi-kinifi system
Several studies have demonstrated the role in regulating of kallikrein-kimn system in 
inflammatory processes in the kidney and its protective effect against the development of 
renal pathology (Bachvarov, et a l. 1998). The kallikrem (KLK3) b allele frequency- is 
associated with ESRD (Yu et a l9 1998). Kinins effects are mediated through B1 and B2 
kiniti receptors. The C allele (G—>C) at position -699 of the promoter region of the 
bradykinin-1 receptor gene (B1R) gene was found to be less frequent among patients 
with ESRD compared with healthy control subjects (Baehvarov, et ahT 1998, Zychma, et 
a l„ 1999). Chi the other hand, there was a significant increase in the frequency of the C- 
allele at B1R gene polymorphisms in diabetic and non-diabetic nephropathy compared to 
controls (Knigge, et a l, 20CMI).
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1.7.2.6 Cytokine genes
The earners patients for the IL-lbeto allele 2 (ILlheta2) or interleukin 1 receptor (IL~ 
IRa) interleukin I receptor antagonist allele 2 (IL1RN*2) in intron 2, was associated with 
a higher risk o f IgA nephropathy (Liu, et a l, 2001). These alleles were tightly Jinked. On 
the other hand, carnage o f the TNF-aJpha aileie 2 (TNF2) was associated with a 
decreased risk of IgA nephropathy (Syijanen, et a l, 2002). C arnap of the IL1RM*2 
allele was associated with a significantly poorer long-term outcome with a median 
survival time of 72 months as compared with those without IL1RN*2 in IgA nephropathy 
(Shu, etaL, 2000).
Biakemore and coinvestigates (1996), showed that IL1RN*2 could be a marker for the 
severity of inflammatory processes and complications of type 2 DM including 
nephropathy. Freedman and colleagues (1997) showed an association between the same 
allele and ESRD.
1.8 Other genes
The A—>G transition at nucleotide 3243 of the mitochondrial tRNA was found to be 
associated with faster progress to ESRF in type II DM (Iwasakt et al,, 2001, Watson, et
al,f 2001).
Grzeszczak and colleagues (2001) reviewed that the Xbal allele in the glucose transporter 
(GLUT!) gene protects against tbs development of diabetic nephropathy in Caucasian 
patients with type 2 diabetes.
In glomerulonephritis, patients with proteinuria had higher apoE2 and apoE4 allele 
frequency and lower apoE3 allele frequency than the controls (Oda, et al., 1999). 
Furthermore, ESRD patients had higher apoE2 allele frequency and lower apoE4 aileie 
frequency than the controls. Higher prevalence of nephrotic syndrome was found in 
proteinuric glomendouephrrtis patients with apoE2 (Oda, et aL, 1999).
L9 TGF-pl and TGF-Bl gene
1.9.1 TGF-Bl gene structure
The transforming growth factor-Bl (TGF-B1) gene has been located to 19q 13.1-13.3 
(Fujii, et a t. 1986). The gene is more than IGOkb and includes seven exons. The active 
part of TGF-p 1 is encoded by parr of exons 5, 6, and 7 (Derynck, e t aL  1987). It was 
reported that there are seven polymorphic regions in the upstream and coding regions 
(Tympany, et a l, 1998). Three biallelie polymorphisms [-988 (C/AX -800 (G/A) and -  
509 (C/T)] untranslated region are located in the upstream regions (promoters). A C 
insertion site was found to be located at position 72 of the untranslated region, and three 
biallelie polymorphisms located at codon 10 (Leu/Pro) and 25 (Arg/Pro)] o f exon 1 and 
codon 263 (Thr/De) of exon 5 (Cambien, et a l, 1996).
1.8.2 TGF-B receptor gene
Separate genes is responsible for the production of each of the three TGFB receptors. 
TGFBRI has been located at 9q33-p34, TGFBRII at 3p22 and TGFBRIII at Ip32-p33 
lhttp://hiolnfo.w€izmasMvac.d/caid-biii^cardship (accessed on 11/12/1999)], The 
transforming growth facior-p type II receptor [which is the most important in signal 
transduction (see section 1.5.3)] gene consists of seven exons and six introns. The sizes 
of the exons range from 128 to 800 bp. Four polymorphic regions were found in 
TGFBRII. One of these polymorphisms (AG) has been located at the seventh base of 
intron 2, another (C/T) (a silent mutation) was found to be located at codon 389. the third, 
(C/T) at codon 439 and the fourth (A/C) at nucleotide 1710 o f the 3* (nun-translated 
region) (Chidambaram, et a l, 1996).
1.8.3 TGF-B1 polymorphisms
Transforming growth factor-Bl polymorphism can influence the pathogenesis of fl biotic 
diseases (For review; Border and Noble, 1994; Basile, 1999). Patients homozygous for 
the G allele at codon 25 have higher systolic blood pressure than those who are C- 
homozygous or heterozygous (Li, et a lr 1999). In type I diabetes mellitus, there is a
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significant association between the presence o f the T allele (Thr2631ie) and the 
development ©f diabetic nqpfinopaflay (Pociot, et al1, 1998). Also there is a significant 
association between the presence o f the T allele and high levels of serum TGF-P J (active 
+ acid-activateble latent) pfoteim levels (Grainger, et al., 1999).
L8.3.J TGF-Bl polymorphisms and diseases
Because of the implication o f  TCF-pi in the pathogenesis o f several diseases, researchers 
have recently given great attention to the association between TGF-Bl polymorphisms 
and different diseases. TGF-Bl polymorphisms are associated with a wide range of 
different diseases (Table 5).
Although there was an association between polymorphism at (C-509T) and circulating 
TGF-P 1, there was no significant associations with the other studied genotypes (G-SOOA) 
(Grainger, et dL* 1999).
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Table 5. TGF-pl polymorphisms and different form s o f diseases
j TGF-pl gene 
\ polym orphism
|| 4 ssoelafio ns j References
i S 1C-5MT (I allele) i * Associated with decreased bone mineral 
density and osteoporosis 
| « Increased both active and add-activated 
latent' TGF-pl in normal people
f Yamada, 2001
1! Grainger, et uL 1999 iLeu Iff Pro (T allele) * Increased risk of osteoporosis
* Associated with higher SBP in whites
* Increased risk of  coronary artery disease 
i * Increased susceptibility to myocardial
infarction in Japanese
* Development of end stage heart failure 
caused by cardlomypathy
* Acute rejection of the heart within one 
year after its transplantation
* dtoowraiion the pulmonary function in 
cystic fibrosis
| la i^ d a U .e ta f, 1991, i1 
j! Bertoftdto* eta l, 2000 
1 Rivera* etaL, 2001 
1 Syrris, et aL, 199S 
i Yokcta, et a l, 2000
!
; Hoiweg, etaL, 2001 
Hofweg, et a l, 2001 1
jAifavright, e ta lr 2000 i
A r g 2 S P m  (G allele) 
(C allele)
* Graft vascular disease diagnosed by 
angiography in one year after heart 
transplantation
* Increased risk of coronary artery disease
* Development of fibrosis in lung graft
* Detesiorafen. of the pulmonary function 
In cystic fibrosis
* hmrmsed risk o f  myocardial infarction 
and reduced risk for systolic hypertension
Yokotau et o f, 2000
Syrrfs, et al, I99S 
EkGameL e ta L  1997_ 
Arfcwogfiy et al, WOO 1
Cambtesi, etaL, 1996
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1.8,4 TGF-Bl polymorphism mid renal diseases
Bean and colleagues (2000) found that there is a significant association between the 
presence of €  aileie at Leu I ©Pro and the development of renal failure in patients 
undergoing heart transplantation who were prescribed cyclosporin and steroids. Picot and 
co-workers (1998) found that there is a weak, but significant association between the 
presence of the T allele at Thr263He and the development of nephropathy in diabetic 
patients. On the other hand, the LeulOPro polymorphism showed no significant 
association with progression o f diabetic nephropathy (Akai, et al„ 2001). Li and co- 
workers (1999) found a significant association between homozygotes for the arginine 
allele (G) at codon 25 and increased systolic and diastolic blood pressure in ESRF 
patients.
It can be concluded that TGF-pl is a strong candidate for association with renal failure 
because o f its known biological effects and because of reported associations with both 
fibrosis and increased blood pressure. Also, it was observed that some patients with CRF 
progress quickly to ESRF compared with others who have stable renal function for a long 
time. This encouraged me to investigate whether TGF-P 1 polymorphisms can answer 
why some patients with CRF develop ESRF faster than those who may hare a constant 
but impaired renai function for a long time although both groups have the same 
management.
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Aim  of this thesis
This thesis investigates TGF-Bl polymorphisms that may he associated with CRF, In 
order to determine if  there is an association between these polymorphisms and:
1- Susceptibility to CRF
2- Progression of CRF
3- Clinical features o f CRF
4- TGF-P 1 levels in the serum, plasma and tissue of patients with CRF 
Overview o f study design
Deoxyribonucleic Acid (DMA) samples tor genotyping were prepared from a cohort of 
patients with CRF recruited ftom die Sheffield Kidney Institute, Northern General 
Hospital, Sheffield, UK, S a w  and plasma for TGF-pl measurement were also stored 
and clinical parameters (including blood pressure, proteinuria, and creatinine levels) were 
recorded. Furthermore, TGF-pl was estimated in the available patients histological 
sections.
I ) Association with susceptibility to CRF was investigated by comparison of allele and 
genotypes frequency in-patients with those in normal controls.
2) Patients were designated as having progressive or non-progressive disease on the 
basis o f the reciprocal o f creatinine slope over 2-9 years, Allele and genotype 
frequencies were compared between these two groups to establish whether 
associations were present with progression of CRF.
3) Associations with clinical features and with circulating and rami tissue TGF-pl 
levels were also investigated.
It was hoped, by this approach, to determine whether sequence variation in the gene 
encoding TGF-pl is an important factor in susceptibility to, and/or progression o f CRF. 
If this is the case, they might be useful as prognostic indicators and, possibly, in the 
future might inform clinical management.
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Chapter 2 
Materials and Methods
2.1 Collection of patients Mood samples
One hundred and forty six samples have been collected from patients with chronic renal 
failure (CRF) (appendix forms). Ethical approval for the study was obtained from the 
North Sheffield Ethics Committee, Northern General Hospital Trust Informed consent 
was obtained from all patients and controls included in the study.
Z I J  hiciusioTi/exeiuswn criteria
The stud}7 included patients with creatinine concentration >150 pmol/L who were white 
Caucasians, o f any gender and age group, with various degrees o f renal insufficiency 
including some on dialysis replacement therapy (ESRF). Patients with all types of 
underlying renal diseases including diabetic nephropathy, hypertensive 
glomerulosclerosis, obstructive urepathy and polycystic kidney disease were evaluated
The study excluded patients with creatinine concentration <150 pm ohl non-Caucasians 
as well as the relatives of patients included in the study.
Blood samples were collected for analysis from CRF/ESRF patients:
Firstly, blood samples were collected from patients ESRF on renal replacement therapy™
a) Forty-one patients on continuous ambulatory peritoneal dialysis (CAPD): From the 
kidney outpatient clinic at the Northern General Hospital, Sheffield.
b) Twenty-nine patients on haemodialysis These samples have teen collected from 
patients at the Sheffield Kidney Institute at the Northern General Hospital, Sheffield.
Secondly, blood samples were collected from patients with CRF not on renal replacement 
therapy:
c) Seventy-six samples were collected from the outpatient clinic at the Northern General 
HospitaL Sheffield
The control DMA samples (80 samples) were obtained from a white Caucasian 
population from Sheffield (UK) ami they were stored in a -20QC freezer at Sheffield 
HaJiam University.
2.1.4 Clinical data
The following parameters were recorded: Patients’ age, gender, renal diagnosis, renal 
histology (when a renal biopsy was available), blood pressure, serum creatinine, 
proteinuria, serum cholesterol and triglycerides levels. Parameters such as systemic blood 
pressure and proteinuria were recorded at the time of diagnosis as well as during follow- 
up (mean of the follow-up values). Treatment was documented.
The slope of the regression analysis of the reciprocal of serum creatinine value (1/serum 
creatinine) against time was taken as an indicator of the rate of progression of CRF. At 
least 5 serum creatinine measurements were included for each patient.
Patients with chronic renal failure (CRF) were classified into: -
(i) Progressors (P) — this group included both patients who had a 1 /serum 
creatinine against time regression slope significantly inferior to zero and 
patients with ESRF who were on renal replacement therapy. End stage renal 
failure patients were considered as progressors because these patients already 
progressed to ESRF.
(ii) Noo-progressors (NP) -  these patients have a i/serum creatinine against time 
regression slope, which was not significantly different from zero.
Analyses were done for all patients first Then individual diseased categories where 
excluded and the analyses were reported. This also involved analysis with and without 
conditions such as adult dominant polycystic kidney disease (ADPKD) and obstructive 
uropathy
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Z L 5  Blood samples collection and processing
Twenty mis of venous Wood was collected from each patient Ten mis was anticoaguJafed 
with EDXA The other lOmJs were not treated with anti coagulant The antieoaguJated 
blood tu p le s  wans used for DN.A extraction and the coagulated blood samples were 
used for seram preparation. These samples were separated by centrifugal ion (1000 g) for 
10 minutes to separate the cells from the plasma from the coagulated Wood and the serum 
from the anticoagulated. samples. Samples were aliquoted and stored at —20°C until 
required for analysis,
2,2 Genomic DN A extraction techniques
2.2.1 B uffers fo r  DM4 extraction
Buffers A, B and Sodium perchlorate, see appendix.
2.2.2 Protocol fo r  genomic DMA extraction
After defrosting, each sample (lOmls) was poured into a 50 mis universal tube (Bioline) 
and 40 mis of buffer A was added This led to the hypotonic lysis of the ceils and 
consequently allowed removal of haemoglobin and other cellular proteins. The samples 
were mixed end-over-end for 4 minutes at room temperature (RT) and were centrifuged 
(Sorvall RT 6000D) at RT, 3G0O g for 15 minutes, The supernatants were discarded and 
the pellets (containing the nuclei o f white cells) were resuspended in Buffer A to 20 ml. 
Samples were centrifuged again, at RT, 3000 g for 15 minutes. The supemants were 
removal and discarded. One ml of Buffer B was added to each tube to resuspend the 
pellets. The contents were transferred to 1.5ml Eppendorf tubes and 300 pi of sodium 
perchlorate (5M) was added to cmh tube, to precipitate the proteins.. The samples were 
mixed end-over-end for 10 minutes followed by microcentrifugation (12.000 g) for 10 
minutes. From each supemanf 600pJ were taken in a clean Eppendorf then 7OOpi of ice 
cold chloroform (Sigma) was added. The samples were mixed end-over-end for 3 min 
and were microcent rifoged (10,000 g) for 10 minutes. The top layer was transferred to 
clean Eppendorf Twice the volume of ice-cold ethanol was added to each Eppendorf.
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The samples were gently mixed end-over-end, then microcentrifiiged (Sorvali Super T21) 
at 10.000 g, for 15 minutes at 4°C. Supernatants were discarded and the DMA was 
exposed to air for 10 minutes to dry. The pellet was resuspended in 200-500 pi of sterile 
distilled water. This was mixed by end-over-end for 1 hour at 4°C.
2,2, 3 Assessment ofDMA parity and concentration
Genomic DMA ccjnceotraticm was estimated by measuring the absorbance at 260 nm 
(using GeneQuant spectrophotometer, Pharmacia Biotechnolog}"). The DMA samples 
were diluted (5 pi o f stock DMA was diluted in 995pi of sterile distilled water). One cm- 
path-length quartz cuvette was used..
One unit of absorbance at 26Ctam corresponds to 50jug/ml of DMA. The DMA 
concentration was calculate! using the equation (absorbance at 260nm/0.02 (constant 
factor x dilution factor). The stock DMA was diluted in sterile distilled water to a final 
concentration of SCMOOog/pL Then samples were stored at —20°C. The ratio of 
absorbance at 260nm to 280om in a Icm-path-length-quartz cuvette was used to assess 
DMA purity. The sample was considered pure when the ratio was I .8. Generally, a ratio 
of 1.6 to 2 was obtained The quality of the DNA was examined by using 0.8% agarose 
gel electrophoresis ,
2 3  Polymorphism analysis
23.1 Polymerase chain reaction (¥CR} screeningfor TG F-fil gene polymorphisms
The polymerase chain reaction was performed on the purified DMA extracted from 
patients with GRFiESRF and the controls. Four polymorphisms in the TGF-Bl gene were 
investigated C-509T. LeulOPro, Arg 25Pro and Thr26311e.
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The pri mers for araphlicatioffl o f the different polymorphisms are shown in Stable 2.1.
Table 2.1. The different primers were used fo r detection o f polymorphisms
i Polymorphic site ! primer Primer sequencei j ReferenceC-509T
| .
| .f CAG ACT CTA GAG ACT GTC AG-3" j' Grainger, et dL, 
1999 |
| R I S' GTC ACC AG A G AA AGA GGA C-3"|
! ILeuIOPro | FI | 5 "CTCCGGGCTGCGGCTOCTGCT-35J . . . jF2 ! S CTCCGGGCTGCGGCTGCTGOG-3T | Yoshiji, et 
! 1998
R ! 5GTTGTGGGTTTCC ACC ATT AG-3’ . . . j
ArglSPm Ft
)_
, S ACT GGT GCT G AC GCC TGG CCC-3”1 j Li, et aLt 1999! I
:
F2 S ACT GGT GCT GAC GCC TGG CCG-3* 61
R S TGC TGT TGT ACA GGG CGG CG A 
GCA-3* 1sIpJ ltr im ie Ft S ACC GGC CTT ICC TGC TTC TCA TOT CCC T-3' Foeiot, el dL, 199S
\ F2 S TGG CCA CCA TTC ATG GCA TGA GTC GGC CTT TCC TGC TIC TCA TGG
ACA C-3* j
1I
\1 '  15’ AM} GCC TCC ATC CAG GCT MCA AGGCTC AC-3* 1
Z3.2 Preparation o f primers
Primers were obtained from the Medical Genetics Department of the Royal Hallamshire 
Hospital. Sheffield Primer pellets were resuspended in lOOjil o f nanopyre water. Five pi 
of the aliquot was added to 995pi o f sterile distilled water. Concentrations were estimated 
by measuring the absorbance at 260mn (by using a GeneQuant spectrophotometer) using 
Icm-patMength quartz cuvette. Concentration was adjusted to 40pmoi/pL The aliquoted 
primers were kept at -20'°C until required for PCR.
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2.3.3 Geiiotyphtg for LeulOPro and Arg25Pro
Amplification Refractory Mutation-Screening Polymerase Chain Reaction (ARMS-PGR) 
was used for this purpose. The system is simple, reliable and non-isotopic. Furthermore, 
it clearly distinguishes between heterozygotes at a locus from homozygotes for either 
allele. The system requires neither restriction enzyme digest nor sequencing of PCR 
products (Newton et aL, 1989). For Amplification Refractory Mutation-Screening 
Polymerase Chain Reaction two sense (forward) primers were used. The sense primers 
had identical sequences except at 3’ nucleotide. If the primer sequence is identical to the 
allele, it will bind to the complementary strand of the allele sequence, permitting 
amplification. On the other hand, if  the primer is not complementary to the allele, 
amplification will be prevented. A common antisense (reverse) primer was used. Two 
reactions were performed for each patient; each one contained one o f the two forward 
primers and the common primer in addition to the other reagents. Polymerase Chain 
Reaction reactions were carried out in a final volume of 50pl Each reaction contained the 
following final concentrations: PCR buffer 20mM Tris-HCl, 5GmM potassium chloride 
(KC1) (Gibco), 1.5mM magnesium chloride (MgCh) (Gibco), 20 pmol of each primer, 
0.2 mM of deoxynucleoside triphosphates (dNTPs) (Gibco), 2.5 units o f Taq DNA 
polymerase (recombinant from Thermus aquations) (Perkin Elmer for LeulOPro) (Gibco 
for Arg25Pro) and lOOng o f DNA template. Negative controls for each reaction were 
used (the DNA template was replaced by 2jli1 of water) to detect any possible 
contamination. The PCR mix was overlaid with 40pl of mineral oil (Sigma). The 
overlying oil prevents evaporation and keeps the temperature of the PCR mix during the 
reaction in the thermocycler. The tubes were put in the thermocycler (Biometra). The 
temperature program was, 1 cycle: 95°C for 10 minutes, 1 cycle: 94°C for 5 minutes; 5 
cycles: 94°C for 60 seconds, 60°C for 60 seconds, 72°C for 60 seconds; 30 cycles: 94°C 
for 30 seconds, 56 °C for 30 seconds, 72°C for 30 seconds; followed by 1 cycle: 72°C for 
5 minutes. PCR products were stored at 4°C until electrophoresis was carried out 
Furthermore, dimethylsulfoxide (DMSO) (7%) was also used to increase the specificity 
of the reaction for the LeulOPro genotype.
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2.3.4 Genotypfngfor Thr263Be
Amplification Refractory Mutation-Screening Polymerase Chain Reaction (ARMS-PCR) 
was also used for the Thr263Ite genotyping. Two sense (forward) primers that differed in 
size and one antisense (reverse) primer were used for amplification of C/T polymorphism 
for each DNA sample. These three primers were used in a single reaction mix with the 
final volume of 50pL Polymerase chain reaction buffer was used in a concentration of 
20mM Tris-HCf 50mM KCI, I.5mM of MgCf, 20pmol of each primer, 0.2 mM of 
deoxynucleoside triphosphates (dNTPs), 2.5 units of Taq DNA polymerase (Bioline) 
(recombinant from Thermm aqmtiem) and lOOng of DNA template. Negative controls 
were used (the DNA template was replaced by 2pl of water) to detect any possible 
contamination. The PCR reaction mix was overlaid with 40pl of mineral o il
The tubes were put in a thermocycler. Standard PCR conditions were, 1 cycle: 95°C for 
10 minutes; 30 cycles: 94°C for 30 seconds, 56°C for 30 seconds, 72°C lor 30 seconds; 
followed by 1 cycle: 72°C for 5 minutes. Polymerase chain reaction products were stored 
at 4°C until electrophoresis was carried out
Following amplification, agarose gel electrophoresis was used to visualize the reaction 
products.
2.3.4 Genotyping C-509Tby restriction digest with Bsu 361
One sense (forward) primers and one antisense (reverse) primer were used for 
amplification of C/T polymorphism for each DNA sample. Reactions were carried out in 
a final volume of 50 jil Polymerase Chain Reaction buffer was used in a concentration of 
2GmM Tris-HCf 50mM KC1, 1.5mM of MgCf, 20pmol of primer, 0.2 mM of 
deoxynucleoside triphosphates (dNTPs), 2.5 units of Taq DNA polymerase (Bioline) 
(recombinant from Thermm aquations) and lOOng of DNA template. Negative control 
was used (the DNA template was replaced by 2pl of water) to detect any possible 
contamination. The PCR reaction mix was overlaid with 40pl of mineral oil. The tubes 
were put in the thermocycler. Standard PCR conditions were, 1 cycle: 95°C for 5
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minutes; 34 cycles: 95®€ for 1 minute, 6tfC for 1 minute, 72°C for 1 minute; followed by 
1 cycle: 72®C for 5 minutes. The PCR products were precipitated with three volumes of 
96% ethanol and 1/10 volume of 3M sodium acetate (pH 5.2) and incubated at -20°C for 
an hour. Then centrifuged at 12000 g. Then DNA was resuspended in 20pl of Bsu36l 
(Promega) digestion mix containing 10 units of enzyme, followed by incubation at 37°C 
overnight The following morning the digestion products were analysed by agarose gel 
electrophoresis.
2,4 Electrophoretic Techniques
Genomic DNA, PCR products and digests were analysed by agarose gel electrophoresis. 
To analyse genomic DMA, 0.8% agarose gels were prepared by adding 0.4 g of agarose 
to 50 ml of Ix of Tris borate EDTA (TBE) buffer. To detect PCR products and digests 
2% agarose gels were prepared by adding 1 g of agarose to 50 ml of Ix TBE buffer. lOx 
TBE buffer was made (0.89M Tris, 0.89M boric acid, and 0.025M EDTA water, pH 8.0). 
This was kept at room temperature until diluted (to Ix TBE) and used Heating for I 
minute in die microwave oven agarose suspension was dissolved After the ge! was 
cooled, 2 pi of etMdtum bromide (Sigma) (stock solution lOmgrml in water) was added 
Then the dissolved agarose was set in the gei apparatus (Biometra, Luton). To check the 
quality o f genomic DNA, 5jjI of loading dye (1% bromophenol blue in 40% sucrose) was 
added to 15 pi of DNA sample and subjected to electrophoresis In the agarose gel For 
PCR samples, Spl of loading dye was added to 10 pi of the PCR products. DNA marker 
($X 174DNA/Haeiff) (Promega) was electrophoresed in each gel to size the product For 
marker ($X174DNA/HaeIIl) preparation, 0.5 pi of the marker stock (1 pgf pi) was added 
to 15ul of water and 5 pi of loading dye. Electrophoresis was carried out at 80 volts for 
one hour at room temperature. Photographs of the gels were taken by Polaroid camera or 
by digital camera (Kodak electrophoresis documentation and analysis system, Rochester).
2.4 Measurement o f circulating (plasma and serum) YGF-fil
Plasma total acid-activated TGFpl protein levels were measured by using an ELISA 
[Quantikine Human TGF-pl immunoassay kit (R&D Systems, Abingdon, Oxford, UK)] 
(Danielpour et a i, 1989, 1993; Tsang et aL, 1990). The assay was carried out according 
to the manufacturer instructions. The sensitivity of the assay was 7 pg/mL The cross 
reactivities were 12.4% for latent TGF-pl, 0.08 for TGF-P2, and 0.12% for TGF-P3 
which are all non-signilicaist The samples were diluted (1:5 in a calibrator diluent) and 
assayed in duplicates. An automatic plate reader (Wallace) read the ELISA plates at 
450nm. Control plasma was collected from healthy 20 volunteers. Furthermore, the 
precision o f the measurement was studied (see chapter 5 section 53. L I)
2.5 Me/ml histology evaluation
Four-micron sections from paraffin-embedded renal biopsy material were stained with 
haematoxvlm and eosin, periodic arid SchifFand Masson’s tricJnome. The severity of the 
histological changes (glomerulosclerosis and tubulointerstitiaJ fibrosis) were scored 
according to an arbitrary scale (from 1-4) where 1 = normal (no pathology), 2 = m ild 
changes (affecting < 25% of the area), 3 = moderate changes (25-50%) and 4 = severe 
(>50%) as previously described (Mnehaneta-Kubara, et a i, 1995). Fn addition, we 
counted the inflammatory cellular infiltrate (ICI) of the renal interstitium by counting the 
number of inflammatory cells per low power field (x200 magnification). The individual 
score was based m  the mean o f the number of cells in the fields evaluated Each 
measurement was carried out on 6 -  10 fields per slide.
Histology reports were reviewed and attributed an arbitrary score from 1 to 4 depending 
on the severity of scoring parameters (no changes = 1, mild changes = 2, moderate 
changes = 3, severe changes=4).
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2.6 Estimation of TGF-flt in renal tissue
ImmunoMsteheofistry was done to localise and estimate TGF-pl protein at tissue level. A 
specific human anti-TGF-pl antibody was used for this purpose (Promega). Renal bionics 
were fixed in 10% neutral-buffered formalin, paraffin-embedded, actioned at 3 jam and 
stained using a standard inimiiMperoxidase staining technique. Briefly, sections were 
deparaffinized and rehydrated in descending concentrations of alcohol Following 
blocking of endogenous peroxidase activity with 3% H2G2 in methanol and nonspecific 
binding sites with a protein blocker, the primary antibody was added with overnight 
incubation at 4€fC On day 2, the biotinylated secondary antibody (Vector) was added at a 
concentration of 2% for 30 minutes (37°C) followed by addition o f the avidm-biotm- 
peroxidase (ABC) complex (Vector). Visualization of the reaction was performed using 3s 
amino- 9' etfayl-caririmaajle (ABC) (Vector) as the chromogen. All steps were performed 
at room temperature in a humidified chamber unless otherwise specified Controls included 
sections incubated in the absence of the primary antibody as well as some incubated with a 
non-mimime appropriate immunoglobii/fn Control renal tissues were obtained from 
cadaveric donor healthy kidneys.
2.6,1 M&rphametrie analysis
For the evaluation of TGF-pl staining, sections were analysed using a drawing tube and a 
25 point squared lattice relying on a standard morphometric analysis based on point 
counting (Williams, et aL„ 1987, Muchaneta-Kubara, et aL, 1995). Data was collected 
from a series of adjacent fields (10-20) extending perpendicularly from the cortex to the 
medulla. The percentage points foiling on stained structures (cell or interstitium) were 
estimated, and the percentage o f glomeruli stained was calculated Slides were scanned 
independently and subsequently; 1 reviewed my scoring with my supervisor who finalized 
the scoring with me.
2,8 Statistical Analy sis
Analysis o f allele frequencies and carnage rates was carried out using the Chi-squared 
test. Comparison of the means (blood pressure and proteinuria and estimated TGF-pl
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protein levels either in blood or in renal tissues) was carried out using F-tests followed by 
the t-tests (unpaired, two-tailed, for equal or unequal variance, as appropriate) (see 
below). Correlation and regression between the different measurements was carried out 
using ANOVA test on Microsoft Excel and SPSS. The Hardy-Weinberg equation 
(O'Neil. 1997, MtpjfautJno.paloniar.edu) was applied to compare the expected versus 
observed distribution of genotypes (see below). A p value < 0.05 was considered 
significant.
Z8.1 ftardy- Wei titerg equathm
The Hardy-Weinberg equation was used to predict the expected distribution of genotypes 
at given allele frequencies.
p 2 +- 2pq +- q1 = I
(p = frequency of the common allele, q = frequency of the rare allele).
Using the above formula, the expected and observed frequencies o f genotyping were 
compared If the differences between the observed and the expected frequencies are not 
statistically significant, the balance of genotypes does not differ from there expected in a 
population in Hardy-Weinberg equilibrium.
2.8.2 Chi-squared analysis ( / )
Chi-squared analysis tests the null hypothesis (no difference between the observ ed 
and expected values).
Expected
Degree of freedom equal number of genotype -  1 for testing the Hardy-Weinberg 
expectations Comparison o f genotypes and carriage rates between different groups (i.e. 
control Vs patients, or progressors Vs non-progressors) was carried out using 
contingency tables. For these, die degree of freedom are calculated by (number of raws — 
I) X (number of columns — 1) An example is given below.
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If Yates' correction for continuity is to be applied, due to cell counts below 5, the 
calculation is the same except for each cell, subtract an additional 0,5 from the difference 
o f G -E , prior to squaring and then dividing by E.
Example o f 2x2 contingency table was used to calculate %2
Variable 1 Total
Progressors Non-progre$sors
i Variable 2 Carriage o f 
allele 2
a b a + b
i
Non-carriage c
d 1
c + d
'...........
o f allele 2
1
a + c b + d
. .... ........... i
a + b + c + d
J2x: = +• b) (c + d) (a +- c) (b + d) x  (a + b + c + d)
The null hypothesis was rejected and the statistic was considered significant if  the p value 
<0.05.
2.8.3 Odds ratio (OR) and confidence interval
Odds ratio analysis was done manually by calculating ab/cd. Confidence interval (Cl) 
was calculated by finding standard error (SE) of Jog e (antilog) of OR.
SE (log e OR) — square roots o f (1/a +- l/b  + l/c  + 1/d)
7= In O R -(L 9 6 xS £ (In  OR)
X= In OR +- (1.96x  SE fin OR)
Cl= is the anti log for the Y and X values.
A p value < 0..05 was considered significant.
2.8.4 F-test
Using F test (EXCEL) tested the significant of differences in tested variance between two 
values. The null hypothesis was rejected if  the p (t) < 0.05 (statistically significant).
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2.8.5 (-test
The significance of any difference between two means was tested by the appropriate 
unpaired t test (for samples o f equal or unequal variance as assessed by the F-test) by 
using EXCEL. The null hypothesis was rejected if the p (t) < 0.05 (statistically 
significant).
2.8.6 Regression and correlation
Regression analysts was used to assess the significance of the slope o f the reciprocal of 
the I/serum creatinine against time. If the p value for the regression < 0.05, the patient 
was considered to have progressive CRF. On the other hand if  the p value for the 
regression > 0.05 the patient was considered to be a non-progressor. Furthermore, for 
comparing the variances regression and correlation were used The null hypothesis was 
rejected if the p(r) < 0.05 (statistically significant).
2.8.7 Coefficient o f variation (CV):
The following formula was used to calculate CV to study the precision of the
measurement o f the circulating TGF-pi protein levels in the plasma.
Standard deviaikmX J00 
Adeem o f assay
ZS.7 Coefficient o f linkage disequilibrium (D ')
The following formula was used to calculate the D' value (departure from linkage 
equilibrium).
I) 5 =  (P&' i\m -Pm " Pm)2 (Path'  Pm  +Pm  ' Pjo)
Abbreviations:
Pah ; proportion of the carrier patients for alleie a and b 
Pab; proportion of the carrier patients for allele A and B 
PaB: proportion of the carrier patients for allele a and B 
?Ah: proportion of the carrier patients for allele A and b
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Chapter 3 
Clinical data
3 J  Introduction
The relative frequency of different causes of CRF varies from country to country'. In the 
UK, chronic glomerulonephritis remains the main cause of ESRF (Wing and Jones, 
2000). An increasing number of patients suffer from ESRF due to diabetic nephropathy. 
In the US, diabetic nephropathy is currently the most common cause o f ESRF aiong with 
hypertensive nephrosclerosis. (USRDS, 2001). Diabetic nephropathy accounts for up to 
40% of at! patients on. renal replacement therapy in the US (USRDS, 2001). Other causes 
of CRF include hypertensive nephrosclerosis, chronic interstitial nephropathies, 
obstructive uropathy as well as polycystic kidney disease (Wing and Jones, 2000).
The progression of chrome renal failure (CRF) characterised clinically by a 
heterogeneous rate o f decline of renal function (El Nahas and Winearls, 1997). 
Histologically, this reflects the various degrees of underlying renal scarring and the 
associated progress we deletion of intrinsic renal cells and their replacement by 
collagenous extracellular matrix (ECM).
There is a wide range of factors known to influence the rate of progression of CRF 
(Silver, et aL, 1989; Seder, 1992), These include genetic, racial and environmental 
factors (USRDS, 2001). In addition, some modifiable factors such as systemic 
hypertension, proteinuria, dyslipidaemia and smoking have been implicated (For review, 
Locate] li and Del Veochio, 2000).
Of all the modifiable risk factors, systemic hypertension is the most important 
(Adamezak, ef, aL, 2002). An elevation of systolic as well as diastolic blood pressure is 
associated with a fester rale o f progression of CRF in patients with diabetic and non­
diabetic nephropathies (Brazy, et aL, 1989; Ruggenenti, et aL, 1998). It is believ ed that 
the transmission of systemic hypertension to poorly autoregulated glomeruli lead to their 
scarring (For review; Dworidn and Weir, 2000). Therefore, the control o f systemic as 
well as glomerular hypertension is crucial for delaying the progression of CRF in 
experimental animals (For review; Dworkin and Weir, 2000). In humans, a growing 
number of references suggest that tire control of hypertension is also protective (Maschio,
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et aL, 1996; Ruggenenti* et aL, 2001; Adamczak, et aL, 2002). In addition, the use of 
angiotensin converting enzyme (ACE) inhibitors has been shown to provide additional 
protection (For review; Dworkin and Weir, 2000).
Proteinuria is also an important prognostic marker for the progression of CRF (For 
review* Harris. 2000). Both diabetic and non-diabetic nephropathies associated with 
heavy proteinuria have a poor prognosis. Recent research suggests that proteinuria may 
also contribute to scarring of the kidney (Harris, 2000). It has been postulated that 
excessive filtration o f proteins and their accumulation in the glomerular ntesangium leads 
to mesangial overload and sclerosis (Bertani and Remuzzi, 1997). Also, excessive 
filtration of proteins and their reabsorpti on by proximal tubular cells activates these cells 
and leading to release of chemokmes, cytokines and growth factors (Harris, 2000). These 
factors can in turn attract inflammatory cells into the renal interstitiuin, which activate 
renal fibroblasts. The proliferation of activated renal fibroblasts and their synthesis of 
extra-cellular matrix (ECM) lead to renal fibrosis (Jemigan and Eddy, 2000). It is* 
therefore, important to reduce proteinuria when we treat patients with progressive CRF 
(Jafar, et aL, 2002). This may fee one of the advantages associated with control of blood 
pressure and the use of ACE inhibitors.
Moorhead and his colleagues (1982) postulated that dyslipidaemia can accelerate the 
progression of glomerular and tubular scarring. In animals, hyperlipidaemia is associated 
with accelerated renal fibrosis and its control ls protective (Keane, 2000). In humans an 
association has been reported between hypercholesterolemia progression of diabetic and 
non-diabetic CRF (KrowteJd, et aL, 1994; Samuelsson, et aL, 1997). It is, therefore, 
important to monitor and treat hypercholesterolemia in patients with progressive CRF 
(Keane* 2000; Fried* et aL*2001).
Lifestyle factors, such as smoking, alcohol consumption and the abuse of recreational 
drugs have all been associated with a higher risk of ESRF (Pemeger, et a L 2001 and 
Bakir and Dunea, 2001).
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3.2 Methodology
One hundred and forty six patients with CRF were studied. The study included patients 
with creatsniise concentration >150 pirtoi/1, white Caucasians, of any gender and age 
group, with various degrees of renal insufficiency including some on dialysis replacement 
therapy (86 end-stage renal failure [ESRF] patients: 46 on continuous ambulatory 
peritonea] dialysis [CAPD] and 40 on haemodialysis [HD], The inclusion and exclusion 
criteria were discussed previously (see materials and methods, chapter 2, section 1.3).
Patients with CRF who were not on renal replacement therapy (RRT) were followed up 
retrospectively for 58.8±4.8 (mean ±SEM) months. Furthermore, patients with chronic 
renal failure (CRF) were classified into: -
(i) Progresses (P) -  this group includes both patients who had a 1/serum 
creatinine against time regression slope significantly inferior to zero and 
patients who were on renal replacement therapy (ESRF).
(ii) Non-progressors (NP) -  these patients have a 1/serum creatinine against time 
regression slope, which was not significantly different from zero.
3.2.1 Parameters
The following parameters were studied: Patients’ age, gender, weight, height, smoking 
habits, renal diagnosis, renal histology (when a renal biopsy had been undertaken), blood 
pressure, serum creatinine, proteinuria, haematuria, serum cholesterol and triglycerides 
levels. Parameters such as systemic blood pressure and proteinuria were recorded at the 
time of diagnosis as well as during follow-up (mean of the follow-up values). The slope 
of the regression analysis o f the reciprocal of serum creatinine value (1/serum creatinine) 
against time was taken as an indicator of the rate of progression o f CRF.
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3.2.2 Renal histology analysis
Renal biopsies were available in 25 patients. Their biopsy material was available in the 
archives of the Mstopathology Department at the Northern General Hospital Trust 
Paraffin-embedded section (4 ji) were stained with conventional dyes as detailed in 
chapter 2, section 6,2,
I analysed, histomorphoraetrically the severity of renal scarring parameters 
[glomerulosclerosis (GS) and tubulomterstitial fibrosis (IF)] according to an arbitrary 
score (from 1= normal to 4= severe) as detailed in the Material and Methods chapter 
(chapter 2 section 6,2), Furthermore, the pathological processes were divided into two 
categories. Glomerulosclerosis (GS) were divided into, a) normal + mild scores and b) 
moderate + severe. For interstitial fibrosis (IF) the available scores were only score 3 
which was considered moderate and score 4 which was considered severe IF. I also 
evaluated the severity o f the interstitial cellular infiltration (ICI) by counting individual 
cells within a microscopic field (x 200). An average of ten consecutive and random fields 
were counted The mean of the cellular count for each patient was the given ICI score.
3.2.3 Statistical Analysis
The results are given as mean ± standard error of the mean (M ± SEM). Analysis of the 
difference between the means of the studied parameters was carried out using F tests 
followed by t tests (unpaired, two tailed, for equal or unequal variance, as appropriate). 
Chi square analysis tests the null hypothesis. Yates’ correction was applied for the 2x2 
contingency table if any of its cell less than 5. Correlation and regression between the 
different measurements was earned out relying on regression analyses. A p value < 0.05 
was considered significant
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3 3  Results
33J  Clinical Obsermtwm
Due bundled and twekre patients (39 females and 73 males) were classified as 
progresses 34 patients (8 females and 26 males) were non-jrogressors. The 
characteristics o f the jsxsgressffls and non progessors are shown in table 3.1
Table 33
The clinical characteristics i»f the CMF patient groups (mean ±SEM )
5—.. ■.. ......... .....-i Parameters | Whole gramp 
; (m = 146}
P — 112 j N P —34
!
m
\
p  m
| Age (years) ! 57..4S ± 1.4 57 ± 1.5 58.9 + 2.3I i 0.2 ! 0.4|j Serum creatinine (juinot!) 345.-5 + 18.7 514 + 32 | 274 + 23i 0.4 0.0005* jI 1/creatinine slope -cmxxmb ± -0.00009 ± 
0.00002
| 0.000009 +
S 0.000004i
0.002 0.000007* !
I SBPd (mmHg)| ; 152.41+2.26 155.1+2.7 ! 146.6 ±4.9[ 0.03 0.13j‘ SBPf (mmHg) 148.52 ±1.8 153.1±2.3 | 140.5+3.8 0.5 0.00s*
; DBPd (mmHg) *731 ± 1.22 88.1 ± 1.4 ! 86.6 + 3.3 0.007 0.5
DBPf (mmHg) S4.65 + 1 85.8 ±1.2 ! 83.7 + 2.9 0.003 0.5
;i Proteinuria ai diagnosis 
'I g/24h 2.49 ± ft 1ST 2.8 ± 0.3 13+0.3 ;!
O.O00O6 9.0@04* |
|iI>1 Proteinuria during tbSow up 
I gj24h
232+0.174 2.7 ±0,3 1.1 ±0.2 1
!
0.OO0O33 ; 0.90607* !|
!
f S.CholesteroI (mmoMiI 5.6+0.14 15.4 + 0.15 6.2 ± 0.4 || © 0.04*{ S.Triglycerides (nsmotl)L  . 28  + 0JS 2.6 ±0.2 ............... 3.6 + 0.6 !; 0.08 0.044* jAbbreviations: SBPd: systolic Mood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf: systolic Wood pressure during follow' up. DBPf: diastolic 
blood pressure during follow up. S.Cholesterol: serum cholesterol, S.Triglycerides: serum 
triglycerides. P: progresses, NP: non-progressors, p (f): p value for f  test, p (t): p value 
for t test.
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Of note the clinical date relating to progression (1/Cr slope) was calculated for patients 
with CRF who were not on RRT
Hie distribution of different disease entities is listed in table 3 .2. 
Table 3.2.
Relative frequency o f different causes o f CRF
| Diagnoses j Total P NP ! % o f total patients
j Hypertensive nephrosclerosis j 28 20 8 ' 19.7! ij CIN j 23 12 11 | 16.2
j Obstructive uropathy j 15 10 5 10.6
1 Glomerulonephritis j 15'i ! 10 5 I1 10.6j DM I 12 10 2 9.21 !|j Systemic vasculitis j 11 I 8-1 1
! i) Wegeners granulomatosis i 6
. . . .  . ?............... 4 2 4.2j it) SLE j 3 1 2 j 2.1
i hi) Rheumatoid arthritis \ 2I. I 1 1 j 1.4 1PKDf i 7 3 4 j 4.91 1| Amyloidosis 2 1 1 1.4
Unknown 29
____
14 15 f 20.4
Abbreviations: CM: chronic interstitial nephritis including analgesic nephropathy and 
chronic pyelonephritis, DM: diabetic nephropathy, SLE: systemic lupus erythematosus, 
PKD: polycystic kidney disease.
3.3.2 Pathological data
Most of the patients did not have a renal biopsy. Pathological study was done on the 
available sections from 24 patients who underwent a renal biopsy. Seventeen patients 
were diagnosed as having glomerulonephritis, 5 patients had chronic interstitial nephritis 
and 2 o f them were diagnosed as having amyloidosis (Table 3.3). According to the 
pathological processes, the patients with glomerulosclerosis were classified into mild (11
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patients), moderate (4 patients) and severe (9 patients) (the assessment o f the severity was 
discussed in section 3.2), The patients with tubuiointerstitial fibrosis (IT) also were 
classified into mild (1 patient), moderate (19 patients) and severe (4 patients). 
Glomerulosclerosis were more severe in crescentic giomerulonepliritis (CGN) than the 
other pathological forms (Table 33% Patients with chronic interstitial nephritis (ON) had 
less severe interstitial fibrosis compared to the other pathological forms (Table 33).
Table 3 3
The distribution o f different pathological diagnoses amongst CRF patients and the 
severity (mean +SEM) o f the rernl scarring parameters
Pathology ! n= GS IF | IC I (celbfM d)
MCGN ! 6
:
3.1+0.4 3.2 ±0.15 1 20 ± 12.6
i FSGS 5
1
| 2 ± 0.5
:
3 ± 0 1 20 ± 14
1 MNj 2 1.5 ±0.5 3 ± 0 7.5 ±7.5 f:
j  DN
i!
2 2.5 ±1.5 3.5 ±0.5 57.5 ± 2.5
i! CGN 2 4 ± 0 3.5 ± 0.5 6 0 ± 0
ON ,
1 ^
5 2.4 ±0.7 2.8 ±0.5 42.6 ± 9
Amyloidosis
i__  .
2 2.5 ± 0.5 3 ± 0 6 0  ± 0
Abbreviations: GS: glomerulosclerosis, I r: interstitial fibrosis, ICI: interstitial cellular
infiltration, MCGN: mesangioeapillaiy glomerulonephritis, FSGS: focal and segmental 
glomerulosclerosis, MN; membranous nephropathy, DN: diabetic nephropathy, CGN: 
crescentic glomerulonephritis, CIN: chronic interstitial nephritis
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There was a signitlcaa% higher number of patients with severe IF in the progressors 
compared to the NP. On the otter hand, sev ere glomerulosclerosis was found in a similar 
number o f?  and NP (table 3.4).
Table 3,4
The distribution o f pathologicalprocesses among the studied CRF patients
!' Pathology P
: 1
NP  | X (at one degree o f P  fo r  j f  
freedom)
GSi: Mild
|
jj
j id
I
I i 12
j
23 0.15
!
| Severe[ 9 4 13
|....... ijTotal 19 5 1 24
!
IF
Moderate 9 S 10 ! 20
1 1
10.2 0.002* |
Severe1: |
5 lO j 2|! j 
!
j
j
Total 14 10 ! 24
1
I
.Abbreviations: GS: gfomenilosd erosis, IF; interstitial fibrosis, P: progressors, NP: non-
progressors.
*= <0.05 (significant).
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It was noted that there were no significant relationship between the different pathological 
processes and any of the studied parameters (table 3.5),
Table 3.5. The relationship between the pathological processes and the different
SC I G S I F
i ---- - ------ i........ ...
L
iCi(A IC f 
w=l4
Without ICI 
n=U
Mild
n= ll
; Severe 
j «=IS
; M oderate 
n=I9
Severe
a=5
; I) Proteinuria (§+24ltrs)
\ t- At diagnosis
\ m
\ Hi)
4.1+1,4 
0.02 
0,97
43+1.5 3.0+09
032
0.5
j 4.011.2
!!
3+0.7
0.0I
0.4
63+2.8
'! 2 -During follow up 
j Pit)
] m
4.7+1.4 
03
m
3.511.3 2.910.8
0.07
0.6
3.7113 2.910.7
0.009
0.5
5.512.7
! H) Blood pressure (mmBg) 
j 1- SBPd
| m
| p(t>
149+3
0.02
0.9
150+8 14417
0.2
0.4
153+9 146+6
04
0.4
160+10
2- DBPd
m
m
93+3
0.85
0.2
84+6 86+6 | 91+7
0.3
0.6
I
90+5
03
0.6
£414
_ -
3- SBPf
m
m
145+6
0.2
0.54
151+6 154.516
0.5
0.2
150+5
L
14815
03
0.5
15617
\ 4- DBPf
! m
j m}
82+4
0.2
03
S 7313.5 8413 | 90+5
0.03
0.4
1
8713.5
0.3
0.5
8715
ID) l/C r slope
| p(f> 
j Ptt)
0.00001+
Q.mom
©..©6
0.2
-0.000051
0.00002
0 0000081 
0.00003 
0.2 
0.9
-0.000021
0.00003
-0.000009
+0.000003
0.4
0.6
-0.000008
+0.000001
IV) Serum lipids (mmofd)
1- Seram Cholesterol 
P(f)
Pit)
4+0.5 
0 M  
0.2
63.4 5113
0.2
0.9
511.5 5.95+0.8
03
03
_________ .
3310.4
!
2- Seram Triglycerides
m
I Pi t )
2.5+0,5
03
03
2811.6 5+0.8
0.07
0.07
1.9+0.5
........
2.710.6
0.1
0.1
1 4+03
Abbreviations,: see tables 3. and 3.4
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3.4 Factors affecting the progression of CRF
Table 3.1 summarizes the data collected (see appendix) for the patients studied.
3.4.1 Gender
The number of males was higher than females. It was noted also that 72 males and 35 
females were classified as progressors. and 23 males and 12 females we.re classified as 
non-processors. The Tereafimne slopes were significantly lower in males (Table 3.6). 
This means that progression is fester in males than in females. Also, proteinuria at 
foliow-up was significantly higher in males than females (Tables 3 .6) (Figure 3.1). There 
was no difference between other parameters studied between males and females (Table 
3.6).
Table 3.6
The clinical characteristics imean ±SEM ) o f the studied patients according to gender
CRF parameters Females (N= 47) j Males (N —99)! . . . . . . . . . .  J P(J) p (»I Proteinuria at diagnosis 
I (gQ4h)
; 1.7+0.3 i  2.5±0.3
I
0.013
'
006
. J| Proteinuria Airing 1.810.3 j 2 9+0.3 i 0.14 0.047* I
j  follow up (g/24h) | sI| SBPd (-mmHg) 155+4 | 153+4\ 0.J4 06j DBPd (mmHg) 89+2 I 87+2 0.3 03
) SBPf (mmHg)'l 152+3 I 14912 0.14 0.2 .| DBPf (mmHg)
-
84.3+4 I 87.211.3|i 0.14 0.2 fi\ S.Cholesterol (ramoM) 5.910.3 j 5.610.3 0.09 0.3 1| S.Triglycerides (nmioi^1 2.5+10 | 3+0.3 i 0.1 0.14 I| SCreatinine (iirocTl)1 340+5© ! 524157 0.006 ©.02* |1| 1 Creatinine slope -00000091 | - 0 . 0 0 0 0 4 1 0 . 0 0 0 3 0.055
I...................................... i 0.000000619 \ 0.000000008 . .  ij CiCl {ml/mm)
1 ' 19+4 j 23+2. . . . . . .  . . J.  . . . . . . . . . . . . . 0 . 0 0 3 1 0.5Abbreviations: SBPd: systolic Mood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPi: systolic blood pressure during follow up. DBPf: diastolic 
blood pressure during follow up. Sxholesterol: serum cholesterol, S. triglycerides: serum 
triglycerides. CiCl: creatinine clearance, p(f): p value for f  test, pit): p value for t test.
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Figure 3,1. Proteinuria (mean ±  SEM) at diagnosis and during follow  up in CRF 
patients according to gender
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3.4.2 Proteinuria
It was found that overall means of proteinuria at diagnosis was 2.5±0_24 g/24brs and 
2.2±0.2 g/24hrs during follow-up. We noted that 41 patients had proteinuria at onset and 
31 patients had proteinuria at follow up (> 300 mg/24hr). Proteinuria, both at onset and 
during follow up, was significantly higher in progressors compared to non-progressors (p 
< 0.0005) (figure 3.2).
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Figure 3.2.
Proteinuria (mean±SEM) at diagnosis and during follow  up in progressors (P) and 
non-progressors (NP) with CRF
2.5je
Proteinuria at diagno sis
*=P<0.05.
Proteinuria during follow-up
Further, I compared the proteinuria in diabetic nephropathy to the remaining patient 
group. In dtabetic nephropathy, proteinuria levels both at diagnosis and during follow up 
were not different from that of the remaining patients (at diagnosis 2.3±0.2g/24h, during 
the follow up 2. l±0.2gQ4h) (Table 3.7).
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Table 3.7
Proteinuria and 1/Cr slope (mean ±SEM) among the different causes o f CRF
ij
1 Proteinuria at 
diagnosis (g/24hrs)
Proteinuria during 
follow  up (g/24hrs)
1/Cr slope
l
] Hypertensive 
I nephrosclerosis
14 I 2.2 ± 0.8 2.410.9 -0.00003±0.00001
j Systemic vasculitis
I
10 2.610.6 2.510.7 ; -0.000001410.000013
GN
; 9
1.710.3 210.27 | -0.00000710.00002
1Diabetic 
i nephropathy
L
7 3.110.8 2.810.7 i -0.0000310.000014
i CIN 1 1.210.4 1.510.3 -O.0QOQ21O.O0OQ 1
1 Obstructive 
uropathy
6 1.910.6 1.710.5 -0.O0G0G310.G00G I
i PKD 1 1.710.5 1.610.4 -0.0000210
j Unknown 13 2.510.5 2.510.5 -0.00001±0,000015
Abbreviations: CIN: chronic interstitial nephritis, PKD: polycystic kidney disease 
GN: glomerulonephritis.
Of note the clinical data relating to progression (1/Cr slope) was calculated for patients 
with CRF who were not on renal replacement therapy (RRT).
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3.4.3 Blood pressure
In the overall population, blood pressure values at diagnosis did not differ significantly 
from those during follow-up (Figure 3.3). However, systolic blood pressure during follow 
up was significantly higher in the progressors than in the non-progressors (Figure 33). 
On the other hand, there was no significant difference in diastolic blood pressure values 
between progressors and non-progressors (Figure 33).
Figure 33 .
Blood pressure values (mean ±  SEM) in CRF progressors (P) and non-progressors 
(NP)
mm
* : p value = 0.01.
Abbreviations: SBPd: systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf: mean systolic blood pressure during follow-up, DBPf: mean 
diastolic blood pressure value during the follow-up period.
76
3.4.4 Serum Lipids
The mean serum cholesterol level was 5.7+0.16 mmol/1 and the serum triglycerides level 
was 2.8+0.39 mmol/1 in the overall patient group.
Both serum cholesterol and triglycerides were significantly higher in non-progsessors 
compared to progressors (Figure 3.4).
There was no significant difference in circulating lipids levels in the patients with 
diabetic nephropathy (S.cbolesterol = 5.5+0.37 mmol/1, S.triglycerides = 3.3+0.8 mmol/f) 
compared to the non-diabetic CRF (S.cholesterol= 5.8±0.17 mmol/1, S.triglycerides= 
2.8±0.19mmoll).
Figure 3,4,
Serum lipids (mean ±SEM ) in CRF progressors (P) and non-progressors (NP)
* PUNP
Abbreviations: S.cbolesterol; serum cholesterol, S.triglycerides; serum triglycerides. 
*= p <0.05
S.choiesterol S.triglycerides
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3,4.5 Correlations between the different parameters o f CRF
There was a significant correlation between the age of the patients and proteinuria, both 
at onset and during follow up. Furthermore, the age was significantly correlated with 
diastolic blood pressure both at onset and during the follow-up (Table 3,8).
There was also a significant correlation between diastolic blood pressure at diagnosis and 
both proteinuria and smim triglyceride levels at diagnosis. Moreover, there were 
significant correlations between serum triglyceride levels and both systolic and diastolic 
blood pressure during the follow-up. There were also significant correlation between the 
1/creatinine slope and both proteinuria at diagnosis and serum cholesterol levels. 
Furthermore, the mean of proteinuria during the follow up was significantly correlated 
with systolic blood pressure at onset (Table 3.8).
Table 3.8. Correlation between the different CRF parameters
j CR'F parameter* ! te=I I r ~ P (r)| i) Proteinuria at onset (g/24kt) week .
123 0.164 0.028 0.048* i
j 2- SBPd (mmHg)( 119 0.144 0.024 0.087!| 3 -DBPd (amiHg) 119 0.174 0.03 | 0.053
| 4- SBPf (mmHg) 119 0.128 © © Ki? 0.15 15-DBPflmmHgf[ 119 0.25 0.06 0.005* |j 6- S.Cholesterol (mmol')} 67 0.026 0.001 0.83
? 7- S.Triglycendes (mrooM)\ 60 0.152 0.023 0.21 8- I/creatinine sJope 76 0.36 0.13 0.001* 11
| II) Proteinuria daring f&Bme wp ; 
; (g/2 4hr) with! i f 1-age ofthepahesis (year) 119 0.29 0.084 !0.001* flj 2- SBPd (mmHg) 113 0.173 0.03 0.056
t 3 -DBPd (mmHg)S ' ; 113 0.163 Q27 ’ 0.074- SBPf {mmHg) ) 113 0.185 0.34 0.365-DBPf (mmHg) 113 0.21 0.05 0.017* )6- S Cholesterol (nunoM) 56 0.231 0.054 0.07 I1; 7- S Ttigtyeerides (mmold) 56 .... 0.144 0.21 i 0.3 18- i/creathime slope ...........  .......... . ........... 67 0.122 0.15 . ..... ............. 1 0.3 a
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; CRF parameters l * “ r — j \P ( r )
III) SBPd (mmHg) w ith 
j i- age (year)
!...
|i 130 0.005 j  0.000 :0.9
::
i 2- S.Choiesteroi (mmoi/l) 1 m 0,1 0.012 0 4i Ij 3- S-Triglycerides (nusol/l) ! 57 0,2 0.04 0.3 j
\ 4-I/creatinine slope : 34 0.128 0.016 0.3
; II ) DBPd (mmHg) mfflk|{ 1 -age ol the patients (jyeaor)
; o o
I
0.215 J 0.046 0,016*
j  2- S. Cholesterol ImmoW) I 6©1 0.128 0.016 0.34
\ 3- S. Triglycerides (mmol/l) || 57 0.04 0.002 0.06
j 4- 1/creatinine slope |j 34 0.1 0.01 0.4
; V) SB P f {mmHgj with
| 1-age (year)I .......
r
; 130 0.015 0 0002
.... j
0.9 ]
) 2- S.Cholesterol (mmol/I) 60 0.005 0.007 0.9
\ 3- S.Triglycerides (mmollf) ! 57! 0.245 0.06 0.06| 4~ 1/creatinine slope | 34 0.13 0.016 0.3
j VI) DBPf fmmHg) m lk  
f 1-age (year) 1 130 0.33 0.102 0.0003*
{ 2- S.Cholesterol (mmolff)
*[.. .
60 0.116 0.013 i1 0.4| 3- S. Triglycerides (juiboM) 57 0.08 0.007 0.028*
34 0.08 0.005 0.6
i VII) S. Ckfytesferii.it {mmcM} with 
i 5 -  a g e  of the patients (year) 72 0.09 !0.034 0.45
j 2- I/creatinine slope 33 0.126 0.01 048
j I I I  I) SL Triglycerides (mtmddj w i t i  
! I - age of die patients (year) 6 8 0.07 0.005
l|
0.6
; 2-l/creatiuine slope 32 0.344 0.118 0.05* IAbbreviations: see table 3.5 
*= p value <0.05
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3,5 Discussion
In this analysis, the clinical and histological parameters and their relationship to the rate 
of progression of CRF were examined.
Initial analysis centered on investigating differences relating to gender and parameters 
influencing the progression of CRF. The 1 /creatinine slope was significantly lower in 
males than females, reflecting the faster progression of CRF in males. Moreover, the 
severity of proteinuria both at diagnosis and during follow-up was higher in men. These 
findings were expected, as it is known that males with CRF haw a faster rate of 
progression than females (Berfhoux, ef aL, 1998). This may be attributed to the 
differences in proteinuria that I have reported. It was also reported that regardless of the 
cause of chronic renal failure, ESRD is more common in males than females (Locatelli 
and Del Vecehio, 2000 and Hannedouche, et aL, 1993).
Age was the second factor studied. There was no significant difference between the 
progressors and non-progressors. This finding was contrary to observations made by7 
Fliser and colleagues {1993) who showed that the progression of CRF was faster with 
increased age. This difference might be due to the small number of patients that I have 
studied. On the other hand, there was a statistically significant correlation between age 
and the severity of proteinuria, both at diagnosis and during follow-up. This may be 
relevant as proteinuria is a known factor affecting the progression of CRF. Age itself 
may not be a strong prognostic factor on its own but it may be the associated risk factors 
such as the increased age-related proteinuria or systemic hypertension which increase the 
risk of progression of CRF (For review, Locatelli and Del Vecchio, 2000). In support of 
that, age of the studied patients was significantly correlated with diastolic blood pressure 
at diagnosis and systolic blood pressure during follow up. A large number of studies have 
shown that systemic blood pressure increase with age (Malberti, et al.T 1997). Flowever, 
very few have made the association of age-blood pressure level and progression of CRF.
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Proteinuria was the third factor studied It has been reported that proteinuria is a marker 
for the progression of CRF (Jafar, et aL, 2001; Locatelli and Del Vecchio, 2000). There 
were significant associations between both proteinuria at onset and mean of proteinuria 
during follow-up as well as the rate of progression of CRF. Many studies also found that 
the level of proteinuria was correlated with the rate of decline of renal function 
(Williams, el aL, 1988 and Wight, ef aL, 1992). It has been argued by that the proteinuria 
itself may be nephrotoxic accelerating the progression of both glomerulosclerosis 
(Bertani and Remuzzi 1993) and that of tubulointerstitial scarring (For review, Harris, 
2000). This may be mediated through the transudation of circulating proteins into the 
mesangsum of damaged glomeruli causing the activation of mesangial cells (For review, 
Harris, 2000). In the tubules, exposure to high amounts of filtered proteins may stimulate 
and activate tubular epithelial cells to synthesise and release cytokines, chemokines as 
well as fibrogenic growth factors (For review, Jemigan and Eddy, 2000; Eddy, 2001).
Hypertension was the fourth risk factor studied. There was no significant difference in 
terms of blood pressure and progression of CRF. This contrasts with data reported by 
Locatelli et aL, (2000). This might be due, firstly to the small size of the studied cohort 
secondly it might be due to the fact that patients were receiving anti-hypertensive therapy 
thus controlling and normalizing some of the blood pressure readings. There was 
statistically significant correlations between systolic blood pressure, diastolic blood 
pressure, at diagnosis and during follow-up with proteinuria both at the time of diagnosis 
and follow-up. Further, this is a well-known fact that with increasing blood pressure 
proteinuria is raised. There were also positive correlations between blood pressure, 
proteinuria and the levels of serum triglycerides.
Surprisingly, there were higher circulating lipid levels (both cholesterol and triglycerides) 
in non-progressors compared to the progressors. This finding was contrary to those 
discussed by Harris (2000). Lipids might be the culprits regarding tubulointerstitial 
inflammation and fibrosis in heavy proteinuric states (Attman, et aL, 1999; Samuelsson, 
et aL, 2000). The discrepancy between my findings and the literature may be explained
8t
by the fact that some of the hyperilpidemic patients may be under treatment thus lowering 
their blood levels.
Pathological processes were studied. There was no significant association between the 
severity of progression of CRF and the severity of glomerulosclerosis. It was assumed 
that this might due to the scanty specimen available for pathological examination and the 
small number of glomeruli available for analysis. On the other hand, it was noted that 
there was a higher severity of tubulointerstitial fibrosis in the progresses compared to the 
noji-progressors. This was also expected, as other workers have reported that there is a 
significant association between the progression of CRF and the severity of interstitial 
fibrosis (Risdort et aL, 1966 and Bohfe, et aL, 1981; For review, Jemigan and Eddy,
2000). The prognostic superiority of the tubulointerstitial scarring over 
glomerulosclerosis may be a simple reflection that the area covered by the former within 
a renal biopsy Is considerably larger than that representing glomeruli, On the other hand, 
it may be a genuine difference reflecting the importance of tubulointerstitial lesions in 
relation to decline In renal function
3.6 Conclusion
• Men were found to have a higher frequency of progressive CRF/ESRF than women.
• The age was significantly correlated with diastolic blood pressure at diagnosis and 
systolic blood pressure during the follow-up.
• There was a highly' significant association between the severity  ^of progression of CRF 
and the severity of proteinuria both at diagnosis and during the follow-up.
• The progression of CRF was associated with tubulointerstitial fibrosis rather than 
glomerulosclerosis.
82
Chapter 4
Investigation of four single nucleotide 
polymorphisms in the TGF-pi gene
4.1 Introduction
Genetic definitions
Each human genome has approximately three billion bases, which are arranged in a 
unique order (the sequence of bases) and is estimated to contain approximately 30.000- 
40.000 genes. Bases that vary within DNA sequences from one individual to another, are 
known as single nucleotide polymorphisms (SNPs). The term “hapJolype"5 refers to a 
combination of SNPs on a chromosome, usually within the context of a particular gene.
Polymorphism is a word derived from the Greek for ‘many forms" variations in the DNA 
sequence. It either occurs at one nucleotide or more than one nucleotide within a certain 
area, which is called polymorphic region of a gene.
An allele is a variant form of a gene. Allele frequency is a measurement of how common 
an allele is in the studied population. Carriage rate is the proportion of individuals 
carrying one copy of the allele. If the co-inheritance of one allele with another at a nearby 
locus is significantly higher than expected within the given population, it is said that 
these alleles are in “linkage disequilibrium” (Sved, 1971). Genetic association is an 
increased frequency  ^of a patieular allele or genotype in a sample of individuals with a 
particular disease trait.
Genotyping is the determination of the specific composition of an individual’s genome 
(the genetic information present which present in a particular organism) with respect to a 
specific set of markers (a marker is specific polymorphic location on a chromosome, the 
inheritance of which can be tested).
Genotyping facilitates analytic studies by allowing determination of whether the alleles 
are associated with, or causing, a particular disease. There are numerous diseases in 
which a particular polymorphism is associated with diseases. This makes research in the 
field stimulating and rewarding. Also, this type of studies may indicate markers of 
disease susceptibility and/or predictors for disease activity. Furthermore, the markers may
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lead to the early diagnosis of the disease or early prediction of the severity of that 
condition. Consequently, early medical intervention, may he applied to control disease 
activity.
TGF-fil polymorphisms mid diseases
AUelles of transforming growth faetor-pl have been implicated in the pathogenesis of a 
variety of fibrotic diseases.
One of single nucleotide polymorphism at LeuIOPro (C—>T) confer a significantly 
increased risk of osteoporosis, as shown by measurements of bone mineral density 
(Langdahi, et a l, 1997, Bertoido, et al., 2000). The same allele was associated with the 
development of end-stage heart failure in patients with cardiomyopathy (Holweg, et a l,
2001).
Another marker at Arg25Pro (G->C) is associated with increased risk of myocardial 
infarction although, surprisingly, it seems to be associated with a reduced risk of systolic 
hypertension (Cambien, et al., 3996). The G allele was associated with the development 
of fibrotic lung pathology in cystic fibrosis prior to lung transplantation and fibrosis in 
the graft (Ei-Gamel, et a i* 1997). Furthermore, carriage of the G and T allele at 
Arg25Pro and LeuIOPro respectively is associated with a deterioration of pulmonary 
function in-patients suffering from cy stic fibrosis (Arkwright, et aL, 2000).
A single base change in the TGF-pi promoter region, at C-509T (C—>T) was associated 
with higher active and acid-activated latent circulating TGF-pi levels (Grainger, et aL, 
1999). Furthermore, the same allele was associated with decreased bone mineral density 
and osteoporosis (Yamada, 2001).
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TGF-fil and the progression o f chrome renal failure
Transforming growth factor-pl la s teen implicated in the pathogenesis ©f renal fibrosis 
and the associated progression o f CRF (Yoshioka, el a l , 1993; Border and Noble, 1994). 
It is believed to t  fins growth fetor is capable o f stim ulating the synthesis and decreasing 
the breakdown o f collagenous extracellular matrix (ECM) { Yoshioka, et. aiL, 1993). 
Circulating TGF-pi levels have teen found to be higher in African-American patients 
with progressive CRF (SuttentMran, e t a l,  2000). Similarly, tissue levels o f TGF-pl 
have been found by temtmoMstoefiemistry, to be up-regulated within the kidneys o f 
patients with diabetic (Yamamoto, e& a l, 1993) and non-diabetic (Datta, et a l , 1999) 
nephropathies. Therefore, the study o f TGF-pi polymorphism has teen undertaken 
recently in patients with renal diseases.
Transforming growth faetor-pi polymorphism at LeuIOPro (T-*C) is significantly 
associated with t o  development o f renal failure in patients undergoing heart 
transplantation and tested with cyclosporin A (Baan, el al., 2000). Also, TGF-pl 
polymorphism at Thr263He in exon 5 (C->T) shows a weak association with the 
development o f nephropathy in diabetic patients (Pociot, et a lT J 99S). Polymorphism at 
Arg25Pro (C-^G) was associated with elevation o f both systolic and diastolic blood 
pressure in ESRF patients (Li, el a l, 1999). Furthermore, in the same study, it was noted 
that carriers o f the same allele also had higher circulating TGF-Bl levels (Li, et a l, 
1999). On the otter hand, a study in African-Americans with ESRF foiled to show any 
significant association between TGF-Bl or PDGF genetic polymorphisms and 
susceptibility to progression o f CRF to ESRD (Fridman, et aI, 1997).
Aim ofthesiudp
With the above studies in mind, I have undertaken to investigate associations between 
TGF-Bl polymorphisms and susceptibility to, and/or, progression o f CRF.
I have studied a variety o f polymorphic regions as shown on table 4.1.
Table 4J , Tmmjomung growth faelor-Bl potymorpMc regions studied
\SSte | Bases | Amino add
| I-C-5Q9T 
j Common allele T S’CFFS Non-c©dirag
| Rare allele C \ years Non-coding
j  H-Le&lOPm
Common allele T 5’CKF3
I Leucine
Rare allele C 5’OCXj 3 j Proline
HI-ArglSPm  
Common allele G 5*000*3 Arginine
Rare allele C 5*C0G53 Proline
m  Thr263Ue
Common allele C 5’AOC3 | Threonine
Rare allele T 5*ATC*3 | Isoleneine
These alleles are common in Caucasians, other ethnic groups may be different
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Material and Methods 
Patients
A hundred and forty four patients with CRF/ESRF and 73 white Caucasian controls (for 
details see Chapter 2 Section 2.1.4) were included in this study. Patients with CRF were 
divided into progressors (?) and non-progressors (NP) depending on their 1/serum 
creatinine against time slope. We therefore studied 112 progressors and 32 non- 
progressors. As previously described, all patients with ESRF were considered 
progressors. Patients who were not on renal replacement therapy (RRT) were followed- 
up retrospectively for 58.8+4.8 months (mean ± SEM). The patients were also classified 
into total CRF patient group (n = 143) and CRF patients without polycystic kidney 
disease (PKD) or obstructive uropathy (DU) (n = 126)
Polycystic kidney disease (PKD) was excluded sometimes from the analysis because it is 
inherited by particular genes: PKD1 an 16p and PKD2 on 4q 13-23. Furthermore, OU was 
sometimes excluded from the analysis because the progression of CRF might be due to 
mechanical causes rather than the effect of TGF-BI polymorphisms.
Blood pressure (systolic and diastolic) at diagnosis and during follow-up, serum 
creatinine lev els during the follow-up period from which the J/serum creatinine against 
time slops was derived and proteinuria at diagnosis and during follow-up. For details see 
Chapter 2 Section 2.1.4.
Twenty four renal biopsies were available for histological analysis. Emphasis was on 
glomerulosclerosis and tubulointerstitial fibrosis scores as well as level of inflammatory 
cellular infiltration. An arbitrary? severity score from 0-4 was applied to all these 
parameters. For details see Chapter 2 Section 2.5.
Methodology
Deoxyribonucleic acid (DNA) was extracted from leukocytes from peripheral blood 
samples using the protocol given in the Material and Methods section (chapter 2 section
2.2.2).
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Genomic DNA concentration was estimated by measuring the absorbance at 260 nm. The 
ratio of absorbance at 26Qnm to 28Gnm (see chapter 2, section 2.2.3), allowed assessment 
of the purity of DNA.
Polymerase chain reaction (PCR) was performed on the purified DNA extracted from 
patients with CRF/ESRF and controls.
Four polymorphisms in the TGF-BI gene were investigated: LeuIOPro; Arg25Pro; 
Thr263Ile and C-509T (see Chapter 2, Section 2.3.1). Genomic DNA, PCR products and 
digestion products were visualised by agarose gel electrophoresis (see Chapter 2, Section
2.4).
Statistical analysis
The Hardy-Weinberg equation was used to predict the expected distribution of genotypes 
at given allele frequencies. Chi squared analysis was used to test the null hypothesis (see 
Chapter 2, Section 2.S) that there was no difference in genotype distributions between 
two groups. Comparisons between groups in relation to a range of clinical parameters 
relied on the student t  test which was carried out using Microsoft EXCEL. A p value of 
less than 0.05 was considered significant P-value were not subjected to Benteroni 
correction (ie. Each p-value multiplied by the number of independent tests carried out), 
since tests were not independent.
The coeffiecient of the linkage disequilibrium (D’) was calculated by using the following 
formula.
D’ = (1W  FaB-ILb PL& P \B - FaB PAb)
Alleles A and a are segregating at one locus, and B and b are segregating at the second. 
There are, therefore, four possible gametes, ab, aB, Ab and AB. The results should be 
between -1 and +1. If D,=l, this means that there is complete association.
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4.3 Results
4.3.1 Investigation of DNA quality
43.1.1 Yield
Deoxyribonucleic acid was extracted from 5 -  10 ml of venous blood Samples were 
resuspetided in 200 - 4G0pJ of distilled water. Optical density at 260nm ranged from 
0.016 to 0.295 (concentration ranging from 8Q0|Lig/ml to 14.75jag/ml). Differences in 
DNA concentrations were due to differences in the initial volume of the Wood amount 
from which DNA was extracted. White blood cell count also affects the DNA 
concentration. The yield ranged from 20 — 30 pg/fnl of blood. The ratio between optical 
density at 260nm and 280nm was used to assess the purity of DNA. In the studied 
samples, the ratio ranged from L6 to 2. Most of samples gave a ratio of around 1.8, 
indicating that most of the extracted DNA samples were pure.
4.3.1.2 Analysis by agarose gel electrophoresis
Agarose (0.8%) gel electrophoresis was used to investigate the quality of the extracted 
DNA from the white blood cells of the CRF patients. Although there was considerable 
degradation of the DNA (Figure 4.1), its ability to act as a template for ICR was not 
affected
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Figure 4A, Agarose gel electrophoresis (0.8%) o f extracted DNA from  the blood 
samples o f the patients with CRF
1 2  J 4 5 6
Legend: samples 1 and 5 are degraded or mainly RNA.
4A  C-5G9T
Polymerase chain reaction (PCR) products of 56 control and 142 patients were digested 
with B.siB&l for 12 hours. The PCR product sizes were 503bp before digestion and 234bp 
if digestion happened. The results of the genotyping were cheeked by the Hardy- 
Weinberg equation (Figure 4.2, Table 4.2).
9]
Figure 4.2. The genotyping at C-5&9T
1 2 3 4 5 6 7 8 9 10 11 12
053%$
L078bpS72bp‘
j Lane 1
i .  .
Marker ($XI 74 DNA/HaeJH}
Lane 2
i
Heterozygote (TC)
i Lane 3 and 4| Homozygote (TT)
I Lane 5 Homozygote (CC)
| Lane 6 Heterozygote (TC)
| Lane 7-10 Homozvgote (TT) |j Lane 11 Negative control
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Table 4.2. C-509Tgenotyping in control and CRF groups
Genotyping TT I TC
i!
CC Total A lldefrequencies
1- Control group 22 1 28j 5 55 (T = 0.66, C = 0.34)
2-CRF group 83 1 52
!
7 142 (T = 0.77, €  = 0.23)
The genotype results were cheeked by the Hardy-Weinberg equation. The genotyping 
was within equilibrium (Table 4.3). The distribution of genotypes observed did not differ 
from that expected from a population in Hardy-Weinberg equilibrium.
Table 43, Hardy- Weinberg analysis o f C-509T
Observed genotypes % Expecting genotypes
1- Control group
1Heterozygous 28 46 25.3
Homozygous T 22 42 23.1
Homozygous C 5 12 6.6
Total 55 100 55
2-CRFgroup
Heterozygous 52 35 49.7
Homozygous T J 83
! 60 0
0 k>
Homozygous C j 7 5 7.1
Total 1 142
1
100 142
Hardy-Weinberg equation in the control group:
X2 = (Observ ed - Expected)2 
Expected
(22-23  A )2 + (28- 25312 + (5 -6 .6 }2 = 0.728
23.1 25.3 6.6
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p value for %' at two degree of freedom = 0.7
Hardy-Weinherg equation in the CRF group:
X2 = (Observed - Expected)2 
Expected
(83 -  85.2r + (52- 49.7T + (7 -7 .  i f  -  0.164
85.2 49.7 7.1
p value for x2 at two degree of freedom = 0.9
The balance of genotypes observed did not differ from that of expected from Hardy- 
Weinberg equation in either control or CRF groups (p value > 0.05).
4.4.1 Susceptibility to CRF
The carriage rate of the T allele was significantly higher in both the whole CRF patients 
group and CRF patients without PKD and obstructive uropathy groups compared to the 
control group (Tables 4.4 and 4.5). According to the significance of the regression of the 
1/serum creatinine slope, CRF patients were classified into progressors and non- 
progressors (chapter 2). The carnage rate of the T allele was significantly higher in the 
progressors compared to the control group in total CRF patients (Table 4.4) and in CRF 
patients without PKD and OU (Table 4.5).
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Table 4.4. Testing fa r  association ofC -509T genotype with susceptibility to CRF
| m th  C  j Without C
) 1(CC+TC) (TT)1
Total £  at one degree
1o f freedom\
' P value
\
i CRF patientsI 59 | 831
142 ! 5.25 0.022* j
i Control group 33 | 22 55
! !Total 92 I 105
1
197 I
1
CRF progressors 41 j 69 110 7.66 0.0056* I
Control group
!. . j
33 | 2251 55 1 1 1
Total1 I74 I 911 .65 | ;I i !
Table 4,5. Testing o f the susceptibility' o f genotype at C-509T to CRF in patients 
without PKD or obstructive uropathy
With C 
(CCFTQ
Without
(TT)
Total £  (at two degree 
o f freedom)
TT"......P value
j CRF patients
I \ ”
7! 126 4.1 0.043*
1Control group 33 22 55 . i
!
Total 88 93 181
!| CRF progressors
1. !
38 60 98 638 0.012* i
! Control group
i
33
{
22 55
Total 171
.........................................................
82 | 153 ;
1
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4.4.2 Progression of CEF
The distribution of progressors and oon-progressors according to genoty pe at this locus is 
shown in table 4.6. The distribution of genotypes in the CRF group following removal of 
the patients with OU and PKD is shown in table 4.7.
The number of progressive CRF patterns was significantly higher in patients homozygous 
for the T allele (TT) compared to others (Tables 4.6 and 4.7) both in the total CRF 
patients (odds ratio 1.67, 95% confidence interval 1.1-2.5) and after removal PKD and 
obstructive uropathy (odds ratio 2.44,95% confidence interval 1.5-3.7).
Table 4.6. Testingfar association ofgenotype at C-509T with progression o f CRF
With C \ 
(CC+TQ U
Total ; at one degree 
o f freedom
P value
CRF progressors 41 i 69
!
110 3.68 P=0.055*
CRF Non-prosressors 18 14
i
32 5
Total 59 i 83
|»
142 J
i !
s
Table 4.7. Testing fo r  association o f genotype at C-509T with progression o f CRF in 
patients without PKD or OU
i| - -----  ----
■
mth c
(CC+TQ
Without C 
(TT)
Total ' /  (at two degree 
offreedom )
P  value !
CRF progressors
- . ............. ...
60 98 4.26 0.039*
CRF Non-pogressors 17 11 28
Total
\
55 71 126
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Figure 4.3. a. The distribution o f progressors and nott-progressors according to C- 
509T genotype in CRF patients without PKD or OU
TT TCC-509T genotypes
i Progressors 0  Non-progressors
Figure 4.3. b. The proportion o f progressors and non-progressors according to C-509F 
genotype
o  0.6
r>=55
■« 0.2
b )
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The number of carriers of the T allele was significantly higher in the progressors 
compared to the non-progressors in all the CRF patients and after exclusion of PKD and 
OU.
It was noted earlier (Chapter 3* section 3.4.1) that some CRF clinical parameters 
(proteinuria at diagnosis and serum creatinine levels) were significantly higher in males 
than females. The allele frequencies were then tested according to the gender (Figure
4.4). It was found that there was no significant difference in allele frequencies between 
males and females (Table 4.6).
Figure 4,4, The distribution o f C-509Tgenotype according to gender
■  Females 
□  Males
TT TC CC
C-5GST genotype
Table 4,6, The atidefrequency o f C-509T genotype according to gender
Females
1
1 Mates Total Chi square fat one 
degree o f freedom)
1 P value
j CC+TC frequency i 17I
42 59 0.103 j 0.75 Jj TT frequency\ 26 1 57 83 I !
| Total
1
f -43 |99
I
142 ! i
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4.4.3 Proteinuria
There was no difference in proteinuria at diagnosis or during follow-up between patients 
with CRF of different C-5G9T genotypes (Figure 4.5).
Figure 4.5. The distribution o f proteinuria (mean±SEM) according to C-5&9Tgenotype 
in the CRF patients
4  —
TT TC CO TT TC GC
nrcAemuria at diagnosis Proteinuria during follow-up
C-509T
On the other hand proteinuria during-follow up was higher in T-compared to €- 
homozygous in the total CRF patients (Table 4.7). Furthermore, proteinuria at diagnosis 
was higher in T-homozygotes compared to C-homozygotes in CRF patients without PKD 
or OU. Furthermore, the F-tesi was significant (Table 4.7) indicating a significant 
difference in variance between groups.
Table 4. 7, Proteinuria in patients homozygous fo r  the T and C aiieies according to 
genotype at C-5&9T
r M eam±SEM Observations s m1 II CRF total patient group 
i) Proteinuria at diagnosis
CC ! L5+0.5! 6 0.03* o o vO
TT 1 2.7+04
!
73 }
iii) Proteinuria during 
foJIow up
| CC 1.4+03 6
0.003* 0.028*
j TT
s
2.4+03 70
CRF patient without PKD 
or Oil{j i) Proteinuria at diagnosis
j cc !
•
\
0.83+03 0.01* 0.0017* |
j TT
1
2.S+0.4 64 !
ii) Proteinuria during 
follow up
1 CC I.I+03
4 0.01* 0.36
|
1 TT
................................. ....................!
23+0.4 59 j
...............................! I
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4.4.4 Blood pressure
There was no significant difference between blood pressure of CRF patients according to 
C-509T polymorphism (Figure 4.6).
Figure 4.6. C-509T genotype according to blood pressure (meandSEM) in the CRF 
without PKD or OF
Abbreviations: SBPd: systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf; systolic blood pressure during follow-up, DBPf: diastolic 
blood pressure during follow-up.
4.4.5 Pathological processes
Twenty-three patients’ renal sections were analysed. The pathological processes were 
classified into two main categories; glomerulosclerosis (GS) and tubulointerstitial fibrosis 
(IF).
4.4.5.1 Glomerulosclerosis (GS)
The distribution of genoty pes in relation to the severity of the GS is shown in figure 4.7. 
There was no difference in distribution of the different allele at C-5G9T genotype 
according to the severity of GS (Chi square at one degree of freedom = 0.38, p= 0.5).
180
oo
m
i l l  mmJ WlL. ( t & i
SBPd OBPd SBPf DBPf
■TT:72 patients OTC:50 patients C3CC:5 patients
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Figure 4.7. a. The distribution o f the severity o f glomerulosclerosis (GS) according to 
C-509T genotype
Figure 4 .7. b. The proportion o f m id  and severe GS according to C-5Q9T genotype
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4.4,5,2 Tubulointerstitial fibrosis (IF)
The distribution of genotyping in relation to the severity of GS is shown in table 4.8, 
There was no difference in distribution of the different allele at C-509T genotype 
according to the severity of IF (p value = 0.1).
Table 4.8, The distribution o f the severity o f IF  according to C-509T genotype
TT j TC/CC
\
T°t(d (Yates9 correction)
; Mild IF .............. 6 !; 10 16 2.7Severe IFj_ 5 J 2 7Total n  11 21 23 | 1
4,4.53 Renal interstitial cell infiltration (ICI)
Genotyping was performed for 21 patients who had pathology sections available.
There was a significant difference in the severity of ICI in T-homozygotes compared to 
C-homozygotes and heterozygotes (p= 0.0098) (Figure 4.8).
Figure 4,8. The distribution o f the severity o f IC I (cell/field) (meandSEM) according to 
C-509T genotype
*; p value -  0.0098
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4,5 LeuIOPro
One hundred and twenty-four CRF patients and 71 white Caucasian controls were 
genotyped Eighteen samples were excluded because they showed very faint bands (they 
might contain only small amounts of DNA). Figure 4.2 shows an example of a typical 
genotyping experiment For each patient, 2 lanes are used, each represents a different 
allele of the polymorphism. Lanes 2, 4, 6, 8 and 10 represent the T allele and lanes 3, 5,
7 ,9  and 11 represent the C allele.
Figure 4,9, ARM S PCR fo r genotyping at LeuIOPro
1 2 3 4 5 6 7 8 9 10 11
| Lane Ii Marker (4X174 DNA/Haelff)Lane 2 & 3 Hetenazygote (TC)
1 Lane4&5 Heterazygote (TC)
\ Lane 6&7 Heterozygote (TC)
1 Lane 8&9I .......t Homozygote (TT)i Lane 10 & 11 Homozygote (TT).
It is important to establish that an ARMS-PCR assay is adequately distinguishing 
between alleles. One way to assess this is to determine whether the balance of genotypes 
observed in the control sample differs from that predicted by the Hardy-Weinberg 
equation from the observed allele frequencies (p and q).
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Table 4.9. LeuIOPro genotypes in the control and CRF patients group
! Genotyping
\
CC TC TT Total Allelefrequencies
I- Control group 11 35 21 73 "St*o'IIOv©©II
2-CRF group 25 71 29 125 (T = 0.52, C = 0.48) |
Table 4.10. Genotyping resultsfor LeuIOPro in the control cohort and in CRF patients
... .................... observed genotypes % of stu died 
population
expected genotypes
I/ -  Control group
Heterozygous 1 35 48
[ 135.04
Homozygous T 27 37 27.01
Homozygous C 1 5 10.95
T o t a l 73 1 0 0 73 j2- CRF patients group 
Heterozygous 71 50 62.5
Homozygous T 29 27 33.8
Homozygous C
.
25 23 28.8 1
T o t a lL ... .........I 125 1 0 0 125
Hardy-Weinberg equation in the control group:
= ( Observed - Expected)*
Expected
(27-27.01)2 + (35-35.04)2 + (13-10.95)2 -  0.08
27.01 35.04 10.95
p value for yf at two degree of freedom = 0.96
Hardy-Weinberg equation in the CRF group:
X2 = ( Observ ed - Expected f  
Expected
(29 -  33.8)2 + (71- 62.5 )2 + (25 -  28.8)2 = 2.3 
33.8 62.5 28.8
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1*p value for yj at two degree of freedom = 0.3
The balance of genotypes observed did not differ from Hardy-Weinberg expectations in 
either control or CRF groups (p value > 0.05).
4*5.1 Susceptibility to CRF
Carriers of the C allele were moie common in the CRF group than in the controls (Table
4.11). Furthermore, it was observed that there was a higher number of carriers of the C 
allele amongst the patients with progressive CRF compared to the control group (Table
4. 11).
Table 4.11. Testing o f the susceptibility o f genotype at Leul&Pro to CRF in patients 
group
u rn
c
(CC+TC)
11 ithout 
C(TT)
Total f  at one degree 
offreedom
P value
\
Total patient group 96 29 125 4.3* 0.038* j
Control group 46 21 73
Total 142 56 198
CRF progressors 73 19 92 5.4* 0.02*
Control group 46 !; 27i 73; Total 119 ; 46 165CRF Non-progressors
23 !
10 33 0.47 0.49
Control group 46 l27 73
Total 69 j 371 106
ioe
4.5.2 Progression o f CRF
The distribution of LeiriOPro genotypes in progressors and non-progressors CRF patients 
is shown in Figures, 4.10 and 4.1L
Figure 4.10, The distribution o f CRFprogressors and non-progressors according to 
LeulOPro genotypes
IT TC
LeulOPro genotypes
■  Progressors 0  Non-progressors
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Figure 4.1 I. a. The distribution o f progressors (P) and non-progressors (NP) among 
Leu 10Pro genotypes
■
a)
TT+TG CCLeuf OPro genotypes
H Non-progressors ■ Progressors
Figure 4.11. b. The proportion of progressors and non-progressors among LeulOArg 
genotypes
05 1©©% 0.8©sz •*>»H-oc  o'€  oQ.ok.CL
b)
0.6
0.4
0.2
ri=99
n=25
TT+TC CC
LeulQPro genotypes
□ Noo-progressors ■ Progressors
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There was no difference in the distribution of any of the alleles between the progressors 
compared to non-progressors (Table 4.11).
Table 4,1L Testing fo r  association o f genotype at LeulOPro with progression o f CRF
! m ih
i 1
Without
C(TT)
Total /  at one degree 
offreedom
P value
1 CRF patient groupj( CRF progressors
i
73 92 127 026
i! CRF Non-proeressors
I
23 ! 10
!
33
: Total
i■........  ... . ..... ... ......................
96 :
I
29 125 i
!
It was noted earVier (Chapter 3, section 3.4.1) that the CRF parameters (proteinuria and 
serum creatinine) mere higher significantly in males than females. The allele frequencies 
were tested according to gender (Figure 4.12). It was found that there was no significant 
difference in allele frequencies between males and females (Table 4.12),
Figure 4.12. The distribution o f Leul OPro genotype according to gender
■  Females 
El Males ii
LeulOPro genotyes
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Table 4.12. The allelefrequency o f LeulOPro genotype according to gender
j Females M ates
. . .
Total Chi square (at one P value 
degree o f freedom)
| CC+TC frequency j 27
i i!
69 96 0.092 0.76
*2 I| TT frequency 1 9
i
20 29
1 |
| Total j 36
1 I
89 125
I I
4.5.3 Proteinuria
There was no difference in proteinuria at diagnosis or during the follow-up between 
patients with CRF of different LeulOPro genotypes [p(F-test) = 0.03, p(t-test) = 0.46] or 
during follow-up [pCT-test) = 0.026, p(t-test = 0.8)] (Pigure 4.13 ).
Figure 4.13. The distribution o f proteinuria (mean±SEM) according to LeulOPro 
genotype in the CRF patients
Proteinuria at diagnosis Proteinuria during follow up
LeulOPro genotypes
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4.5,4 Blood pressure
There was no significant difference between blood pressure in CRF patients according to 
Leu 1 OPro poljmorphism (Figure 4, J 4).
Figure 4.6. LeulOPro genotype according to blood pressure (meandtSEM) in the CRF 
patients group
m i \ :z6 paoenss m j u:t>y querns u u u z y  patients
Abbreviations: SBPd; systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf: systolic blood pressure during follow-up, DBPf: diastolic 
blood pressure during follow-up.
4.5.5 Glomerulosclerosis (GS)
Twenty-two patients were analysed. Three of the 5 patients homozygous for the T allele 
(TT) had severe GS compared to 9 of 17 the heterozygotes and homozygotes for the C 
allele (Figure 4.15). This result was not significant (p value > 0.05 at one degree of 
freedom).
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Figure 4A 5. cl The distribution o f seventy o f glomerulosclerosis (GS) according to 
LeulOPro genotype
TT TOCC
Leu 10P*o genotypes
m Mild G S 
■ Severe GS
Figure 4.15, b. The proportion o f mild and severe GS according to LeulOPro genotype
n=17
GMldGS 
■  Severe GS
TT TC+CC
b) LeulOPro
j_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
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4.5,6 Tubulointecstitial fibrous
The distribution of patients with tubulointerstitial fibrosis according to LeulOPro 
genotype is shown in (Table 4.13). The result was not significant (p value = 0.4 at one 
degree of freedom).
Table 4.13. Distribution o f genotypes among patients with interstitialfibrosis (IF)
! cc
s
TC/TT
;
Total ] (Tates' correction)
I IMild IF i s
;
\ 12I 17 1 0.7! !Severe IF
' r 5 1! )Total ri j 16i 22. ! J
4.5.7 Renat interstitial celI infiltration (ICS)
Genotyping was done for 19 patients who had pathology sections available. There was no 
significant difference between the severity of IC1 in T-homozygoles compared to other 
patients (Figure 4.16).
Figure 4,16. The distribution o f the severity o f IF  according to Leu 1ftPro genotype
  ------
- , v -
« i p ahmmrnmm
LeulOPro
] 13
4.6 Arg25Pro
One hundred and forty three CRF patients and 78 white Caucasian individuals from 
Sheffield were genotjped (Figure 4.17). There are two lanes for each subject tested Even 
numbered lanes represent the C-allele and odd numbered lanes (expect lane 1) represent 
the G-allele.
Figure 4.17. Figure 4.2. ARM S PCR fo r  genotyping at Arg25Pro
I 2 3 4 5 6 7 8 9 10 It
; 1st row
I Lane 1 Marker (<j>X174 DNA/Haelll)
Lane 2&3 Homozygote (GG)
Lane4&5 Heterozvgote (CG)
Lane 6&7 Homozygote (GG)
Lane 8&9 Homozygote (GG)
Lane iO&i 1 Homozygote (GG)
2nd row
Lane 1 Marker (4X174 DNA/Haelll)
Lane 2&3 Homozygote (GG)
Lane4&5 Homozygote (GG)
Lane 6&7 Homozygote (GG)
Lane S&9 Heterozygote (CG)
Lane IG&I1 Negative control (no DNA template)
L353bp-—------
872hfs
310hp 
281tsp
1 9 4 h p  — '
Allele frequencies were not significantly different in CRF patients compared to the 
control group (Table 4.14).
Table 4.14, Arg25Pro genotypes in the control group and CRF patients
f Genotyping [ GG GC cc Total Allele frequencies
1- Control group ) 59 j 19 0 78 (T =0.87, C = 0.13) 12-CRFpatients group 112
_ L
I 30
.  i! . . . . . . . . . . . . . . . . . . .
1 143
.
(G = 0.89,0 = 0.11)
.................................I
The balance of genotypes did not differe from that expected in a population in Hardy- 
Weinberg equilibrium in either the patients or control groups (Table 4.15).
Table 4.15. Hardy- It einherg analysis fo r  Arg25Pro in the control and CRF patients 
groups
|.................... ........ .. ....IJ - -f Observed genotypes
I
% Expected genotypes
1 i) Control
Heterozygous 19 2 1 16.5
Homozygous G 1 59 77 6 0 . 1
Homozygous C \ 0
ji . . .  . . .
2 0 . 0 2
Total j 78 1 0 0 78
it) CRF patients j 
group !Heterozygous J 112 78 111
Homozygous G j 30 21 30 j
Homozygous C 1 I 1
2Total 143I . ! 100 143
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Hardy-Weinberg equation in the control group:
X2 = (Observed -Ex 
Expected
(59 -60 . i f  -t- (19-16.512 + (0-0.0212 = 0.42
60.1 16.5 0.02
p value tor x2 at two degree of freedom = 0.77
Hardy-Weinberg equation in the CRF group:
X  = (Observed - Expected)*
Expected
(30 -  30)2 + (112 - i 11)2 + (1 -  2 f  = 0.5 
30 111 2
p value for %2 at two degree of freedom = 0.8
The balance of genotypes observed did not differ from Hardy-Weinberg expectations in 
either control or CRF groups (p value > 0.05).
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4.6.1 Susceptibility to CRF
There was no significant difference in the carriage of the G allele in the CRF patient 
group compared to the control group.
Table 4.16. Testing o f the susceptibility o f genotype at Arg25Pro to CRF in CRF 
patients group
Without c  
(GG)
With C 
(CG+CC)
Total P value (at one 
degree o f freedom)
CRF patients 
group
112 31 143 0.2 0.65
Control group 59 19 78
I 1
Total 171 50 221
CRF pogressors 94 18 112 2 I 0.15
Control group 59 19 78 1I I
Total 153 37 190
“  I ........ !
When patients with PKD or OU were excluded from the analysis, there was a trend for 
the G allele to be higher in patients with CRF compared to the control group (Table 4.17).
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Table 4L 17. Testing fo r  association o f genotype at Arg25Pro with susceptibility to CRF 
in  CRF patients without FED or obstructive uropathy
Without C With C Total ? P  value fat two 11 (GG) (CG+CC) degree o f freedom ) !;
i CRF progressors m 14 102 3.35 0.06
\j Control
\
59 19 78 j I |
! Total 147
:
33 180 I 9 
I 1
4.6.2 Progression o f CRF
The distribution of genotypes among progressors and non-progressors patients is shown 
in table 4.16, and figures 4.1 S.
Table 4.16. Testing fo r  association ofArg25Pro genotype with progression o f CRF
[ | Without C ff llh C Total P value (al one jI " j!
:
(GG)I j (CG+CC)
Fj 1degree o f freedom)) ' i;j CRF progressors 1 94 I 18
|
112 9.57 10.00198* 1
!S 1I CRF non-progressors
!
sg | 13
i
31
1 |
! Total !12
I
: 3i
!
143 1
1 i
Figure 4,18. a. The distribution o f progressors and non-progressors according to the 
Arg25Pro genotype
n=84
a)
GG CG+GG
Arg25Pro genotypes
! Progresses O Non-processors
Figure 4.18. b. The proportion o f progressors and non-progressors according to the 
Arg25Pro genotype
n=112 j
- I
rr=31
Arg25Pro genotypes
[Progresses 0 Noo-progressors
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There was a higher risk of progressive CRF in the G-homozygotes (GG) compared to 
patients with other genotypes in both the total CRF group (Table 4.16) and after 
exclusion of patients with PKD and obstructive uropathy. The homozygous patients for 
the G allele had a significantly higher number of progressors compared to the other 
genotypes in the total CRF patients group (odds ratio 3.77, 95% confidence interval, 2.2 - 
6) and after excluding PKD and obstructive uropathy (odds ratio=5.0O, 95% confidence 
interval 2.7 - 9).
It was noted earlier (Chapter 3, section 3.4.1) that some CRF parameters (proteinuria and 
serum creatinine) were significantly higher in males. The allele frequencies were then 
tested according to gender (Figure 4.19). It was found that there was no significant 
difference in allele frequencies according to gender (Table 4.18).
Figure 4.19. The distribution o f the Arg25Pro genotype according to gender
■  Females 
U Males
Table 4.18. The allele frequency ofArg25Pro genotype according to gender
r j Females j Males Total Chi square (at one j P value j| r degree o f freedom)
| G-frequency 1 37I f 76 113 1 j 0.31 IJ C-frequency 7j ij 23\ 30 ! A; Total 44
!
I; 99 143 1\
i 1
4.6.3 Proteinuria
There was no difference in proteinuria at diagnosis or during the follow-up between 
patients different Arg25Pro genotypes.
On the other hand it was noted that in CRF patient without PKD or obstructive uropathy, 
there was a higher level of proteinuria at diagnosis in G-homozygoles (P = 0.038) (Figure 
4.20).
Figure 4.20. Proteinuria (mean±SEM) according to LeulOPro genotype in the CRF 
patients
3.5 
3
2.5 
2
1.5 
1
0.5
0
'v'WjSJrt’.’.V,',.'
mm-f f i  j wills
GG CG+CC GG CG+CC
At diagnosis During follow upArg25Pro
4,.6,4. Blood pressure
Although there was no significant association between Arg25Pro genotype and increased 
systolic blood pressure at diagnosis, there was a significant association between the 
presence of the C allele and increased diastolic blood pressure at onset in the CRF group. 
There was no significant association between genotype and systolic or diastolic blood 
pressure during foilow-up in the CRF group (Figure 4.21). On the other hand there was 
no association between the blood pressure and genotype in CRF patients without PKD or 
OU.
Figure 4,21, A rg2 5 Pro genotype and blood pressure (meandSEM) in the CRF patients 
group
Abbreviations: SBPd: Systolic blood pressure at diagnosis, DBPd: Diastolic blood 
pressure at diagnosis, SBPf; Systolic blood pressure during follow-up, DBPf; Diastolic 
blood pressure during follow-up.
*= statistically significant (p=0.045).
Twenty eight patients were diagnosed as having hypertensive glomerulosclerosis. There 
was a highly significant association of hypertensive nephrosclerosis with homozygosity 
for the G allele (%2 = 11 at one degree of freedom, p = 0.0009) (Table 4.19).
Table 4.19L The distribution ofArg25Pro genotyping according to CRF progression in 
hypertensive nephrosclerosis
j ................ GG
\
— ........  "| ■ ' .....Total j jjf (Yates' correction)
............  |I CRF Progressors [9 1 1 20 j 11
j CRF Non-progress 
ors
3 j 5
!i
8
i
Total 22 ] 61 28 I
4.6.5 Pathological processes
Twenty-four renal sections were analysed. The pathological processes were classified 
into two main categories; glomerulosclerosis (GS) and tubulointerstitial fibrosis (IF).
4.6.5.1 Glomerulosclerosis (GS)
Twenty-four sections from the CRF patients were studied It was noted that 
homozygosity7 for the G allele was much more common in severe GS compared to mild 
GS [x“ ( Yates7 correction = 4.2, p value = 0.04 at one degree of freedom] (Figure 4.22).
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Figure 4 ,2 2 a. The distribution o f severe and mild glomerulosclerosis (GS) according 
to Arg25Pro genotype
SlSevereGS HMIdGS
*: p value = 0.04
Figure 4.22,b The proportion o f m ild and sei’ere GS according to ArglSPro genotype
c.22
fl#a,
<SiA■+*
©C©
©S l©S-&m
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
n = l7
W SW B1 Vw
GG
n=7
Arg25ProCG
b) ere M ild  G S
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4.6.5.2 Tubulaintersiitialfibrosis (IF)
The distribution of genotypes according to the severity of IF is shown in table 4,20, There 
was no statistically significant difference between the Arg25Pro genotype and the 
severity of IF (p= 0.65 at one degree of freedom ).
Table 4.20. The distribution ofArg25Pro genotype according to the severity o f 
interstitialfibrosis
r GC/CC Total X  (Tates* correction) )i Moderate interstitial fibrosis 131 6 19 0,2 j1 Severe interstitial fibrosis I 31 j »2 5 1
i Total | 161! I I
8 24
5
4.6.5.3 Renal interstitial cellular infiltration (ICI)
Genotyping was performed for 22 patients who had pathology sections available. There 
was no significant difference between the extent of ICI in patients homozygous for the G 
allele compared to others (p value = 0.3) (Figure 4.23 ).
Figure 4.23. The distribution o f ArglSPro according to interstitial cellular infiltration 
(mean±SEM)
Arg25Pro genotype
]25
4.7 Thr263Ite
One hundred and foil}7 two CRF patients were genotyped by using mutation screen PCR 
(figure 4.24).
Figure 4.24I Gen&typing at Thr263Me
1 2 3 4 5  6 7 8 9 10 11
Lane I is the marker ($K174 DNA/'Haelll), lanes samples 2 -8  are homozygous fo r the C 
allele, sample 9 is heterozygous (C l)
Five patients were heterozygous (CT), the remaining patients were homozygous for the C 
(CC) allele- There was no significant association between the different alleles at 
Thr263Ile and the different parameters of CRF.
The genotyping results were checked by the Hardy-Weinberg analysis. The genotyping 
balance of genotypes did not differ significantly from that expected from a population in 
Hardy-Weinberg equilibrium (Table 4.21).
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Table 4.21. Hardy-Weinberg analysis o f Thr2631le
I No o f observed genotyping 
\ frequencies
% No o f expecting genotyping 
frequencies
CRF patients group
Heterozygous 5 3.5 4.97 i
Homozygous C Jj 137 96.43 136.9
Homozygous T ! 0 0.0031 0.043 |
Total 1421 100 142
Hardy-Weinberg equation in CRF group
Expected
(137-136.9j2 + (5-4.971? + (0-0.Q43)2 = 0.0.00042
136.9 4.97 0.043
p value for x  at two degree of freedom = 0.9
The balance of genotypes observed did not differ from Hardy-Weinberg expectations (p 
value > 0.05).
4.7.1 Progression o f CRF
There was no significant difference between the genotypes of the progessors and non- 
progressors (Table 4.22) (odds ratio 2.9, 95% confidence interval -1.1 - 9).
Table 4.22. The progression o f CRF according to Thr263Re genotype
CC TC
I !
Total f  at one degree of freedom 
(Yates* correction)
P value
CRF patients
Progressors j 108 j 3 142
0.72 0.4
IMon-progressors I 29 !| 2
1 Is
55
Total 1 92 |j 105..........  I I 197
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There was no significant association between 1111263116 genotype and proteinuria at 
diagnosis or during the follow-up (Table 4.30). Further, there was no significant 
difference between Thr26311e genotype and blood pressure at diagnosis or systolic blood 
pressure during the follow-up. There was a significantly higher diastolic blood pressure 
during follow-up in the C-homozygotes compared to heterozygotes (Table 4.23).
Table 4.23. D ifferent parameters in CRF patients according to genotype a t Tltr263Ile
MeamdSEM Observations pm m
i) Proteinuria (g&4ftr) at
diagnosis
CC i 2.451025
.
134 0.3 0.7
TC 2.9610.4 5
ii) Proteinuria (g/24hr) during 
follow-up
CC 1 2.310.22 133 0.5 0.7
TC 2.810.1 5
SBFd (nunHg)
CC 15312.5 130 0.6 0.5
TC 143114 3
SBPd (mmEg)
CC 8811.4 130 0.1 0.2
TC 'I 7613 3SBPf (nunHg) 
CC 149.812 130 0.3 0.6
TC 143114 3
DBPf(mmHg)
CC 8511.1 130 0.5 0.03*
TC 7015 3
Abbreviations: SBPd: systolic blood pressure at diagnosis; D BPd: diastolic blood
pressure at diagnosis; SBPf: systolic blood pressure during follow up; DBPf: diastolic 
blood pressure during follow-up.
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Because of the rarity,7 of this polymorphism it was found that all of the studied 
pathological sections were of the CC genoty pe.
4.8 Linkage disequitibium studies
There was significant linkage disequilibrium between alleles at the studied loci, There 
was a strong linkage disequilibrium between the alleles at the Arg25Pro and T (-509) C 
polymorphic sites, for example, the G-allele of Arg25Pro and the T-allele of C-509T 
(Table 4.24). Linkage disequilibrium was also noted between the different alleles of 
Arg25Pro and LeulOPro polymorphisms (Table 4.24). Furthermore, linkage 
disequilibrium was found between C-509T and LeulOPro (Table 4.24).
The coefficient of linkage disequilibrium (D') was calculated for the studied 
polymorphisms using the formula given earlier in this chapter (section 4.1).
D' for LeulOPro and Arg25Pro was -0.57 which means that there is a negative 
association between the G allele at Arg25Pro and the T allele at LeulOPro.
D’ for C-509T and Arg25Pro was 0.87 which means that there is a strong association 
between the G allele at Arg25Pr© and the T allele at C-509T.
D' was 0,8 for C-509T and LeulOPro. This means that there is a strong association 
between the T alleles of both polymorphisms.
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Table 4.24. Linkage disequilibrium between alleles o f studied polymorphisms
1 I- C-509T and j WithC allele at
!; LeulOPro LeulOPro
Without C-allele 
at LeulOPro
Total p=0.©2
!
| With C-allele atC-509T j IS
) j
14 32
\ Without C-allele at C- j J 
! 509T1 1
7 8
| Totali i 19! 21 40 || n-C-S09Tand 
Arg25Pro
I Without C-allele 
at Arg25Pro
With C-allele at 
Arg25Pro
Total p=a©o©9 |
ij
1 With C-afleie at C- 
j 509T
71
i .
14 85 ;
| Without C-allele at C- 
509T
7
1
:
5 j 7
! iTotal 73 19 i 92
| I| III- LeulOPro aad 
j Arg25Pro
Without C-allele 
at ArglSPro
With C-allele at TotalsArg25Pro
p=6.034 |
1
\ Without C-allele atij LeulOPro
15 11 126
ij With C-allele at
I LeulOPro
■
25
.
5 j 30
I 1
| Total 40 16 561 1
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D o u b l e  h o m o z y g o t e s  f o r  t h e  G  a l l e l e  a t  A r g 2 5 P r o  a n d  t h e  T  a l l e l e  a t  C - 5 0 9 T  w e r e  m o r e  
l i a b l e  t o  p r o g r e s s  t o  E S R F  t h a n  p a t i e n t s  w i t h  o t h e r  g e n o t y p e s  ( T a b l e  4 . 2 5 ) .  O n  t h e  o t h e r  
h a n d ,  t h e r e  w a s  n o  s i g n i f i c a n t  d i f f e r e n c e  i n  t h e  o t h e r  s t u d i e d  p a r a m e t e r s  a s s o c i a t e d  w i t h  
d o u b l e  h o m o z y g o s i t y  ( O R = 3 . 8 ,  C l :  1  -  9 )  ( T a b l e  4 . 2 6 ) .
Table 4.25. Distribution o f A rg2 5 Pro and C-509T genotypes among CRF progressors
and non-progressors
Progressors
i
Non-progressors Total
1GG + TT j 59 8 67[_
GG + TC j 20 8 28
GG + TT | 2
I 0 2
CG + TT IQ
1
4 14
CG + TC (6 4 10
CG + CC !i 1
j
4 5
Total j 98
.................................  i. ...........
28 126
J
Table 4.26. Arg25Pro and C-509Tgenotypes among the different parameters
Double homozygotes (GG + TT)
j  ( n = 6 7 )
Other genotypes
(n=59) |
C R F  p r o g r e s s o r s 5 9 * 3 9
C R F  n o n - p r o g r e s s o r s 8 * 2 0
P r o t e i n u r i a  ( g / 2 4 h r s ) 2 . 8 1 0 . 5 2 . 1 1 0 . 3
B P  ( m m H g ) 1 5 1 . 6 1 2  A 1 4 9 . 9 1 2 . 8
Ij
S l o p e
.................................
- 2 . 7 E - 0 5 U  . 2 E - 0 5 - 8 . 6 1 9 E - 0 6  |
 I_______
^ s i g n i f i c a n t  d i f f e r e n c e  ( p H ) . 0 0 2 )
4.9 Discussion
In this study TGF-B1 gene polymorphisms were screened to investigate susceptibility to, 
and progression of, CRF in a Caucasian population of patients with CRF.
The calculated allele frequencies at C-509T of the control group were simailar to those 
reported in European (Sergio, et aL, 1997), UK (Lympany, et aL, 1998) and Japanese 
(Yamada, et at., 2001) populations. On the other hand, they were different from those 
reported in one UK study (Grainger, et aL, 1999). The allele frequency at C-509T 
reported by Grainger and Ms colleagues (1999) was also different from other published 
studies (Lario, et aL, 1997; Lympany, et aL, 1998; Yamada, et aL, 2001). The allele 
frequencies of control and CRF patients at LeulOPro were similar to other published 
work (Cambien, et aL, 1996, Lympany, et aL, 1998, Yamada, et aL, 1998, Syrris, et aL, 
1998, Yasuhiro. et aL, 2001). Furthermore, it was noted that there was no difference m 
allele frequencies at Arg25Pro between this study and other published studies (Cambien, 
et aL, 1996, Lympany, et a l, 1998, Li, et aL, 1998, El-Gamel, et aL, 1998). Moreover, 
there was no difference between the allele frequency of the studied group and the 
published frequency at Thr263IIe (Cambien, et a l, 1996, Pociot, et aL, 1998, Lympany, 
et a l, 1998, Syrris et al.* 1998).
Carriage of the €  allele at LeulOPro and the T-alleie at C-509T was significantly more 
frequent in the CRF patient group than in the control group. Furthermore, the same alleles 
were significantly more frequent in progressors with CRF compared to the control group. 
This means that carriers of these alleles are at greater risk of progression of CRF.
Subsequently, when the frequency of progressive renal insufficiency amongst different 
genotypes was analysed, those patients who were homozygous for the G alleie 
(Arg25Pro) and those who were homozygous for the T allele (C-5G9T) were found to be 
at higher risk. No such difference was noted for the other studied genotypes including 
LeulOPro and Thr263Ile. These findings are novel. Previous authors have noted an 
association between the G allele at Arg25Pro and early onset of cardiac allograft 
vasculopathy (Densem, et al., 1999). However, others failed to observe an association
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between GG al Arg25Pro or TT at C-509T and atherosclerotic coronary artery' disease in 
native hearts (Syrris, et al[ 1998, Holweg, et a l, 2001). The Etude Cas-Temoin de 
rinfarctus du Myocarde (ECTIM) study on TGF-B1 polymorphism in relation to 
myocardial infarction and blood pressure observed an increased risk of myocardial 
infarction and reduced risk of hypertension in patients homozygous for the C allele 
(Cambien, et al, 1996). Homozygosity for the G allele at codon 25 of the leader sequence 
of TGF-pl was associated with fibrotic lung disease (EI-Gamel, et a l, 1998). 
Furthermore, these authors noted that this genotype was associated with the development 
of pulmonary fibrosis in lung allografts. The G allele was also more frequent in patients 
with progressive cystic fibrosis ( Arkwright et al., 2001). Grainger and colleagues (1999) 
reported a relationship between high levels of circulating TGF-p 1 and homozygosity for 
the T allele at C-509T in normal individuals.
The association between carriage of the G allele (Arg25Pro) and the T alleles (C-509T) 
and the progression of CRF may be a reflection of the impact of these genotypes on other 
risk factors associated with the progression of renal diseases. Of these, systemic 
hypertension and proteinuria are known to be important prognostic factors (Harris, 2000; 
Locatelli and Del Vecchio, 2000). In this study, no association was observed between 
levels of systemic blood pressure and disease progression or the studied alleles. On the 
other hand, proteinuria levels correlated with the rate of decline in renal function. Further, 
proteinuria at diagnosis was significantly higher in patients homozygous for the G 
(Arg25Pro) than other genotypes of the same polymorphism. Proteinuria during follow- 
up was also significantly  ^ higher in patients homozygous for the T aiieie than those 
homozygous for the C allele at C-509T. These observations may explain the higher 
frequency of progressors with these genotypes in view of the severity of proteinuria in 
these patients. It has been postulated that heavy proteinuria is not only a marker of 
progressive renal diseases, but that it also contributes directly to the renal scarring 
process (Burton and Harris, 19%; tor review, Harris, 2000). This has been attributed to 
the activation of proximal tubulaT cells by excessive proteinuria and its reabsorption by 
these cells, leading to their stimulation and release of pro-inflammatory chemokines and 
cytokines (Prodjosudjadi, et a if 1995; for review, Harris, 2000; Eddy, 2001). This, in
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turn, would contribute to the exacerbation of interstitial cellular infiltration and 
inflammation leading to renal interstitial fibrosis (For review, Harris, 2000), Of note no 
correlation between the severity of proteinuria and that of the interstitial cellular infiltrate 
was observed in tin’s study. However, there was significantly more tubuiointerstitia! 
cellular infiltration in homozygotes for the T allele (C-509T), Interstitial inflammation 
has been previously implicated as an important prognostic factor for the progression of a 
wide range of renal diseases (Alexopoulos, et al, 1989, Eddy 2001).
Bean and colleagues (2000) reported a significant association between the presence of 
proline at codon 10 and the development of CRF, but this association was found in 
patients who underwent a heart transplantation and treated by cyclosporin and steroids, It 
is well established that heart M ure affects renal function. In addition to that the patients 
studied by Bean and colleagues (2000) were on cyclosporin, which perse  induce renal 
toxicity. So, in the presence of the heart failure, cyclosporin and steroids, Pro 10 might 
potentiate the impairment of renal function. Also, there was a significant association 
between the presence of ProlO and the development of end-stage heart failure, caused by 
cardiomyopathy, rather than by ischaemic heart diseases (Holweg, et ah, 2001). So, it 
might be concluded that the if ProlO was associated with renal impairment, it was mainly 
due to other factors rather than primary renal impairment. Pociot and colleagues (1998), 
however, found a weak significant association between the presence of the T allele at 
Thr263Ile in exon 5 and the development of nephropathy in diabetic patients. This study 
revealed no significant associations with other renal functional parameters. This was 
probably due to the rarity of the allelic variant.
Finally, I found that there was linkage disequilibrium between the promoter marker (C- 
509T), Arg25Pro and LeulOPro. This is a reflection of the proximity of these 
polymorphic regions within the TGF-B1 gene. Furthermore, 1 noted the presence of both 
G (Arg25Pro) and T (C-509T) homozygosity conferred the worst risk of decline in renal 
function.
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In conclusion, 1 describe for the first time in this thesis, a range of associations between 
TGF-B1 gene polymorphisms and the progression of CRF. More specifically, 1 report a 
higher frequency of progressing renal failure in homozygotes for the G (Arg25Pro) and T 
(C-509T) alleles. These associations may be related to increased proteinuria and 
glomerulosclerosis in homozy gotes for the G allele at Arg25Pro. On the other hand, the T 
allele at C-509T appears to be associated to proteinuria, tubular TGF-p I over-expression 
and interstitial inflammation.
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Chapter 5 
Circulating and tissue TGF-jil levels
5.1 Introduction
Transforming growth faclor-pl is a key factor in the regulation o f mesangiai and 
interstitial ECM turnover (Pete;, el a l, 1997, Gaedeke, el a l, 2001).
Both circulating and local TGF-pi may contribute to the development of renal fibrosis 
(Datta, et a l, 1999; Grande, el a l, 2002). Increased production of TGF-pl is essential for 
induction of progressive renal disease in both animal and human models (Border and 
Noble, 1994, 1997). Sustained abnormal production of TGF-pl alters both production 
and degradation of extracellular matrix and has been associated w ith the development of 
glomerulosclerosis (GS) in several models of renal disease (Border and Noble, 1994; 
Basile, 1999; Yu, ei a l 2002). Furthermore, high plasma levels o f active TGF-pi induce 
tubulointerstitial fibrosis, which occurs after induction of GS (Kopp, et a l, 1996). 
Transforming growth faetor-p! actions are associated with hypertension. Kopp and 
colleagues (1996) found that Mood levels o f TGF-pl were higher in “Afto-Caribbean™ 
and “Caucasian** with high blood pressure than in those with normal blood pressure. 
African Americans had higher levels of TGF-pl than their white counterparts whether or 
not they had hypertension (Sutfaanthiran, et al., 1998). Transforming growth factor beta 1 
is not the sole cause of high blood pressure, but gene variations could be used to identify 
individuals who make higher levels o f TGF-pl and might benefit from a more aggressive 
approach (American Heart Association meeting report September 14,1999).
Transforming growth factor-pl levels are markedly increased in the plasma of 
hypertensive patients. The same study postulated that TGF-pi contributes substantially to 
the development of end organ damage in essential hypertension, independently of blood 
pressure levels (Derhaschnig, el al., 2002). Complications associated with high blood 
pressure, such as kidney failure, stroke, and heart disease, may be related to a variety of 
processes that involve overproduction o f various proteins, such as angiotensin 11 and 
TGF-pl (August, et a t, 2000).
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There is no accurate method to assess the biological role of TGF-pl. Also, measurement 
of absolute levels o f TGF-p l  either at protein or messenger RNA (mRNA) level may not 
reflect biological activity. This is because of the complexities o f TGF-pi release and 
activation (Jain, et eiL, 2000). Furthermore, once TGF-pl has been activated it may be 
inhibited by local factors, so that measurement o f active TGF-pl is not more informative 
than measurement o f total TGF-pl ha assessing biological activity. Some groups have 
used deferential antibody staining o f active and latent TGF-pl, but there are few data to 
confirm the accuracy o f this method At present, there is no gold standard method to 
assess TGF-pi activities (Jain, et a t, 2000). Because there are many factors affecting 
TGF-pl after its production (activation and inhibition), it is considered more reliable to 
measure the natural processed TGF-pl (Jain, et a l, 2000).
In the kidney, TGF-pl is released mainly from activated mononuclear cells, renal 
proximal tubule cells (which may contribute to the pathogenesis o f tubulointerstitial 
injury), glomerular cells and platelets (Nathan, 1987, Erwig, et a if 2091) (see general 
introduction). Transforming growth factor-pl inhibits renal tubular epithelial cell 
proliferation, which may promote tubular cell hypertrophy, which is characteristic of 
tubulointerstitial fibrosis (For review, Jemigan and Eddy, 2000).
The intensity of interstitial TGF-pi fsotein expression was significantly related to the 
degree o f interstitial fibrosis, tabular atrophy, interstitial collagen HI expression, and 
serum creatinine values (Goumenos, et. aL„ 2001).
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5.2 Methodology
5.2.1 Circulating TGF-pl
Plasma and serum total acid activated TGFpt protein levels were measured by using sm 
ELISA Human TGF-pl Immunoassay kits (R&D Systems, UK)]. The assay
was carried out seconding to the manufacturer instructions (For detail. Materials and 
Method, Chapter 2 section 2.6).
5.Z1 Renal TGF-fil (immunostaimng)
Renal biopsies were fixed in 10% neutral buffered formalin, paraffin-embedded, sectioned 
stained using a standard immimoperoxidase staining technique (Muchaneta-Kuhara et a l, 
1996) (for details see Materials and Method Chapter 2 section 2.6). Two independent 
observers counted the presence of staining for each section. Omitting adding die primary 
antibodies (negative control) tested the non-specific binding of the secondary antibody.
5.2.3 Statistical Analysis
Analysis of the means o f the studied parameters (blood pressure and proteinuria, creatinine 
levels and serum lipids) according to the progression status of CRF are carried out using F- 
tests followed by? t-tests (unpaired, two tailed, for equal or unequal variance, as 
appropriate). Chi square analysis tests the null hypothesis. Yates’ correction was applied 
for the 2x2 contingency table if any of its cell less than 5. Correlation and regression 
between the different measurements was carried out using ANOVA test on Microsoft 
Excel. A p value < 0.05 was considered significant
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5 3  Results
53.1 Circulating TGF-pl
One hundied and thirty five patients bad tbeir circulating TGF-pi measured both in 
serum and plasma. Seven samples were excluded from the study because they looked 
autolysed. The plasma TGF-pi levels were 18479±981 pgriil (meaniSEM) and the 
serum levels were 23739±1 149 pgfrnl.
5.3.1.1 Validity o f die measurement
The inter and intra-assay coeflecients o f variations (CV) was tested on patient samples. 
The results showed that the readings o f the absorbance were very close for die same 
samples in both intm and inter-assay comparisons (Table 5.1).
Table 5.1. Precisian o f dm measurements o f plasma TGF-pl
1 Intra-assay Precisian Inter-assay Precision 1
j
I Samples I 2 I (2  Ij| |
n 20 20 10 j  10
Mean (pg/ml) I 28640
1
677 40200 38600
Standard deviation i 1200 1320 1520 1560 I|  j
CV(%) 4.2 4.8 3.7 3.9 1
. ......... ............. 1. . . !
Serum TGF-pi protein levels (23605±849 pg/ml) were significantly higher (p=0.0002) 
than the plasma TGF-p l protein levels (I8603±1016 pg/ml). This might be due to the 
feet that the platelets contribute to the serum levels of TGF-pl. There was a significant
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correlation between the serum and plasma measurements (r =0.4, p = 0.000003) (Figure 
5.1). Furthermore, excels for the significant difference between the serum levels of TGF- 
p l and the progression o f CRF (see below), both plasma and serum TGF-pi 
measurements showed compilable results in relation to the different studied parameters 
across the study.
So, plasma levels of TGF-pi protean were chosen to represent the circulating TGF-pl 
protein levels to minimise tie  effects of platelet release of TGF-p I.
Figure 5,/. Correlation between serum and plasma TGF-fil levels
m m .
r aa.
3©. c
u .0H
a
£»JB
CL
50000
40000
r = Q.4
p = 0.000003
30000 ♦, 
20000 
10000
0 ♦  ♦
0 20000 40000 60000 80000 100000
Serum TGF beta 1 (pg/mi)
140
Table 5,2. Hamm TGF-pi levels according to clinical parameters
Prameters|| ; MeandtSEM (pg/ml) ' Observations !| P(j)I : m  |J- Clinical parameters\1 Gender 
| Males
r Females1
20421±1515 
1778S±1606
93 j 0.054 
42
j
0.37
Proteinuria at diagnosis
\ < 3 g/24hrs 
> 3 g/24his
'i
I77S5±1255
20421+2550
186 1 0.054 
26
0.37
Proteinuria during follow  upjij < 3 g/24hr$
> 3 g/24hrs
19023.8±1210
19998+2875
81
35
0.01* 0.4
SBPd
! < 140 mmHg 
>140 mmHg
18812+2275
19169±1409
46
66
0.27 0.4
DBPd
< 90 mmHg 
>90 mmHg
19202+1464
18954±1954
72
40
aoo7‘ 0.19
SB P f
; < 140mmHg 
! > 140 mmHg
17592+1938
.19469+1439
42
70
0.18 0.7
D BPf
< 90 mmHg 
> 90 mmHg
17216+986
18948+765 -
72
40
&005* 0.4
I CRF pnogressars 
CRF non-progressors
17444+1909 
19373+11S7
98
37
0.1 0.4
Abbreviations: SBPd: systolic jJood pressure at diagnosis, DBPd:diastolic blood pressure
at diagnosis, SBPf: systolic blood pressure during follow-up, DBPf: diastolic blood 
pressure during the follow-up. *: significant difference in variance.
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There was no significant difference between mean plasma TGF-pl levels in the CRF 
progressors and non-progressors. On the other hand, the mean serum level of TGF-pi 
was significantly higher CRF in non-progressors than progressors (p=0.0028) (Figure 
53).
Figure 5,3, Serum TGF-fil levels (mean ±SEM ) and the progression o f CRF
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The highest levels of plasma TGF-pl were found in the vascutitic causes of CRF 
(Wegner’s granulomatosis, system lupus erythematosus and rheumatoid arthritis). Mean 
plasma TGF-pi levels in vaseulitie CRF was significantly h itte r than in patients with, 
hypertensive causes (p=0.G5) or obstructive uropathy (p=0.02) (Figure 5.4) (Tabie 53).
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Figure 5.4. Plasma TGF-pl (mean ±SEM ) according to different causes o f CRF
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Table 5.3, Plasma TGF-pl (wmm ±SEM ) and both clinical diagnosis
j Clinical parameters| a Plasma TGF-pl (pg/ml}
f Hypertensive glomerulosclerosisi 26 16G801350G
| Chrome interstitial nephritis 23 15030±2949
! Glomerulonephritis 15 2004412617
! Obstructive uropathy 14 130281253!
Diabetic nephropathy n 1668013283
• Systemic vasculitisI J0 1 21711+2839fi iPolycystic kidney disease 7 | 15095±3336
'l ................................................... . .. ..... !! Unknowni .................................... 29 ! 19714±20681 I
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5.3.1.2.3 Plasma TGF-pl protein levels and pathological diagnoses
The highest levels o f plasma TGF-pl were found in mesangsocapillaiy
glomerulonephritis (MCGN) (Table 5.4).
Table 5.4. Plasma TGF-pl (meanJSEM) and pathological diagnoses
Pathology diagnosis | ^ Plasma TGF-pl (pg/ml) IIMCGN 16 26469+4190 jf !
| FSGS
. . .  I 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1641614173
MN j  2 2247211110
1
DN || 2 13414±1017 IjICIN I 5
j
18927±5930 |
Abbreviations: ON: chronic interstitial nephritis, MCGN: jnesangrocapiJJary
glomerulonephritis, FSGS: focal segmental glomerulosclerosis, MM: membranous 
nephropathy DM: diabetic nephropathy, CGM: crescentic glomerulonephritis.
There was no significant difference in plasma levels of TGF-p l in the different levels o f 
severity o f glomeruloscleros is or tubulointerstitial fibrosis (Table 5.5).
Table 5.5. Plasma TGF-pl levels (Mean ±SEM ) and scarring parameters
Pathological parameters TGF-pi (pg/ml) Observations j  P(f) m
GS
Mild 17702±1553
” ........ .. j
13 0.4fi 0.5
j Moderate and severe 2Q995±m$ 12 J
IF j
Moderate 20378+1790 20 0.09 0.4
Severe 14904±2S15 5
i!Abbreviations: GS: glomerulosclerosis, IF: interstitial fibrosis.
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53.1.3 Plasftm TG F-fff protein levds and genotyping
Overall, there was no significant difference in piasma TGF-£H levels between genotypes. 
This might be doe to the variety of different pathological mechanisms operating in 
different sobjects.
When patients with PKD and obstructive uropathy were excluded, highly significant 
differences in variance and in mean levels were observed (Table 5.6).
Table 5.6. Plasma TGF-fil fewwfs (mean ± SEM) and the polymorphisms studied
Genotypes plasma TGF-flt (jpg&nf) Observations ; P(f) P(t)
C-5G9T
TT
TC-CC
20030+1636
1714811090
! . 63 10.00031
53 I
 ^ 0.2
JFJ*
CCi
2003011636
1571914424
63
5
0.38 : o.5; 1
Leu 10Pro
CC
TC+TT
1947811883
1778811131
22
51
0.06 ; 0.49
CC
TT
1947811883
2032612181
22
27
0.04" 0.7
ArglSPw
GG
j CG + CC
1888611419
1381711442
90
24
0.00045* 0.01*
Tkr263Ile
TT
TC
1861311005
1469414272. 1
113
3
0.4 0.5
!j
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The data ware analysed according to the different causes of CRF (Table 5.7). There was 
no significant difference between mean plasma TGF-pl levels in the different genotypes 
according to different the causes o f CRF except for CIN. In CEN, the mean plasma TGF- 
pi was higher in the homozygotes for T allele (TT) compared to heterozygotes (TC) plus 
homozygotes for C allele (CC) at LeulOPro polymorphism (Table 57). Again, significant 
differences in variance were observed between different genotypes. This was particularly 
marked in patient with CRF o f unknown causes. After division o f the patients according 
to the causes o f CRF the scanty numbers of patients might give unreliable data to be 
analysed
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Table 5. 7. Hamm TGF-pi levels (pg/ml) (mean ±  SEM) according to polymorphisms
a nd the causes o f CRF
Hypertensive
nephrosclerosis
(Meao+SEM)
Obsffivatious
P(f)
P(tJ
C-5&9T LeulOPro j A rg lS P ro
T T TC+CC I j j TC+CC GG CG+CC !
2124813002
10
0.0006*
0J8
13835+2756
7
| 25575+3841
; 4
0.053 
| 0.28
16540+2395
12
18890+2341
16
0.5
(16
114041+2541 ; 
8
!DN
MeanirSEM
Observations
P $
P(t)
I§360+6836 
6
0.07
0.3
11212+1942
4
13772+3690 
2 
| 0.1 
! 0.3
10559+4868
8 10 1
!CIN
Mean+SEM
Observations
P 0
P(i)
17733+2645
5
0.01*
0.3
17633+1432
9
9649.6±i231
3
0.3
0.02*
19856+1432
ii
19587+1133
11
©J
0.24
j
10633+1621 1
!
OU+PKD
Meast+SEM
Observations
pm
pm
16952+2160
1©
0.17
0.9
16234+2654
7
CC TC+7T
17177+2153
13
0.27
0.5
i
14319+3019 ; 
5
18723+1342
6
0.14
0.4
15097+1543
11
GN + Vasculitis
Mean+SEM
Observations
pm
pm
18157+4748
15
0.1
0.36
14748+3567
13
18053+3032
19
0.13
0.28
14485+4969
12
16948+3342
21
0.4
0.4
17227+7424
11
Unknown causes
Mean+SEM
Observations
m
P(i)
— .
22333+322©
19
0.0002* !0.3
....................................... !
17152+1835
15
22275+6149
7
0.0007*
0.48
16832+1907
19
21333+2657
27
0.004*
0.04*
14333+1624
6
Abbreviations: DN: diabetic nephropathy, CIN: chronic interstitial nephritis, FKD: polycystic kidney 
disease; OU: obstructive uropalhy
US
There was a higher plasma TGF-pl level among patients homozygous for the G allele at 
Arg25Pro (p=O.04) in unknown causes of CRF (Figure 5.5 ).
Figure 5.5. Plasma TGF-fil levels (mean ±SEM ) according to Arg25Pro in unknown 
causes o f CRF
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Furthermore CIN patients were found to have lower TGF-pl plasma levels in T- 
homozygous at LeulOPro compared lo the other genotypes at that locus (Table 5.5). On 
the other hand, 1 tailed to find any significant relationship between any o f the other 
studied genotypes and plasma TGF-pi levels according to causes of CRF (Table 5.5).
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5.5 Correlatiom between plasma TGF-pl levels and the different CRF parameters
It was found that there were no significant correlation between the plasma TGF-pl levels 
and the different clinical parameters (Table 5.8).
Table 5.8. The correlations between the plasma TGF-pl levels and the different 
clinical parameters
1 n ~ P (r)
A) Clinical parameters
1) Proteinuria (g/24hrs) at diagnosis 116 0.003 0.000 0.97
2) Proteinuria (g!24hrs) during follow up 114 0.009 0.000 0.92
3) SBPd (mmHg) j 112 0.03 0.001 0.75
4) DBPd (mmHg)
| 112
0.002 0.000 0.98
5) SBPf (mmHg) ! 112 0.08 0.006 0.39
6) DBPf (mmHg) 112 0.003 ! 0.000 0.9S
7) Serum cholesterol (mmol4) 53 0.27 0.07 0.2
8) Serum triglycerides (mmolil) 49 0.19 | 0.04 0.4
B) Progression parameters 1 I
1) CrCl (mhmin) 49 0.05 | 0.002 10.7
1) Serum creatinine (prnold) j 59 0.04 f 0.001 0.8
2) 1/Creatinine slope i 59
1
0.09 | 0.007 0.5
Abbreviations: SBPd: systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf: systolic blood pressure during follow up, DBPf. diastolic 
blood pressure during the follow up, CrCl: creatinine clearance.
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5.4 Renal immunostainable TGF-pl
The control renal sections (three normal kidney donors) were obtained from the Pathology 
Department of Northern General Hospital, Sheffield, UK. The control sections were 
processed as the CRF patienfs sections.
Slides were scored independently and subsequently, I reviewed my scoring with my 
supervisor who finalized the scoring with me.
The intra-observers variations were tested. The intra-observers correlation coefficients 
were 1.2% for glomerular (MeaniSD: 3.15±0.005%)9 1.7% for tubular (MeaniSD: 
9.4+0.23%), immimostammg and 1.2 (celFfield) for IQ (MeaniSD: 21.6 ±0.35).
The control renal tissues did not stain for TGF-p l  (Figure 5.10&5.12). On the other hand, 
the tubules and glomeruli o f the CRF patients (23 patients renal sections) stained with 
TGF-pl (bright red staining). The glomerular percentage of TGF-pl staining ranged from 
0 to 13.7 % (median = 0). The tubular percentage of TGF-pi staining ranged from 0.05 to
20.9 % (median = 12.1%) (Figure 5.11).
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Photomicrographs o f hmtmnostaddng (red) o f TGF-pl in normal (Figure 5.6) and 
diseased glomeruli (Figure 5.7  & Figure 5.8)
Figure 5.6. Glomerulus control (Magnification X 400)
Figure 5.7. Figure 5.8.
Diseased glomerulus stained with TGF-pl (arrows) (Magnification X 400).
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5.5./ Relationship o f glomerular (G) immunostainable TGF-pl and the clinical 
parameters
There was no significant difference in glomerular immunostaining o f TGF-pl (gTGF-pl) 
between the progressors (gTGF-pl =  2.2%) (mean+SEM) and non-progressors (gTGF- 
pi=4.8%) (meaniSEM) CRF (Table 5.10). Also, there was no significant correlation 
with serum creatinine, proteinuria levels, blood pressure or the 1/serum creatinine slope 
(Table 5.9). Furthermore, them was no significant difference in glomerular TGF-pl 
immunostaining between different pathological categories.
Table 5.9. Imimmostainable gTGFfil and clinical CRFparameters (mean ±SEM )
CRF parameters gTG F -pl+ (n=9) gTGF-pl ~ (n = ll) \ m
1
P(t)
Proteinuria at diagnosis 
(g/24hr)
4_94±1.6 5.15±1.7 I 0.9
1
0.8
Mean of proteinuria 
(g/24hr)
3 .7 ± 0 5.8±1.8 j 0.2 0.34
SBPd (mmHg) 149.6±9 149.7±5 1 0.06 0.3
DBPd (mmHg) SS±6.5 84.2±5
1“
0.67 |
SBPf (mmHg) 142.8+6 I47.3±5 1 0.4 0.5 1
iDBPf (mmHg) 89.5±5 81.7±4 10.24 0.2
Plasma TGF-pi (pgW ) 17474+3804 17778±3258 0.4
!
0.2
Abbreviations: SBPd: systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf systolic blood pressure during follow-up, DBPf diastolic 
blood pressure during the follow-up; gTGF-pl+: patients whose glomeruli stained with 
TGF-pi; gTGF-pi-: patients whose glomeruli did not stained for TGF-pl.
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Table 5.10L ImmunostamMe gTGF-fil and progression o f CRF
gTGF-pl- gTGF-pl+• Total £  Yates' correction (at
I; one degree o f freedom)
P value
!
CRF Progressors 6 9 1.5 i 2.73 0.098
; CRF Non-progressors 6 2
.
8 1Total J 12 ii 73 1......... ............... , I  I 1 —Abbreviations; gTGF-pl+: patients whose glomeruli stained with TGF-pl; gTGF-pl-: 
patients whose glomeruli did not stained for TGF-p 1.
5.5.L7 TGF~fil polymorphisms
There was no significant difference between the mean of glomerular TGF-pl and the 
different studied polymorphisms (Table 5.11). On the other hand, there were significant 
differences in variance.
Table SAL Glomerular TGF-fll and the studiedpolymorpltisms
r MeaoiSEM P(f) m
5 C-509T
\ TT '! 121>; t o c c  >; 9!; 1;
3+1.3% 
1.4 ±0.5%
0.0017* 019
; LueW Pmi 1!| ’TT j 8
1 TC+CC || 12!|
3.7± 1.9% 
1.5 ±0.75%
0.015* 0..2
) Arg25Pm
! GG I 15
| €G | 1
1
3.1 ±1.1%
1.2 ±0.6%
0.007* 013
Thr263!ie
TT 23 
TC 1 0I I
2.9+1.3% 
0
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5*5.1 Tafealar(T) TGF-pl
Photomicrographs o f Immunostaining (red) o f TGF-fll in normal (Figure 5.9) and 
diseased tubules (Figures 5.10& 5JI)
*  +  > •  *
? *
% •  *  *  '  *  *!
* .. * .
. -  V .  .  * ;■ V I  S ,  .•  at V .mg&gjt <
•  /  v
Figure 5.9. Control Tuboii (Magnification X 400)
Figure 5.10. Figure 5.1L
immunostaining TG F-fil (arrow) in iubufes (M agnification X  200)
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S.S.2,2 Proteinuria
There was no significant difference between tubular TGF-pl in patients with different 
proteinuria levels (Table 5.12). There was also no significance difference with the other 
CRF parameters (Table 5.12).
Table 5 J2 , Levels o f tubular immunostainable TGF-pl according to the severity o f 
different clinicalparameters
CRF parameters
1
| If= Tubular TGF-pi 
\(MeandSEM)
m P(t)
Proteinuria at diagnosis (g!24k)
<3g/24hr S 10.4+2.2% 02 0.9
>3g/24hr I 13 10.6£2.3%
Proteinuria during follow-up fg?24fer)
<3g/24hr 11 9.3i2% 0.4 0.5
>3g/24hr | 1© ll.7i2%
SBPd (mmHg)
<140mmHg | 7 7.9±2.3% 037 0.5
>140nunHg 13 10.7±2%
DBPd (mmHg)
<90mmHg 9 8.812.2% 03 0.6
>90mmHg 11 10.5i2.5%
SBPf (mmHg)
>14©mmHg 7 8.512.2% 03 0.46
<140mmHg 13 10.912%
DBPf (mmHg)
<90mmHg 1© 10.6+2.2% | 0.4 | 0.5
>90mmHg 1© 9252%
Abbreviations: SBPd; systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf: systolic blood pressure during follow up, DBPf: diastolic 
blood pressure during the follow up.
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5.5.2.6 Progression o f CRF
There was no significantly difference in tubular immunostainable TGF-pl (tTGF-pl) 
(mean±S£M) between the pmgiessois (tTGF-pi = 9.4%) and non-progressors (tTGF-pi 
= 11.7%) patients groups (Figure 5.12).
Figure 5JZ  Tubular TGF-pl (tTGF-pi) (mean ±  SEM) immunostmmng and the 
progression o f CRF
Non-progressors
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S.5.2.5 TGF-pi polymorphisms
There was no significant difference between tubular TGF-pl and both Arg25Pro and 
LuelOPro. On the other hand, there was a statistical significant difference between 
tubular TGF-pl and C-509T (P = 0.001) (Table 5.13).
Table 5.13. TGF-pl polymarpMsrtts according to tubular TGF-pl
B — Mean ±  SEM m m  |
C-509T
IT 12 143 ± 1.6% 0.5 0.03*1*
TC+CC 9 5.3 ±1.7%
LeulOPro
TT 8 S.7 ± 2.9% 0.3 0.5
TC+CC 12 10.6 ±1.8%
Arg25Pw
GG 15 7.8 ± 1.1% 0.3 0.25
CG 7 10.8 ±0.6%
Thr263He
TT 23 2.9±1.3%
TC 0 0
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5.5,3 RenaI Infiantmaioty cellular infiltration (ICl)
The patients (n = 23) with ICl were Abided into those with (n = 13) and those without (n 
= 10) moderatd^severe ICL
Photomicrographs o f the diseased kidneys showing the inflammatory cellular 
infiltration (1CI)
fig u re  5.13. M agnification X  200
Figure 5.14. M agnification X  400
15 9
There was no difference in the clinical parameters of patients with or without ICl (Table 
5.14).
Table 5J4. The associations o f inflammatory cellular infiltration and the clinical 
parameters
Parameters I i a - ( n = 9 )i i a + ( n  = l l ) P0> mProteinuria at 
diagnosis (gCMhr)
3.58±1.4
j
5.95±1.3 0.5 0.3
Proteinuria during 
follow up (g'24hr)
1 4.t±1.4
1
5±1.3 0.6 0.7
SBPd (mmHg) | 147.5+2.4 150±5 0.1 0.8
DBPd (mmHg) 192+2.5 84±5 0.01* 0.2
SBPf (mmHg) 146±5
| .
145+4 0.4 0.9
DBPf (mmHg) i 83+3.2
j.«...............
86±4 0.1 | 0.8
Abbreviations: SBPd: systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf: systolic blood pressure during follow up, DBPf: diastolic 
blood pressure during the follow up, ICI-: without inflammatory cellular infiltration; 
ICI+: with inflammatory cellular infiltration.
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There was a significant difference in TGF-pl immunostained tubules in sections with 
inflammatory cellular infiltration (XQ+) compared to those without inflammatory cellular 
infiltration {ICl-) {Table 5.15).
Table 5.15, The associations between inflammatory cellular infiltration and TG F-fil
1
IC l-  !; IC I+
1
m  ! m
1 i
) Plasma TGF-PJ
i <pg^o
18551+4610 1 17035±J704|
n -  S ! n - 12f
0.37 0.7
j gTGF-pl <%)1 2.3±1 ( 2.6+0.5 (n — 9) S (n = 14)
0.83* 0.8
| tTGF-pi (%) S.fetl 1 1 13.7±0.8
1(n —9) (n = 14)i
0.5 0.0048* j|
Abbreviations: 1C1-: without inflammatory' cellular infiltration; 1CI+: with inflammatory 
cellular infiltration. gTGF-pr glomeruli TGF-pl; tTGF-pi: tubular TGF-pl. 
^significance <0.05.
5.5.3.6 TG F-fil polymorphisms
There was a higher ICl in homozygous patients for the T allele at the promoter site (C- 
509T) (TT) 44.6 ± Tcellsifield) compared to the heterozygous (TC) plus the homozygous 
for the C allele (CC) 16.3 ± 8 5cellsfield) (p = 0.01). On the other hand, there was no 
significance difference (p > 0.05) between ICl and genotype either at Arg25Pr© (GG
37.1 ± 6.7cellsffield, CG .17.5 ± I j cells/field) or at LeuiOPro (TT 34.1 ± 9 cells^field, 
CC + TC 27.7 ± 8.7 ce lM d d ) {Table 5.16).
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Table 5.16. The distribution o f the different polymorphisms according to whether there
is inflammatory cellular infiltration or not
Genotyping ICI+ ICT­ Chi square at two degree of freedom 
(Yate’s correction)
P value !
C-599T
TT
TC4CC
2
6
US
3
5.6 0.010*
LealOPro
TT
TC+CC
2
4
6
5
037 0.3 1
Arg25Pro
GG
CG
4
4
12
2
3.2S 0.07 j
Abbreviations: II□*-: with inf ammatory cellular infiltration, ICI-: without inflammatory
cellular infiltration
5.6.1 Correlations between imnnmostainable TGF-fl and different parameters 
There was no significant correlation between glomerular TGF-pt and renal ICL Of note 
when 1 divided the patients to those who had inflammatory cell infiltration (ICl) and 
those who did not, there was a significantly higher tubular TGF-pi in the former (13.2 ±  
1.7%) compared to the latter (5.6 ± 2%) (p = 0.0047). There was also a significant 
correlation between tubular iTGF-pl and renal ICl (r = 0.447, p = 0.03) (Table 5.18). 
Furthermore it was noted that there was a significant correlation between the tubular 
TGF-pl and proteinuria during the follow up (Table 5.18). Although there was no 
significant correlations between the ICl and the severity o f tubulointerstitial fibrosis, we 
noted that there was a significant correlation between the ICl and the severity o f 
glomerulosclerosis (Table 5.19).
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Table 5.17. Correlations between glomerular TGF-pl (gTGF-pl) and different CRF
parameters
gTGF-pl with | n r R1 ! m
Proteinuria at diagnosis (g!24hr) 20 0.04 0.002 0.8 j
Proteinuria during follow up (g04hr) ! 20 0.2 0.04 0.4 |
SBPd (mmHg) 20 0.08 0.006 0.8 !
DBPd (mmHg) 20 0.226 0.05 0.4
SBPf (mmHg) 20 0.2 0.04 0.4
DBPf (mmHg) 20 0.35 0.119 0.2 |
Plasma TGF-pi (pg/ml) 20 0.223 0.05 0.4
GS 22 0.002 0.000 0.9 i
IF 22 0.008 0.000 0.9 . . . . . JAbbreviations: gTGF-pi: glomerular TGF-pi; SBPd: systolic blood pressure at 
diagnosis, DBPd: diastolic blood pressure at diagnosis, SBPf: systolic blood pressure 
during follow up, DBPf: diastolic blood pressure during follow up, GS: 
glomerulosclerosis, IF: interstitial fibrosis.
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Table 5.18. Correlations between tabular TGF-pl ((TGF-pl)  and different CRF
parameters
tTGF-pi with n=  jr  R'i !
1 1
P(r)
; P r o t e i n u r i a  a t  d i a g n o s i s  ( g f 2 4 h r ) 2 0 0 . 2 5
j
j
0 . 0 6 0 . 7
1
|  P r o t e i n u r i a  d u r i n g  f o l l o w  u p  
( g / 2 4 h r )
2 0 0 . 4 7 0 . 2 2 3 0 , 0 4 8 *  I1!
!
1 S B P d  ( m m H g ) 2 0 0 . 0 4 0 . 0 0 1 5 0 . 1 7
; D B P d  ( m m H g ) 2 0 0 . 1 7 0 . 0 3 0 . 5
i  S B P f  ( m m H g )I J 2 0 0 . 0 4 6 0 . 0 0 2 0 . 8 5j D B P f  ( m m H g )
1
2 0 0 . 0 6 4 0 . 0 0 4 0 . 8
P l a s m a  T G F - p l  i p g  m l )  J  2 0 0 . 0 2 5 0 . 0 6 0 . 2 9
G S  ! 2 2 0 . 1 6 0 . 2 6 0 . 4 9 !
I F  |  2 2
t!
0 . 0 2 5 0.000 0 . 9
]
Abbreviations: t T G F - j J l :  t u b u l a r  T G F - 0 1  S B P d :  s y s t o l i c  b l o o d  p r e s s u r e  a t  d i a g n o s i s ,  
D B P d :  d i a s t o l i c  b l o o d  p r e s s u r e  a t  d i a g n o s i s ,  S B P f :  s y s t o l i c  b l o o d  p r e s s u r e  d u r i n g  f o l l o w  
u p ,  D B P f :  d i a s t o l i c  b l o o d  p r e s s u r e  d u r i n g  f o l l o w  u p ,  G S :  g l o m e r u l o s c l e r o s i s ,  I F :  
t u b u l o i n t e r s S i t i a ]  f i b r o s i s .
* =  s i g n i f i c a n c e  <  0 . 0 5 .
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Table 5.29. Correlations between inflammatory cellular infiltration (ICl) (cell/field)
and different CRF parameters
ICl with |B - r R2 P (F )
Proteinuria at diagnosis (g^24hr) 20 0.158 0.025 0.5
Proteinuria during follow up (g^24hr) 20 0.14 0.019 0.6 |
SBPd (mmHg) 20 0.06 0.003 0.8 |
DBPd (mmHg) 20 0.25 0.06 0.36
SBPf (mmHg) 20 0.103 0.11 0.7
DBPf (mmHg) 20 0.15 0.021 0.5
Plasma TGF-pi (pgi24hr) 20 0.002 0.000 0.99 !
gTGF-pl (%) 23 0.02 0.0003 0.9 !
tTGF-pi (%) 23 0.404 0.164 0.06
GS 22 0.46 0.21 0.037* 1
IF 22 0.025 0.0006 0.9
Abbreviations: SBPd: systolic blood pressure at diagnosis, DBPd: diastolic blood 
pressure at diagnosis, SBPf: systolic blood pressure during follow up, DBPf: diastolic 
blood pressure during follow up, G.S: glomerulosclerosis, IF: interstitial fibrosis. gTGF- 
pl: glomerular TGF-pi; tTGF-pi: Tubular TGF-pl.
*= significance < 0.05.
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5.5 Discussion
In this chapter I have measured the circulating and tissues levels of TGF-pl.
Firstly, I have found that there was no significant difference between plasma TGF-pi 
protein levels and any of the clinical parameters (proteinuria, progression o f CRF, blood 
pressure and pathological processes). On the other hand, plasma TGF-pl protein levels 
were significantly higher in patients homozygous for the G allele at Arg25Pro compared 
to heterozygotes and homozygotes for the C allele. This finding is in agreement with the 
data of Li and co-workers (1999) who found that there was a significant difference 
between high TGF-pi plasma protein levels and systolic blood pressure in G- 
homozygotes allele at Arg25Pro. Of relevance, high circulating TGF-pl levels are 
associated with atherogenesis both in mice (Grainger, et a i, 1994) and humans (Grainger, 
et a i, 1999). There is a significant difference between the C allele and increased risk of 
myocardial infarction, although the C allele was associated with lower diastolic blood 
pressure (Langdahl, et a t, 1997). These contradictions make the role o f TGF-pi in 
hypertension controversial and unsettled. Futhermore, there was a significant correlation 
between the presence o f the T allele at -509 promoter and high levels o f plasma TGF-pl 
(Grainger, et ah, 1999). This may be explained by the observations made in this thesis 
(Chapter 4) of a linkage disequilibrium between the T allele at —509 promoter and the G 
allele at codon 25. On the other hand, there was no significant difference between plasma 
TGF-p 1 protein levels and the other studied polymorphisms.
There were no significant difference between serum TGF-P 1 protein levels and clinical 
parameters. Patients with progressive CRF had lower serum TGF p i levels compared to 
non-progressors (NP). Although this finding was at first surprising, many explanations 
could account for it  While TGF-pl is thought to be a fibrogenic growth factor, a growing 
body of evidence suggests that this growth factor has anti-inflammatory and anti­
proliferative functions (Park, et aL, 2000; Cheng, et a i, 2001). The progression o f 
chronic renal failure is associated with a brisk inflammatory interstitial response. Low 
TGF-pl may, therefore, facilitate such interstitial inflammation which is known to lead to 
fibrosis. Also, glomerular, tubular as well as interstitial cell proliferation may go
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uninhibited in the absence o f TGF-pl. Low TGF-pl have been recently reported to be 
associated with atherosclerosis (Grainger, ei a i, 1995). Glomerular and interstitial 
fibrosis pathways are similar to those of atherosclerosis, involving inflammation, 
proliferation and fibrosis. In atherosclerosis it has been argued that TGF-pl initially 
inhibits the proliferation o f smooth muscle cells, but later on in the process may 
encourage fee production ofECM (Grainger, et ai., 1995). A similar explanation can be 
advanced for fee progression o f renal scarring. Other studies have reported feat high 
circulating TGF-pi levels were associated wife higher blood pressure (Grainger, et a i,
1999). 1 failed to observe such an association. This may be due to two factors, firstly, 
most patients in fee present study have secondary rather than primary hypertension. 
Further, the majority o f our patients wife secondary hypertension were treated wife 
antihypertensive drugs wife adequate blood pressure control, making any difference of 
genotype with hypertension difficult to ascertain.
Plasma TGF-pl levels were significantly higher in patients wife primary and secondary 
glomerulonephritis compared to the other groups. This is of interest, since TGF-pl has 
been implicated in the injury and repair o f experimental and clinical glomerulonephritis. 
Furthermore, there are reports o f elevated urinary TGF-pl in membranous 
glomerulonephritis (Hellmich, et aL„ 2000). Also, reports of high circulating levels of 
TGF-P 1 have been published in systemic vasculitis including ANCA-associ ated 
vasculitis (AAV) (Kekow, et 1997). In SLE, however active disease was associated 
wife decreased circulating TGF-P 1 levels (Robak, et a t, 2001).
There was a close association between levels of immu nostainable tubular TGF-P 1 and 
proteinuria. This might due to fee feet that proteinuria can be considered a marker o f 
renal damage. Also, a link between proteinuria and fee progression o f renal scarring has 
been suggested (For review, Harris, 2000). Incubation of proximal tubular epithelial cells 
wife high levels o f proteins (albumin, transferin) is capable of stimulating the induction 
of TGF-P I by these cells (For review, Harris, 2000). This thesis is fee first report linking 
proteinuria to elevated tubular TGF-p l in human nephropathies.
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On the other hand, there was no association between immunostainable tubular TGF-P I 
and plasma TGF-pl levels or blood pressure levels. Overall, there were no significant 
associations between any of the studied polymorphisms and either glomerular or tubular 
TGF-pl immunostaining. This might be attributable to the small number of available 
sections, as there was a trend (albeit not significant) between glomerular and tubular 
TGF-pi immunostaining levels and the presence of the G allele at Arg25Pro and T allele 
at C-509T.
Homozygosity for the G allele (GG) at Arg25Pro was found to have a weak but 
significant association with severity of renal inflammatory cellular infiltration. Also, 
there was also a significantly higher renal inflammatory cellular infiltration in patients 
homozygous for the T (TT) allele at C-509T compared to heterozygotes (TC) or C- 
homozygotes (CC). The severity o f interstitial inflammation in chronic renal diseases is a 
major prognostic factor (For review, Jemigan and Eddy, 2000). A genetic association or 
predisposition to inflammatory renal changes would be a major detrimental influence on 
the progression of renal disease. As discussed in Chapter 4, the number o f patients with 
progressive CRF was significantly higher in the patients homozygous for the G allele. 
The predisposition to interstitial inflammation may explain this association. Surprisingly, 
this polymorphism was not associated with more severe interstitial fibrosis. Similarly, an 
association has been described in Chapter 4 between the presence T allele on the C-509T 
and the progression of progressive CRF and, as mentioned above interstitial 
inflammation. Here again, this allele was not directly associated with interstitial fibrosis.
Furthermore, there was a strong association between the severity of renal inflammatory 
cell infiltration and tubular TGF-pl levels. This would suggest interactions between 
tubular cells and cellular infiltration involving TGF-P 1. Transforming growth factor-pi 
may be increased in tubular cells through increased production or increased uptake. 
Tubular cells have receptors for TGF-pl. It may be that the TGF-P 1 released by 
inflammatory cells is taken up by the adjacent tubular cells. On the other hand, it could be 
that tubular cells release TGF-pl in response to peritubular interstitial inflammation.
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TGF-pl production in this context would be the natural response of the kidney to
interstitial inflammation.
In conclusion, the measurements o f TGF-pl in the circulation and renal tissue have 
identified potential links with interstitial inflammation as well as proteinuria. Whether 
TGF-pl is pathogenic or a reaction to these factors is difficult to ascertain from this 
work.
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Discussion
There is a large number of studies published on the association of TGF-B1 
polymorphisms and a variety’ o f renal diseases. For example, there is an association 
between increased frequency o f the C allele at LeulOPro and development o f renal failure 
in patients who have undergone heart transplantation (Baan, et a i, 2000), the T allele at 
Thr263Ile and the development o f nephropathy in diabetic patients (PocioL et ai., 1998), 
and the G allele at Arg 25Pro and increased blood pressure in ESRF (Li, et aLf 1999).
Most o f the studies are case control and population-based rather than pedigree-based 
analysis o f families. This is because genetic analysis in case control studies can be used 
directly to identify functional SMPs contributing to a particular phenotype. Furthermore, 
population screening might conceivably be useful in identification o f the minority of 
people whose environment or lifestyle could be changed On the other hand, family-based 
studies (case-sibimg and case-paieots design) have a reduced statistical efficiency due to 
overmatching and reduced sample size on the studied genotype.
In this thesis, genotypic polymorphisms o f the TGF-Bl gene were analysed in relation to 
susceptibility and progression o f CRF in Caucasian patients with renal diseases. I noted 
that carriers o f the T allele at C-509T and the C allele at LeulOPro were significantly 
more common in CRF patients (particularly those with progressive disease) than in the 
control population. The implication of tin's is that carriers o f these alleles are more 
susceptible to chronic renal diseases (CRD). This observation is original to the best o f my 
knowledge.
Furthermore, I analysed the frequency of progressive renal insufficiency amongst 
different genotypes and noted that G-homozygotes (Arg25Pro) and T-homozygotes (C- 
509T) were significantly more common among patients with progressive renal disease 
and in those who reached ESRF when compared to those with non-progressive disease 
and stable renal function. No such difference was noted for the other studied genotypes 
including Leu lOPro and Thr263fle. Again, this is, to the best o f my knowledge, the first 
observation of such associations in renal diseases. I have therefore identified both
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susceptibility markers (-509T and lOPro) tor the development of CRD and progression 
markers (-509T and 25Aig) that identify patients who have progressive CRF and those 
who reached ESRF. This study indicated that there is increase risk o f carriers of the C 
allele (LeulOPro) developing CRD. Other investigators reported that there was a 
significant association between the T allele (LeulOPro) and the development of CRF in 
heart-transplanted patients (Baao, et a t, 2000) as well as in those with end-stage heart 
failure due to cardiomyopathy (Efolweg, et a l, 2001).
The deleterious effect o f the -509T allele on the progression of CRF might be due to its 
direct effect or indirectly through many factors involved in progressive renal scarring.
Firstly, proteinuria was higher in die T-homozygotes at C-509T than die C-homozygotes. 
Also, proteinuria was higher in the progressors compared to the non-progressors. It is 
now well known that proteinuria levels are significantly higher in patients with 
progressive CRF compared to those with stable renal function (For review, Locatelli and 
Del Vecehio, 2000). In support o f to t  observation, I have observed to t  proteinuria levels 
in the patients I studied correlated with t o  rate of decline in renal function as measured 
by the reciprocal o f serum creatinine against time slope. Proteinuria is now thought to be 
a cause as well as t o  consequence o f progressive renal damage (For review see Harris, 
2000). Proteinuria induces mesangral cells proliferation, infiltration and activation of 
macrophages, deposition of ECM and, consequently, glomerulosclerosis (For review see 
Harris, 2000). Glomerular damage leads to the appearance of protein in the glomerular 
ultrafiltrate and its subsequent uptake by the tubular epithelium. This leads to release o f 
pro-inflammatory cytokines and chanokmes, chemo-attraction o f inflammatory cells and 
stimulation o f ECM protein production (For review see Harris, 2000). Of relevance, I 
confirmed that there is a significant correlation between proteinuria and renal 
inflammatory cellular infiltration in patients with a variety of causes o f CRF. I found that 
proteinuria was significantly higher in males than females. However, there was no 
significant association between a particular allele at the studied polymorphisms and 
different gender. This indicates that gender is not a confounding in t o  allele association 
with proteinuria.
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Secondly, renal inflammatory cellular infiltration was significantly associated with the T- 
allele at C-509T. The severity ©f the interstitial inflammatory infiltrate has been shown to 
correlate with tire rate o f decline in renal function both in experimental and in human 
nephropathies. Inflammatory cellular infiltration plays an important role in renal fibrosis. 
This is because the inflammatory cells are a source of fibrosis-promoting growth factors, 
vasoactive molecules and ECM proteins (Nathan, 1991). Circulating monocytes migrate 
into the renal mtexstitiran when inflammation is present The chemotactic factors that 
involve monocytes recruitment are becoming better known (For review, Jemigan and 
Eddy, 2000). Many cytokines and chemokines have been implicated. These include 
interleukins, tumour necrosis factor-o, monocyte chemo-attractant protein 1 (MCP-l), 
macrophage inhibitory factor-2 (MlF-2) as well as RANTES. Many of these factors have 
teen shown to be up-regulated in scarred and inflamed kidneys. They have also teen  
shown to be released % proximal tubular epithelial cells when activated by injury o f 
proteinuria (For review, Jemigan and Eddy, 2000).
Thirdly, there was a significant increase in immunostainable tubular TGF-pl in patients 
who were homozygous for the T allele. Increased expression o f TGF-pi has been 
associated with progressive renal fibrosis in experimental and human nephropathies 
(Border and Noble, 1997). TGF-P I is a fibrogenic molecule and it has a role in the 
potentiation o f interstitial monocyte recruitment Of relevance, 1 found that there is a 
significant correlation between tubulo-interstitial inflammatory cellular infiltration and 
tubular immunostainable transforming growth factor-pi. TGF-pl also stimulates the 
synthesis o f ECM proteins and decreases matrix degradation (Border and Noble, 1994). 
The sources of TGF-pi are infiltrating monocytes, fibroblasts and myofibroblasts 
(Yamamoto, e t al„ 1994; Pankewycz, et a l, 1996). In addition, proximal tubular 
epithelial cells are capable o f the synthesis and release of TGF-pl. In my study, I noticed 
the presence o f immunostainable TGF-pl predominantly in the cytoplasm of tubular 
epithelial cells. Some TGF-pl was also present in the peritubular interstitium. TGF-pl 
also stimulates cells at the sites o f tissue injury resulting in increase o f its own production
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(Wei, et at., 1998). This leads to a vicious cycle of TGF-pl production, inflammation and 
fibrosis.
The G allele (Arg25Pro) is associated with increased blood pressure in patients with 
ESRF (Grainger, et dL, 1999). Similar observations were made in cardiac allograft 
vasculopathy (Densem, et aL, 1999), fibroiic lung disease (El-GameL et a t, 1998) and 
progressive cystic fibrosis (Arkwright et aLt 2001).
The deleterious effect o f the G-allele (Arg25Pro) on the progression o f CRF might be due 
to its influence o f some o f the risk factors associated with progressive renal insufficiency. 
Firstly, proteinuria was higher in the G-homozygotes at Arg25Pro than the C- 
homozygotes or heterozygotes. The effect of proteinuria was discussed above. Further, I 
noted that proteinuria was correlated with diastolic blood pressure at the time o f 
diagnosis. Again as discussed earlier, both blood pressure and proteinuria affect renal 
function.
In patients with hypertensive nephrosclerosis, carriage of the G-allele was significantly 
more common in the progressors than non-progressors. I failed to find a significant 
association between carriage o f the G allele and increased blood pressure. This might be 
due to the feet that patients were treated with anti-hypertensive agents and had a thirty 
uniform and well-controlled blood pressure during the follow-up period. Elevation in 
systolic blood pressure is a strong predictor of ESRF (Klag, et a l, 1996). Also, I noted 
that systolic blood pressure during follow-up was significantly higher in progressors than 
non-progressois. Also elevation in systolic blood pressure accelerates the rate o f loss o f 
renal function (Brazy, et aL„ 1989). In systemic hypertension associated with the loss of 
renal function, the decrease in resistance of the afferent glomerular arteriole allows the 
transmission of the elevated Wood pressure to the glomerular capillaries (For review’ see 
Dworkirt and Weir, 2000). Therefore, deficient arteriolar auto-regulation renders 
damaged kidneys particularly sensitive to systemic hypertension. Intraglomerular 
hypertension promotes proteinuria, which further activates the rcnin-angiotensin system 
(RAS). Angiotensin II, apart from its vasoconstrictor effects, induces local pro-
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inflammatory and pro-fibrotic signaling molecules resulting in renal scarring (Soergel
and Schaefer, 2002),
Homozygosity for the G allele was significantly more frequent in patients with severe 
glomerulosclerosis. The other two risk factors associated with the G allele (proteinuria 
and hypertension) lead to glomerulosclerosis as described earlier in this chapter. I also 
noted a significant correlation between inflammatory cellular infiltration and 
glomerulosclerosis.
Increased plasma levels o f TGF-pl was associated with the presence of the G allele. This 
is in agreement with the observation of Li and co-workers (1999) who found that 
circulating TGF-pl levels were significantly higher in G-homozygotes with ESRF. 
Grainger and co-workers (1999) found an association between T-homozygotes at C-509T 
and increased TGF-pl levels in the normal population. Circulating TGF-pl levels are 
higher in African-Americans with ESRF compared to Caucasians (Suthanthiran, et aL, 
2000). Surprisingly, in this study I noted that there are significantly lower levels of serum 
TGF-P 1 in progressors compared to non-progressors. The progressor group in this study 
included patients with ESRF on renal replacement therapy. Stefoni and co-workers 
(2002) found that TGF-P 1 was significantly reduced in haemodiahsis patients 
particularly in those with severe cardiovascular disease. The same authors concluded that 
low TGF-pi serum levels are a risk factor for atherosclerotic disease in ESRF patients. I 
found that plasma TGF-pl levels were significantly higher in patients with vasculitic 
cause o f CRF compared to other causes of CRF. This is the first time such an association 
has been described and may be attributable to the release of TGF-B1 from inflamed 
vascular endothelium.
The frequency of the rarer, T-allele at Thr26311e was very low to be analysed as a marker 
for CRF in this sample group. The allele frequencies o f this polymorphism were similar 
to the published frequencies in the normal population. However, one study has reported a 
significant association between the T allele at this site and the development o f diabetic
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nephropathy (Pociot et aL, 1998). In this study, the number of the studied diabetic 
patients was too small for meaningful analysis with this marker.
Finally, I found that the deleterious alleles (T at C-5G9T, C at LeulOPro and G at 
Arg25Pro) were in linkage disequilibrium. This reflects the fact that these polymorphic 
regions located in proximity to each other within the TGF-B1 gene on the long arm of 
chromosome 19. Of interest, this region o f chromosome 19 has been linked to numerous 
genetic abnormalities related to the development of proteinuria and consequently 
glomerulosclerosis. For instance, mutations in the NPHS1 gene (coding for nephrin) as 
well as in the gene coding for p-actmin4 are located on the long arm o f chromosome 19 
and have been associated with steroid resistant forms of glomerulosclerosis (Patrakka, et 
aL, 2002).
Genetic associations may either result from a direct functional effect o f the sequence 
variation, or may simply reflect linkage disequilibrium in the region with the tested 
alleles acting as markers for a nearby functional variation. In the case o f C-509T and 
coding dequence variations, there is reason to suspect a possible direct functional effect 
The polymorphism at the promoter site may disrupt a consensus half-site for the binding 
of the nuclear factor cAMP response element binding protein (CREB). The -5G9T may be 
involved in the modulation o f expression o f the TGF-p 1 gene (Syrris, et aL, 1998).
The signal sequence o f which functions to translocate the synthesized TGF-pl protein 
across the membrane o f the endoplasmic reticulum consists of three regions: a positively 
charged NH2-terminal region, a central hydrophobic core and a polar-terminal region 
(Randall and Hardy, 1989). The LeulOPro (amino acid 10 polymorphism) is located in 
the hydrophobic core. Both leucine and proline are non-polar and polymorphism at this 
site may not significantly affect the function of the single peptide (Camhien, et aL, 1996 
and Syrris, et aL, 1998). Conversely, Yamada (1998) postulated that the lOPro amino 
acid increased export o f TGF-p protein in extra-cellular matrix.
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In the case of the Arg25Pro polymorphism, arginine is a bipolar amino acid replaces the 
proline, which is small apolar amino add This replacement is reported to affect the 
export and post-translational modification of the pro-TGF-P protein (Densem, el aL,
2000). The Thr263Ile polymorphism is located in the part o f TGF-P proprotein that is 
cleaved from the active part at amino acid 278 (Langdahl, e t aL, 1997). The substitution 
o f threonine which has one hydroxyl group by isoleucine which is non-polar, could affect 
the stability o f latent TGF-pl and/or the activation of TGF-P 1 (Pocioi, et aL, 1998).
In conclusion, this study has revealed a number of associations between TGF-B 1-gene 
polymorphisms and susceptibility to as well as progression of CRF. More specifically, 
higher rate o f carriage of the T (C-509T) alleles in patients with CRD compared to the 
normal population. Also, carriage of the C allele at LeulOPro appeared to be a 
susceptibility marker. On the other tend, homozygosity for both the G allele at Arg25Pm 
and the T allele at C-509T were found to be risk factors for a faster rate o f progression o f 
CRF. These associations may be related to changes in proteinuria, elevated circulating 
TGF-P I levels and glomerulosclerosis in those with the high-risk genotypes. On the other 
hand, the T allele at C-509T appears to be associated with proteinuria, tubular TGF-pl 
over-expression and interstitial inflammation.
The clinical implication of these findings could be that genotyping o f CRF patients for 
the TGF-P 1 polymorphisms at C-509T and Arg25Pro may be indicated, in order to 
identify those at risk o f progressive CRF and, ultimately, ESRF. Patients with high risk 
genotypes would consequently warrant additional attention to prevent the progression o f 
their underlying kidney disease.
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A J. Consent form
After approval o f this study by Ethical committee from the South Sheffield Ethics 
Committee, Northern General Hospital, all the patients gave informed consent, which 
included:
Ethics No:
Brief Title:
Prosper:
The study’s title is the effect o f the growth factors polymorphisms on the progression of 
the chronic renal impairment 
To be completed by the patient
Patient consent form
Have you read the information sheet about this study?
Have you been able to ask questions about this study?
Have you received answer to your entire question?
Have you received enough information about this study?
Do you understand that you are free to withdraw from this study 
at any time
Without diving the reason for withdrawing?
Without affecting your future medical care?
Do you agree to take part in this study?
YES/NO
YES/NO
YES/NO
YES/NO
YES/NO
YES/NO
YES/NO
Signed
Name (Block Letters)
A1
A.II. Clinical data form
Patient’s name:
Hospital No. Research No.
Age: Gender M F
Weight: Height: BMI:
Race: Smoking: Diet:
Diagnosis:
Other conditions:
Family history: 
Renal biopsy: 
Blood pressure 
Serum Creatinine
Date:
At onset: 
Serial reading:
Slope 1/Creatinine: 
Proteinuria 
Hematuria 
Serum Cholesterol: 
Serum Ttiglyseride: 
Treatment:
Creatinine Clearance: 
At onset:
Yes:
Results:
Mean blood pressure: 
Time:
Mean of proteinuria: 
No:
A2
A.IIL Buffers for DNA extraction:
1-Buffer A:
For 1 litre o f buffer
Chemical Final concentration Amount 9
Tris Base (Sigma) 0.01M u g  j
Sucrose (Sigma) 0.32M 108.5 g |
MgCh (Sigma)
■
G.15M lS j
Distilled water to 990ml iThe pH was adjusted to 8.0 by using hydraulic acid.
The buffer was auiocfaved and JGml of Triton X 100 (Sigma) was added
2-Buffer B:
For 1 litre of buffer
Chemical I Final concentration Amount
Tris Base (Sigma) | 0.4M 48.44g
EDTA (Sigma) 1 0.06M 22.33g
TSIaCh (BDH) | O.150M 8.766g
Distilled H20  j to 900ml
The pH was adjusted to 8.0 in a similar manner to buffer A.
The buffer was autoclaved. SDS was added to give a final concentration of 1%.
3- Sodium perchlorate (Sigma) at final concentration of 5M.
A3
A.TVL Equipment and reagent supplier 
Blo-rad
Bio-Rad laboratories, ltd.
Bio-Rad House 
MaylandAve 
Hemel Hempstead 
Hertfordshire, HP2 7TD (GB)
Bioline
16 The Edge Business Centre 
Humber Road 
London NW2 6YF
Gibco BRL,
OfeTedmcJogiesJLtd,
3 Fountain Drive,
Enchinnan Business Park,
Paisley, PA4 9RF.
Perkin Elmer
Parkin Elmer Life Sciences 
BRU/BRUMB49 
Hounslow, TW5 9RT
Promega UK*
Enterprise Road 
Qiillworth Research Center, 
Southampton,
D0167NS.
R&D Systems,
R&D System Europe, Ltd.
4-10 The Quadrant,
Barton Lane,
Abingdon,
Oxon, 0X14 SYS.
Sigma,
Sigma Aldrich Company Ltd- 
Fancy Road,
Poole,
Dorest, BH12 4QH
SORVALL
SORVALL (UK) ltd, 
International Centre 
Boulton Road, Stevenage, 
Hertfordshire SGI 4QX
Wallace,
Wallac Oy,
P.O. Box 10,
FIN-20101,
Turku,
Finland
A. VL Clinical data o f CRF patients
Entrant ID Gender SBPd SBPf DBPd DBPf
1- m
2- F 170 155 100 85
3- M 170 169 110 100
4- F 120 120 80 75
5- M 155 152.5 100 92
6- M 110 110 70 72
7- M 175 160 85 83
8- F
9- M | 120 119 80 60
10- M 150 158.3 80 78
11- M j 120 118 70 71
12- m  ;
13- F
14- M 160 155 82 81
15- M 130 125 90 76
16- F 120 125 60 62.5
17- M 170 164 90 78
18- (V5 100 115 50 70
19- M 178 CD(0T"> 82 70
20- M 210 200 120 105
21- M 130 125 95 87.5
22- M 100 117.5 80 85
23-
24- M 180 156.5 80 72
25- M 132 131 90 85
26-
27- M j 210 180 140 140
28- M 150 140 90 85
29- F 160 140 97 83.5
30- M 120 135 70 80
31- F 1®) 160 SO 95
50- M \ 140 130 70 65
51- M 190 175 100 90
52- F 105 102.5 50 62.5
53- M
54-black
55- M 200 175 100 95
56- M 175 170.8 75 75.8
57- F 180 180 100 100
58- F 170 160 110 100
59- F 200 200 100 100
60- F 190 187.5 90 80
61- F | 150 135 100 85
62- M I 125 152.5 85 90
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Entrant ID Gender SBPd SBPf DBPd DBPf
63- F 170 168.5 90 91.5
64- M 160 179.5 100 103
65- M 150 162.5 90 92.5
66- m 150 147 100 95
67- u 140 142 80 75
68- F 150 150 85 82.5
69- M 160 160 70 70
70- M 180 180 100 90
71- F 140 142.5 85 70
72- F 170 176 100 110
73- F 210 210 100 104
74- F 160 160 100 91.67
75- F
76- F 140 144 75 72
77- M 150 150 110 112
78- F 220 200 110 110
79- F 200 200 120 114
80- M 130 130 84 84
81- M 140 140 95 95
82- M 150 150 100 90.8
83- M 130 130 90 90
84- 140 140 80 91.6
85- M 120 120 70 71
86- F 150 170 90 109
87- M 160 160 80 88
88- F
89-
90- M 130 130 90 90
91- M
92- M
93- M 204 204 99 99
94- M 159 159 88 88
95- M 190 190 85 85
96- M 140 140 70 78.8
97- M 130 130 60 60
98- F 100 120 60 70
99- M 155 155 105 99.6
100- M 180 135 80 78
101- U 180 172.2 86 84.2
102- F 120 134.2 80 90
103- F 160 160 95 95
104- M 156 155 115 100
105- m 170 170 95 95
106- F
107- F
108-
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Entrant ID Gender SBPd SBPf DBPd DBPf
109- M 150 146 80 98
124- F
125-
126- F
127- F
129- M 190 167.5 80 85
133-
142- M 180 159 80 70.25
143- M 132 132 74 74
144- M 163 171 67 75.67
145- F 120 111 80 78.5
146- M 180 182.5 100 100.83
147- M
148- F 150 152.6 100 95.8
149- F 170 163 95 90
150- M 160 162.5 90 92.75
151- M 170 170 70 70
152- F 150 145.4 70 84.8
153- M 173 173 67 67
154- M 140 140 90 90
155- 1W1 140 126.67 100 94.3
156- F 140 144.5 80 77.4
157- F 180 146.67 110 110
168-
178- M 190 143.8 110 81.2
181- M 160 140 90 73
182-
184- F
185- M 150 141 80 82.5
186- F 120 160.67 77 91.3
187- M 148 148 94 93
188- F 120 120 80 85
189- M 150 150 95 96
202- M 140 140 70 74
203- M 140 140 80 79
204- F 130 130 80 89
211- M 140 110.5 90 72.8
212- M 100 136 70 75
213- M 160 140 110 93
214- F 150 150 97 100
215- M 120 122 80 89
216- M 140 140 70 72
217- M 140 148.33 90 96.7
218- F 190 190 100 95
219- F 138 138.4 90 89.2
220- M 158 158 75 75
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Entrant ID Gender SBPd SBPf DBPd DBPf
221- F
223- M 140 142 95 96
225- F 190 176 90 84.5
226- M 165 137.5 100 80
227- M 110 112.5 75 75
228- F 1®) 170 100 100
229- M
230- M 140 130 80 75
231- F 130 105 70 55
232- F 80 100 50 55
233- M 118 118 60 70
234- M
235- M 160 170 80 80
236- M 150 150 80 80
237- F 160 159 85 86
238- M 155 140.5 90 85
239- m 214 214 109 98.5
240- M
241- F 140 140 80 89
242- M 130 134.5 80 79.75
243- M
244- 140 142 80 83
245- M 160 165 90 83.75
246- M 160 147.4 82 83
247- M 150 136 95 83.8
248- M
249- M 140 136.8 80 82.5
251- F 170 139.5 110 92.7
252- M 170 168 90 87
253-
254-
255- F 130 132 85 86.8
256- M 200 169.2 110 85.8
257- M 140 147.5 80 77.5
258- m 85 145 55 80
259- m 132 102.5 76 67.5
260- M 173 102.5 105 100
261- F 140 140 75 86.7
262- F
270- M
271- M 140 127.7 75 67
272- M 125 148.33 80 80
273- M 150 152.8 90 91
274- M 170 178.2 90 92.2
276- M 150 161.75 85 79.25
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Entrant ID Gender SBPd SBPf DBPd DBPf
277- M 130 152.2 80 81.25
300- F
301- M
302- F
303- F
305- F
306- M
307- F
321-
322- M
323- m
324- M
325- M
341-
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Entrant ID Proteinuria at 
onset
Proteinuria during 
follow up
Creatinine Slope Progression of CRF
1- 0.2 1.05 0.000094 NP
2- 357 2.09 -0.0000013 NP
3- 1-6 2.01 -0.0000078 NP
4- 1 2.41 ESRF
5- 10-7 10.68 ESRF
6- 42. 3.84 -0.000027 P
7- ESRF
8- 4.3 2.47 -0.000067 P
9- 0.5 1.03 0.000019 NP
10- 1.83 1.75 ESRF
11- 0.9 ESRF
12-
13- 1.29 1.25 -0.00008 P
14- 0.36 0.27 -0.000048 P
15- 3.3 2.4 -0.000039 P
16- 0.3 0.34 0.000011 NP
17- 2.3 1.31 -0.000021 NP
18- 0.3 0.133 0.000053 NP
19- 1.5 2.47 ESRF
20- 2 8 7.6 ESRF
21- 0.5 0.26 0.000005 NP
22- -0.000003 NP
23-
24- 0.2 0.32 ESRF
25- 2.8 3.07 -0.000076 P
26- ESRF
27- 2.6 2.22 0.0000412 NP
28- 1.34 1.16 0.0000532 NP
29- 0.22 0.49 0.000013 NP
30-
31- 0.3 0.3 0.0000007 NP
50- ESRF
51- 5.1 3.58 ESRF
52- 3 3 ESRF
53-
54-bIack
55- ESRF
56- 7.8 7.8 ESRF
57- 1 1 ESRF
58- 0.4 0.4 ESRF
59- ESRF
60- ESRF
61- 1.5 1.4 ESRF
62- 2.95 2.95 ESRF
63- 2 2 ESRF
ALO
Entrant ID proteinuria at 
onset
Proteinuria during 
foffow up
Creatinine Slope Progression state
64- 0.9 0.73 ESRF
65- 5.9 4.7 ESRF
66- 1.8 1.8 ESRF
67- 0.6 0.83 ESRF
68- 0.7 1.73 ESRF
69- ESRF
70- 1.7 1.7 ESRF
71- 1.5 1.5 ESRF
72- 4.1 4.1 ESRF
73- 2.53 2.35 ESRF
74- 1.4 1.4 ESRF
75- 1.3 1.63 ESRF
76- ESRF
77- 1.6 0.58 ESRF
78- 0.1 0.19 ESRF
79- 0.25 0.25 ESRF
80- 3.5 2.13 ESRF
81- 3.5 2.87 ESRF
82- 5.1 3.28 ESRF
83- 3.16 1.87 ESRF
84- 2.53 2.53 ESRF
85- 3.1 3.1 ESRF
86- 1.1 1.1 ESRF
87- 16.7 15.87 ESRF
88- 5.4 4.78 ESRF
89-
90- 1.6 2 ESRF
91- -0.0000065 NP
92- 1.9 1.9 ESRF
93- 7.8 7.8 ESRF
94- 7 7 ESRF
95- 2.7 2.32 ESRF
96- 0.3 0.3 -0.000018 NP
97- 0.2 0.15 -0.0000048 NP
98-
99- 2.8 2.61 ESRF
100- 0.8 0.88 0.0000007 NP
101- 0.9 1.14 -0.00008 3
102- 5.6 6.63 ESRF
103- ESRF
104- 12.8 12.8 ESRF
105- 6.6 6.6 ESRF
106- 3.3 2.17 ESRF
107- ESRF
A ll
Entrant ID proteinuria at 
onset
Proteinuria during 
follow up
Creatinine Slope Progression state
108- 0.74 0.57
109- 3.1 2.07 ESRF
124- 5.85 4.1 ESRF
125-
126-
127- 3.57 2.64 0.0000307 NP
129- 3.6 2.17 ESRF
133-
142- 0.2 0.3
143- 0.78 1.32 -0.000061 P
144- 1.5 2.97 ESRF
145- 0.29 0.3 -0.000011 NP
146- 0.1 0.1 -0.00002 NP
147- 0.37
148- 0.2 0.15 -0.00008 P
149- 0.2 0.2 -0.0000027 NP
150- 3.6 2.56 ESRF
151- 2.8 2.8 -0.000037 P
152- 0.1 1.6 -0.000054 P
153- 1.79 1.5 -0.0000048 NP
154- 2.1 1.33 -0.000044 P
155- 0.43 0.4 ESRF
156-
157-
168-
178- 3.74 2 ESRF
181- 3.5 2.87 ESRF
182-
184- 0.29 0.4 ESRF
185- 3.1 3 ESRF
186- ESRF
187- 0.92 0.92 ESRF
188- 1.1 1 ESRF
189- 0.4 2.24 ESRF
202- 0.2 0.3 -0.00004 P
203- 8.3 7 -0.000006 NP
204- 0.72 1 0.00006 NP
211- 0.06 0.07 -0.00005 P
212-
213- 3.9 2.57 -0.0000026 NP
214- 1.2 1.2 -0.00002 NP
215- 0.8 0.9 ESRF
216- 2.8 3.07 -0.00006 P
217- 7.2 9.6 -0.0001 >
218- 0.000022 NP
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Entrant ID proteinuria at 
onset
Proteinuria during 
fellow up
Creatinine Slope Progression state
219- 1.47 1.9 -0.000003 NP
220- 3.14 1.8 -0.00008 P
221- 1.28 1.3 0.00004 NP
223- 3.42 -0.00003 P
225- 0.2 0.2 -0.000003 NP
226- 0.2 0.3 -0.000032 P
227- 0.49 0.5 -0.0004 P
228- 0.2 0.15 -0.00003 P
229- 5.4 5 -0.00003 P
230- 1.34 1 ESRF
231- 0.4 0.4 ESRF
232- 0.6 0.5 0.000027 NP
233-
234- 0.34 0.34
235- 1.1 1.1 -0.00003 P
236- 2 2 ESRF
237- ESRF
238- 4 4 -0.0000042 NP
239- 4.4 6.25 ESRF
240- 1.3 1.3 0.000003 N.P
241- 8.9 6.3 ESRF
242- 2.71 2.71 -0.000022 P
243- 2.7 2.3 ESRF
244- 8.1 5 ESRF
245- 0.9 1 -0.000012 NP
246- 0.36 0.3 -0.000036 P
247- 1.62 1.62 -0.000072 P
248- 0.1 0.1 -0.00003 P
249- 2.8 2.6 -0.00006 P
251- 1.3 1 -0.00002 NP
252- ESRF
253-
254-
255- 1.47 1.79 -0.0000006 NP
256- 0.4 0.5 ESRF
257- 0.1 0.1 0.00001 NP
258- 0.08 0.08 ESRF
259- 0.1 0.3 -0.000007 NP
260- 1.04 0.93 0.000008 NP
261- 3.94 3.94 -0.00004 3
262-
270- -0.00001 NP
271- ESRF
272- 0.53 0.58 ESRF
273- 0.1 0.2 ESRF
A13
Entrant ID proteinuria at 
onset
Proteinuria during 
follow up
Creatinine Slope Progression state
274- 0.81 0.81 0.00008 NP
276- ESRF
277- 0.3 0.25 0.00002 NP
300- 0.2 -0.000001 NP
301- 1.23 0.00004 NP
302- 0.79 0.000004 NP
303- 2.18 0.00005 NP
305- 0.93 -0.0003 P
306- 19 -0.00034 P
307- 0.28 -0.00025 P
321- ESRF
322- 5.9 ESRF
323- 5.1 ESRF
324- 9.6 ESRF
325- ESRF
341- -0.00015 P
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A. VII. TGF beta I polymorphisms
Entrant ID C-509T LeulOPro Arg25Pro Thr263He
1- CC TC CG CC
2- TC TT CC CC
3- TO TC CG
4- TC TC
5- TC TC GG CC
6- GG CC
7- TC TC GG CC
8- TT GG CC
9- TC TC GG TC
10- TT CC CC CC
11- TT TC GG CC
12-
13- TT TC GG TC
14- TT TC GG CC
15- TT TC GG CC
16- TT GG CC
17- CC CC CG CC
18- TC TT GG
19- TC CC
20- TT TC GG CC
21- TT TT CG CC
22- TC CC CG CC
23-
24- TC TT GG CC
25- TC TC GG CC
26-
27- TC TT CC
28- CC TC CG CC
29- TT CC CG CC
30-
31-
50- TC CC GG CC
51- TT CC GG CC
52- TC TT GG CC
53- TC
544>lack
55- TT TC GG CC
56- TC TT GG CC
57- TC TT CG CC
58- TC TC GG CC
59- TC TC GG CC
60- TT CC GG CC
61- TT GG CC
62- TC TC CG CC
63- TT GG CC
A \5
Entrant ID C-509T LeulOPro Arg25Pro Thr263«e
64- TC TT CG CC
65-
66- TT CC GG CC
67- TT CC GG CC
68- TC TT GG CC
69- TC TT CG CC
70- TC TT GG CC
71- TT GG CC
72- TT TT GG CC
73- TC CC GG CC
74- TT TC GG CC
75- TT TC CC
76- CC TC CG CC
77- TT TC GG CC
78- TT TC GG CC
79- TT CC GG CC
80- TT TC GG CC
81- TC CC CG CC
82- TT CC CG CC
83- TC TC GG CC
84- TT CC GG CC
85- TT CC GG CC
86- TT CC CG CC
87- TT GG CC
88- TT GG CC
89-
90- TT TT GG CC
91- TC TC GG CC
92- TT TT GG TC
93- TT GG CC
94- TC TC GG CC
95- TC TC CG CC
96- TC TC
97- TC TT GG CC
98-
99- TC GG CC
100- TC CC CG CC
101- TC TC GG CC
102- TC TC GG CC
103- TT GG CC
104- TT TC GG CC
105- TT GG CC
106- TT TC GG CC
107- TT GG CC
108-
109- TC TT GG CC
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Entrant ID C-509T LeulOPro Arg25Pro Thr263He
124- GG CC
125-
126-
127-
129- TT TC GG CC
133-
142-
143- TC GG CC
144- TT TT GG CC
145- TT TT GG CC
146- TT CC CG CC
147-
148- TT CC GG CC
149- TC TC GG CC
150- CC TC GG CC
151- TT TC GG TC
152- TT CC GG CC
153- TT TT GG CC
154- TC TC GG CC
155- TT TC GG CC
156-
157-
168-
178- TT TC GG CC
181- TC CG CC
182-
184- CC TC GG CC
185- TC CC GG CC
186- TT GG
187- TT CG
188- TC GG
189- TT TT GG CC
202- TT TC GG CC
203- TT TC GG TC
204- TT TC GG CC
211- TC TC GG CC
212- CC
213- TT TC CG CC
214- TC GG CC
215- TT TC GG CC
216-
217- TT TC CG CC
218-
219- TC TC GG CC
220- TT TT GG CC
221- TT TC GG
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Entrant ID C-509T LeutOPro Arg25Pro Thr263SSe
223- TT TC GG CC
225-
226- TT TT GG CC
227- TT TC GG CC
228- TT TC GG CC
229- TT TT GG CC
230- TT TC CG CC
231- TT TC GG CC
232- TT TC GG CC
233-
234-
235- TT CC GG CC
236- GG CC
237- TT TC CG CC
238- TT TT GG CC
239- TT TC CG CC
240- TT TC GG CC
241- TC GG CC
242- TC GG CC
243- TC GG CC
244- TT TC GG CC
245-
246- TC GG CC
247- TT GG CC
248-
249-
251- TC CC
252- TT TC GG CC
253-
254-
255- CC TC CG CC
256- TC GG CC
257- TT CC GG CC
258- TC TC GG CC
259- TC TC
260- TT TC CC
261- TT GG CC
262-
270- CG CC
271- TT TC CG CC
272- TT TC GG CC
273- IT CG CC
274- TT TT GG CC
276-
277-
300-
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Entrant ID C-509T LeutOPro Arg25Pro Thr263»e
301- TC
302-
303-
305-
306-
307-
321- TT CC GG CC
322- TT GG CC
323- TT TC GG CC
324- TT TC GG CC
325- TC GG CC
341-
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A. VIII. Pathology and TGF beta I immunostaining data
Entrant ID GS IF Cellular
Infiltration
{cell/field)
% of Glomeruli 
stained with TGF 
beta 1
% of tubules 
stained with TGF 
b e te l
3- 1 1
5- 3 4 0 3 3
8- 4 3 60 0 20
11- 3 3 0 8 15
16- 3 3 25 10 15
18- 3 3 58 0 5
28- 3 3 0 0 5
51- 4 4 60 0 14
56- 3 3 0 2 1
68- 2 3 0 3 4
76- 2 4 0 2.8 16
81- 2 3 0 0 0.5
87- 3 4 60 9.4 17
104- 3 3 60 0 12
109- 4 4 60 0 2.5
154- 3 3 20 Ql 5
157- 3 3 15 0 22
I00COV* 0 0 0.5
217- 2 3 60 2.5] 1.3
220- 4 3 60 0.5 5
221- 4 3 60 0 21
238- 3 3 55 14 22
271- 2 4 45 0 7
273- 2 3 0 2 6
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A.XI. Circulating TGF-gl levels
Entrant ID Plasma TGF level Serum TGF beta
1- 40074
2- 152724 39303
3- 7080 23610
4-
5- 22471 27555
6- 24105 25710
7- 20517
8- 38663 37092
9- 4687 39474
10- 4682 26574
11- 46170 37014
12- 2580 997
13- 4459 21322
14- 1924 20298
15- 3508 29142
16- 24343 37533
17- 24092 19824
18- 25355 29949
19- 15437 22128
20- 10406 20517
21- 21002 38724
22- 24218
23- 21310 29874
24- 16305
25- 16403 27417
26-
27- 26207
28- 6371 20310
29- 10850 18117
30-
31-
50- 21966 25410
51- 24309 29628
52- 14790 19599
53- 15549
54-bIack
55- 21574 19728
56- 10099 14850
57- 11072 22740
58- 6795 8124
59- 4129 13842
60- 13767 12624
61- 6699 10353
62- 13524
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Entrant ID Plasma TGF level Serum TGF beta
63- 22917
64- 7327 11874
65- 6917
66- 31845 27054
67- 7583 11067
68- 11681 17124
69- 10316 16110
70- 9939 21525
71- 14046 16299
72- 17580 24903
73- 21030 30417
74- 27474 26385
75- 20950
76- 18459 17889
77- 13033
78- 31081
79- 24363
80-
81- 24742
82-
83- 27912
84- 16020 32667
85- 13116 20553
86- 7777 25710
87- 10689 18024
88- 18431 35367
89- 19985 30885
90- 16225 30924
91- 14122 28074
92- 18296 14685
93- 84664 31899
94- 14542 15399
95- 18039 20760
96- 21404 26910
97- 26593 43167
98-
99- 27757 19317
100- 18658 29424
101- 18336 27867
102- 9592 9414
103- 12382 12135
104- 18249
105- 20599 27378
106- 7128 13128
107- 13026 10167
108-
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Entrant ID PSasma TGF level Serum TGF beta
109- 12397 19599
124-
125- 16105 24903
126- 22004 30378
127- 1560
129- 29985
133- 21621 16503
142-
143-
144-
145-
146-
147-
148- 16579
149- 22525 32724
150- 16910 29517
151- 20922 24792
152- 19235 34053
153- 35553 31428
154- 3932 4017
155- 26574
156- 56407 660
157- 1017
168-
178- 13141 25503
181- 24435
182- 31922 28824
184- 29319 32799
185- 17274 24717
186- 51660
187- 21074 31165
188- 8969 1353
189- 60789 34635
202- 14013 12852
203- 25107 38469
204- 23984 28698
211- 16134 29994
212- 50524 45012
213- 48842 32973
214- 30035 36273
215- 46170 28137
216- 33380 13194
217- 10677 18612
218- 33960
219- 16276
220- 18128 20412
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Entrant ID Plasma TGF level Serum TGF beta
221- 12835 13119
223- 21851 20319
225- 23748
226- 9943 27687
227- 16416
228- 19465 13044
229- 14336
230- 12151 16962
231- 22134 14655
232- 21460 17823
233- 11424 13812
234-
235- 26864 17244
236- 11154 22437
237- 17969 38670
238- 14430
239- 23903 12312
240- 2981 25749
241- 13163 30849
242- 8942 24885
243- 10919 22524
244- 15799 30717
245- 44460
246- 1972.5
247- 7776 25803
248- 17199 28428
249- 21135
251-
252- 13828
253-
254-
255- 354 30960
256- 31175 48453
257- 43593 14274
258- 10556
259- 14305
260- 12039
261- 25360
262-
270- 11703 21180
271- 8661 14055
272- 19313
273- 8411
274- 16518 21144
276-
277-
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Entrant ID PJasma TGF level Serum TGF beta
300-
301- 25402
302-
303-
305-
306-
307-
321- 5333
322-
323-
324-
325-
341-
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